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CHAPTER 1 
 
General introduction 
 
  
  
 
Short introduction and aim of the thesis 
Safrole, 4-allyl-1,2-methylenedioxybenzene, is a constituent of spices like nutmeg, mace 
and star anise and of some food products to which safrole containing spices are added such 
as pesto sauce, cola beverages, Bologna sausages and Vienna sausages (Siano et al., 2003). 
In addition, safrole containing spices are used as source of natural flavouring and as 
traditional medicine for illnesses related to the nervous and digestive system (Leela, 2008). 
Current European Council Directive (EC) on food flavouring regulation No 1334/2008 has 
prohibited the use of safrole as such in human foods and restrictions have been set on the 
concentration of safrole in foods that are prepared with safrole containing flavourings or 
food ingredients with flavouring properties (European Commission, 2008). In the U.S. 
already in 1960 the U.S. Food and Drug Administration (FDA) prohibited the use of pure 
safrole and sassafras oil (content of safrole >80%) in food (FDA Ban 21 CFR 189, 180; 
revised April 1 2008) due to the potential carcinogenicity of safrole as demonstrated in 
rodent studies (Borchert et al., 1973; Miller et al., 1983; Wislocki et al., 1977). 
Several risk assessments have been performed to evaluate the safety of human exposure to 
safrole. In 1997, the Committee of Experts on Flavouring Substances (CEFS) of the 
Council of Europe evaluated safrole and concluded that safrole is a weak hepatocarcinogen 
in experimental animal studies but also a genotoxic and a transplacental carcinogen, and 
that efforts should be made to reduce its consumption through foods and beverages as much 
as possible (Council of Europe, 1997). The Scientific Committee on Food (SCF) of the 
European Union (EU) concluded in their evaluation that safrole is genotoxic and 
carcinogenic and that reductions in the exposure and restriction in the use levels are 
indicated (SCF, 2002). These opinions are all based on carcinogenicity data from rodent 
studies because adequate human data were not available. At present, discussions are 
ongoing on how to translate the results from animal bioassays at high dose levels of the 
pure compound to the risk for the human population exposed to safrole at relatively low 
levels via dietary intake. This translation of cancer risk from the animal data to humans at 
relevant dietary intake levels needs a better understanding of species dependent, dose 
dependent, and interindividual differences in bioactivation and detoxification of safrole and 
the possible influence of the food matrix on these processes.  
  
 
The aim of this thesis was to obtain insight into the effects of dose-, species-, 
interindividual- and matrix dependent differences on the bioactivation and detoxification of 
safrole using physiologically based biokinetic (PBBK) modeling.  
 
Exposure to safrole 
Although use of safrole has been banned in the EU and U.S., intake of safrole at very low 
levels occurs in daily life via the diet from consumption of spices containing safrole such as 
nutmeg, mace, star anise, cinnamon and black pepper and from food products to which 
these spices are added such as cola beverages, Bologna sausages and Vienna sausages 
(Siano et al., 2003). The content of safrole in essential oils of nutmeg, mace, star anise and 
black pepper is 2.33, 1.05, 0.14, 0.14 and 0.1% (JECFA, 2009). The content of safrole in 
Bologna and Vienna sausages was determined to amount to 2 and 0.2 mg/kg of product, 
respectively which can most likely be ascribed to nutmeg addition (Siano et al., 2003). The 
intake of safrole may also result from consumption of soft drinks which may contain safrole 
up to 3-5 times the use limit of 1 µg/mL (Choong and Lin, 2001). Furthermore, exposure to 
safrole occurs in some countries in Southeast Asia as a result of the popular habit of 
chewing a betel quid containing Piper betle (containing 15 mg/g fresh weight of safrole), a 
habit that was linked to the incidence of oral squamosa cell carcinoma (Chen et al., 1999; 
Hwang et al., 1992; Ko et al., 1995). 
The average daily intake of safrole from consumption of foods that contain safrole was 
estimated to be 0.3 mg/day corresponding to 5 µg/kg body weight (bw)/day for a 60 kg 
person (SCF, 2002). This value was based on a selection of 28 food categories to which 
safrole could still be added at the time of the evaluation. Given current regulations that 
restrict safrole use in food, this average daily intake may be lower at present, although 
recent estimates from other assessment bodies report comparable intakes. The Joint 
FAO/WHO Expert Committee on Food Additives (JECFA), at the sixty-ninth meeting, 
estimated the intake of safrole from food consumption to amount to 569 µg/person/day 
(equivalent to 9.5 µg/ kg bw/day for a 60 kg person) in the U.S. based on the highest 
reported levels of volatile oil in spices and the highest reported safrole concentration in the 
oil (JECFA, 2008). From EU import data of nutmeg, mace and its essential oils, the 
  
 
maximum daily intake of safrole was estimated to be 879 µg/person (equivalent to 14.7 µg/ 
kg bw/day for a 60 kg person) (JECFA, 2008). The FDA estimated the intake of safrole 
from only essential oil of nutmeg and mace to be 4 µg/kg bw/day (SCOGS, 1973).  
Safrole metabolism  
Upon oral intake, safrole is rapidly absorbed from the gastrointestinal tract by passive 
diffusion (Fritzh, 1975). Biotransformation of safrole occurs mainly in the liver (Benedetti 
et al., 1977; Klungsøyr and Scheline, 1983). The metabolism of safrole including its 
bioactivation and detoxification pathways is presented in Figure 1.1. The metabolic 
pathways of safrole include oxidative dealkylation of the methylenedioxy group resulting in 
1,2-dihydroxy-4-allylbenzene (DHAB) which is the major metabolite of safrole in rat, 
guinea pig and man exposed to safrole (Benedetti et al., 1977; Chang et al., 2002; 
Klungsøyr and Scheline, 1982; Stillwell et al., 1974). This metabolite may be further 
oxidized to an o-quinone metabolite, 4-allyl-o-quinone, which isomerizes non-
enzymatically to a more electrophilic p-quinone methide (Bolton et al., 1994). DHAB can 
be excreted following conjugation at its hydroxyl moieties through sulfation and/or 
glucuronidation prior to oxidation to the quinone/quinone methide or upon GSH 
conjugation of its quinone/quinone methide which has been observed to occur in rat 
hepatocytes (Nakagawa et al., 2009). However, GSH conjugation was a minor pathway 
compared with the sulfation and/or glucuronidation of DHAB (Nakagawa et al., 2009).A 
small amount of 3′-hydroxysafrole as conjugated form has also been detected in the urine of 
rats exposed to safrole, but not in the urine of humans exposed to safrole (Benedetti et al., 
1977). This metabolite is formed upon the direct hydroxylation of the alkyl side chain at the 
3ʹ position and is subsequently conjugated with glycine to give 3,4-methylenedioxybenzoyl 
glycine and 3,4 methylenedioxy-cinnamoyl glycine which are excreted in the urine (Boberg 
et al., 1986). Epoxidation of the double bond of the allyl side chain results in 2ʹ,3ʹ-safrole 
oxide which is rapidly hydrolysed by microsomal epoxide hydrolase forming 2ʹ,3ʹ-
dihydroxysafrole (Ioannides et al., 1981; Klungsøyr and Scheline, 1983). The major 
bioactivation pathway of safrole is initiated by formation of the proximate carcinogenic 
metabolite 1ʹ-hydroxysafrole in a reaction catalysed by cytochromes P450, with P450 2A6,  
  
 
 
         Figure 1.1. Biotransformation pathways of safrole. 
  
 
P450 D6.1, P450 2C9, P450 2C19 and P450 2E1 being the main P450 enzymes involved in 
human (Jeurissen et al., 2004; Liu et al., 2004; Ueng et al., 2004). 1′-Hydroxysafrole 
subsequently undergoes several further reactions. One of these reactions is further 
bioactivation to the ultimate carcinogen 1ʹ-sulfooxysafrole catalyzed by sulfotransferases 
(SULTs). Detoxification of 1ʹ-hydroxysafrole may result from the conjugation reaction 
catalyzed by UDP-glucuronosyltransferases (UGTs) resulting in 1′-hydroxysafrole 
glucuronide which is excreted in the urine in rodents and humans. Another reaction of 1′-
hydroxysafrole is its oxidation forming 1′-oxosafrole which was detected in small amounts 
as conjugated form in the bile of  rats accounting for 6.5% of the dose of 1ʹ-hydroxysafrole 
injected intraperitoneal (i.p) to rats (Fennell et al., 1984). 1′-Oxosafrole is subsequently 
conjugated with glutathione forming 3′-(glutathion-S-yl)-1′-oxo-2′,3′-dihydrosafrole which 
can be converted to the corresponding mercapturic acid 3′-(N-acetylcystein -S-yl)-1′-oxo-
2′,3′-dihydrosafrole (Fennell et al., 1984).  
Carcinogenicity of safrole 
Long term carcinogenicity studies of safrole in rodents have been performed. Table 1.1 
presents an overview of the available carcinogenicity data from long term studies with 
safrole in mice and rats. Wislocki et al. (1977) employed oral administration of safrole via 
the diet to rats for 51 weeks. In this study, the incidence of hepatomas was increased (17%) 
at a dose of 200 mg safrole/kg bw/day. Rats exposed to 68 mg safrole/kg bw/day and 
controls showed no hepatomas. Three independent studies using mice and rats were 
reported in the publication by Borchert et al. (1973). In study 1, administration of safrole 
via the diet to male CD-1 mice at dose levels of 390 and 488 mg safrole/kg bw/day for 56 
weeks resulted in a significant increase in the incidence of hepatocellular carcinomas, by 44 
and 53%, respectively, compared to controls (0%). In study 2, rats were administered 
safrole via the diet at dose levels of 82 and 138 mg/kg bw/day for 47 weeks and this 
resulted in the formation of hepatocellular carcinomas but not at levels that were 
significantly different compared to the levels in controls. In study 3, increasing levels of 
hepatocellular carcinomas were observed in male CD-1 mice dosed by subcutaneous (s.c) 
injection with 9.45 µmol of safrole (given in four injections on days 1, 7, 14, and 21 of age 
to preweanling mice) but no hepatocellular carcinomas formed in female CD-1 mice 
  
 
(Borchert et al., 1973). When safrole was administered to post weaning mice, a significant 
increase in hepatocellular tumors was observed in females (48%) but not in males (8%). 
Male offspring (34%) nursed by mothers treated treated with safrole during lactation had 
hepatocelluler tumors but not female offspring (Vesselinovitch et al., 1979). The results 
suggested that safrole or its metabolites may cross the placenta to the fetuses and be 
transferred from lactating mothers exposed to safrole to the offspring through the milk 
(Vesselinovitch et al., 1979). 
Table 1.1. Overview of carcinogenicity data from rodent studies with safrole reported in 
literature 
Species Sex Route of 
administration 
Duration of 
exposure 
Sacrifice Dose # of animals 
with liver tumor 
or 
hepatocellular 
carcinoma/#ani
mals 
Inciden
ce (%) 
References 
Mice B6C3F1 
 
M 
 
Transplan-
cental 
 
18 days 
(12,14,16,18  
days of 
gestation) 
92 wk 
 
 
 
0 3/100  3 Vesselinovitch  
et al. (1979) 
 
 
 
 
Total dose 500 mg/kg bw 2/63  3.2 
F 0 0/98  0 Total dose 500 mg/kg bw 0/71  0 
M gastric 
intubation 
 
90 wk (twice 
weekly) 
0 3/100  3 
120 mg/kg bw/day 4/60  8 
F 
 
0 0/98  0 
120 mg/kg bw/day 22/60  48 
M 
 via milk 
 
3 wk (2 days 
interval) 
0 3/100  3 
Total dose 1500 mg/kg bw 28/85  34 
F 0 0/98  0 Total dose 1500 mg/kg bw 2/80 2.5 
Rat CD1 
 
M diet 
 
74 wk 
96wk 
0 0/18  0 Wislocki et al. 
(1977) 
 
0.22% (68 mg/kg bw/day) 0/18 0 
96 wk 0 0/15 0 0.5% (200 mg/kg bw/day) 3/18 17 
Mice CD1 
 
F 
 
diet 
 
 
 
52 wk 
78wk 0 0/30  0 Miller et al. (1983) 
 
0.5% (176 mg/kg bw/day) 21/30 70 
F 
 
 
86 wk 
0 0/50 0 
0.25% (80 mg/kg bw/day) 34/47 72 
0.5% (160 mg/kg bw/day) 39/49 80 
Mice CD1 
 
M 
 
 
diet 56 wk 70 wk 
0 4/50  8 Borchert et al. 
(1973) 
 
0.4% (390 mg/kg bw/day) 11/25  44 
0.5% (488 mg/kg bw/day) 8/15 53 
M 
 s.c injection 
 
3 wk (at day 
1,7,14,21) 56 wk 
0 4/36  11 
Total 9.45 µmol 20/35 57 
F 
 
0 0/31 0 
Total 9.45 µmol 0/27 0 
Rat (SD) 
 
 
M 
 
 
diet 
 
 
47 wk 52 wk 
0 0/18 0 
0.3% (82 mg/kg bw/day) 0/18  0 
0.5% (138 mg/kg bw/day) 1/18  6 
 
Note : M: male; F: female; i.p: intraperitoneal; s.c: subcutaneous; s.t: stomach tube; wk: week 
  
 
In addition, also several carcinogenicity studies which administered the proximate 
carcinogenic metabolite of safrole, 1ʹ-hydroxysafrole, were performed in both mice and rats 
through various routes of administration. Table 1.2 presents the data of these 
carcinogenicity studies with 1ʹ-hydroxysafrole. In general, the results show that the 1ʹ-
hydroxy metabolite of safrole also induces hepatocellular tumors in rodent studies. Male 
rats dosed with 1ʹ-hydroxysafrole at 77 mg/kg bw/day for 43 weeks and 100 mg/kg bw/day 
for 73 weeks showed incidences of hepatocellular carcinoma of 40 and 90%, respectively 
(Wislocki et al., 1977). Boberg et al. (1983) showed that oral dose levels of 125 mg/kg 
Table 1.2. Overview of carcinogenicity data from rodent studies with 1ʹ-hydroxysafrole 
reported in literature 
 
Species Sex Route of 
administra
tion 
Duration 
of 
exposure 
Sacrifice Dose # of animals with 
liver tumor or 
hepatocellular 
carcinoma/#anim
als 
Inciden
ce (%) 
References 
Mice CD-1 
 
F diet 
 
52 wk 
70 wk 
0 0/32  0 
Boberg et al. 
(1983) 
125 mg/kg bw/day 17/29 60 
260 mg/kg bw/day 25/32  78 
Rat CD 
M diet 
73 wk 
96 wk 
0 0/18  0 
Wislocki et 
al. (1977) 
 
43 wk 0.25% (77 mg/kg bw/day) 7/18  40 
73wk 0.55% (100 mg/kg bw/day) 16/18  90 
Mice 
B6C3F 
 
M 
 
i.p 
Injection 
on day 8, 
12 
44 wk 
0 4/33  12 
Boberg et al. 
(1983) 
0.05 µmol/g bw/day 12/34  36 
0.1 µmol/g bw/day 31/36  86 
0.2 µmol/g bw/day 32/33  97 
Mice CD-1 
 
M i.p 
Injection 
on day 
1,8,15,22 
52 wk 
0 7/46  15 
Miller et al. 
(1983) 
 
 
 
4.72 µmol /g bw/day 30/46  65 
Mice 
B6C3F1 
 
M 
 
s.c 
 
Injection 
on 
day1,8,15 
and 22) 
52 wk 
 
0 5/35  14 
3.75 µmol/ g bw/day 24/26  92 
Rat Fischer 
 
M 
 
s.c 
 
Injection 
twice 
weekly 
(10 wk)  
104 wk 
 
0 0/20 0 
Total dose 2 mmol/rat 11/20  55 
 
Note : M: male; F: female; i.p: intraperitoneal; s.c: subcutaneous; s.t: stomach tube; wk: week 
 
  
 
bw/day and 260 mg/kg bw/day of 1ʹ-hydroxysafrole given to female mice caused 60 and 
78% increase in the hepatoma incidence as compared to control, respectively (Boberg et al., 
1983).  
DNA adduct formation and genotoxicity of safrole  
Safrole was not mutagenic in the Salmonella reverse mutation assay (Ames test) (Swanson 
et al., 1979). 1′-Hydroxysafrole was mutagenic for S. Typhimurium strain TA 100 
(Swanson et al., 1979). Bioactivation of safrole by sequential 1′-hydroxylation and 
sulfation to 1′-sulfooxysafrole results in a reactive intermediate capable of forming protein, 
RNA and DNA adducts, the latter of which may lead to carcinogenesis (Randerath et al., 
1984; Boberg et al., 1983; Miller et al., 1983). DNA adducts induced by safrole and its 
reactive metabolites 1′-hydroxysafrole and 1′-sulfooxysafrole have been characterized. 
Phillip et al. (1981) have identified DNA adducts formed in the liver of adult female CD-1 
mice after administration of 3H-labelled 1′-hydroxysafrole. The major adduct was 
characterized as N2-(trans-isosafrol-3′-yl)-2′-deoxyguanosine (S-3′-N2-dGuo). Minor DNA 
adducts detected were N2-(safrol-1′-yl)-2′-deoxyguanosine (S-1′-N2-dGuo) and N6-(trans-
isosafrol-3′-yl)-2′-deoxyadenosine (S-3′-N6-dAdo) (Phillips et al., 1981). Daimon et al. 
(1998) isolated four DNA adducts from the liver of rats exposed to safrole. Two DNA 
adducts were identified as S-3′-N2-dGuo and S-1′-N2-dGuo which are similar to the ones 
reported by Phillips et al. (1981) and Randerath et al. (1984), while two other safrole-DNA 
adducts remained unidentified (Daimon et al., 1998). Figure 1.2 presents the schematic 
pathway for bioactivation of safrole and the nature of the DNA adducts formed. The safrole 
metabolite 2′,3′-safrole oxide is also an electrophilic metabolite that was shown to react 
with DNA bases to form DNA adducts in vitro but these adducts were not detected in mice 
exposed to safrole (Qato and Guenthner, 1995). This absence of DNA adduct formation by 
2′,3′-safrole oxide in vivo may be due to rapid detoxification of 2′,3′-safrole oxide by 
glutathione S-transferase and epoxide hydrolases (Ioannides et al., 1981; Klungsøyr and 
Scheline, 1983; Guenthner and Luo, 2001).  
  
 
 
 
Figure 1.2. Bioactivation pathways of safrole and the structure of DNA adducts as identified in literature (Chung 
et al., 2008; Daimon et al., 1998; Randerath et al., 1984; Phillips et al., 1981). S-3′-N2-dGuo= N2-(trans-isosafrol-
3′-yl)-2′-deoxyguanosine, S-1′-N2-dGuo= N2-(safrol-1′-yl)-2′-deoxyguanosine and S-3′-N6-dAdo= N6-(trans-
isosafrol-3-yl)-2′-deoxyadenosine. 
  
 
Studies with hepatocytes isolated from F344 rats exposed to safrole by gastric intubation 
showed that safrole was able to induce chromosome aberrations, sister chromatid 
exchanges (SCEs) and DNA adducts (Daimon et al., 1998). Five repeated administrations 
of 125 and 250 mg/kg bw of safrole increased the aberrant cells in the liver dose 
dependently. Both administration of a single dose (100 - 500 mg/kg bw safrole) and five 
repeated doses (62.5 and 125 mg/kg bw safrole) induced SCEs in the liver (Daimon et al., 
1998). In another in vivo study, it was reported that adduct formation in the female mice 
liver was approximately linear with the dose of safrole down to the lowest dose tested in a 
range from 1-10 mg safrole/mouse with no indication of a threshold. Only at the highest 
concentration of safrole tested (10 mg/mouse), a slight deviation from linearity was 
observed (Gupta et al., 1993). 
Formation of DNA adducts upon exposure to safrole was also observed in humans; in a 
sample of oral tissue obtained from an oral cancer patient having a habit of betel quid 
chewing the presence of DNA adducts identified as S-3ʹ-N2-dGuo was reported (Chung et 
al., 2008). 
Cancer risk assessment  
The presence of safrole in herbs, spices or processed foods cannot be avoided resulting in a 
certain level of daily exposure. Because safrole is both genotoxic and carcinogenic, the 
prediction of the resulting cancer risk at low dose levels representing realistic human 
dietary intake is needed. At present there are different approaches that are available for 
assessing the risk of substances that are both genotoxic and carcinogenic (EFSA, 2005). 
There is no international harmonised approach for risk assessment of compounds that are 
both genotoxic and carcinogenic. The difficulties in risk assessment of compounds that are 
both genotoxic and carcinogenic originate from the fact that the carcinogenic process 
induced by genotoxicity is normally regarded to have no threshold, thereby, eliminating the 
possibility for definition of a safe level of exposure (EFSA, 2005). The mutagenic 
carcinogenic process may be initiated already upon exposure at very low levels and 
therefore a NOAEL cannot be identified. A principle of ALARA (as low as reasonably 
achievable) was used in risk management of compounds that are both genotoxic and 
  
 
carcinogenic but this approach does not enable a risk manager to assess the urgency and the 
extent of the risk reduction measures needed (EFSA, 2005). The extrapolation of tumor 
data obtained at high dose levels in rodent studies to the risk for humans at realistic low 
dietary exposure levels is particularly important. This implies that animal data from 
bioassays using high dose levels have to be translated to the human situation with very low 
levels of intake. For the extrapolation from high doses in animal studies to lower exposure 
in human, some mathematical models are available. A Virtual Safe Dose (VSD), a dose 
which provides a response equivalent to 1 extra tumor case in 1.000.000 upon lifetime 
exposure, can be estimated by extrapolation from the dose causing a certain cancer 
incidence to the lower dose range estimating the dose that would give this incidence of 1 in 
a million upon life time exposure. This implies extrapolation far outside the experimental 
dose and tumor incidence range and an outcome for the VSD that depends very much on 
the extrapolation model applied (EFSA, 2005). Linear extrapolation for assessing the risk 
of chemicals that are genotoxic and carcinogenic and calculating the VSD is criticized 
because it is unknown whether linear extrapolation actually reflects the underlying 
biological processes and because it does not take species differences into account (EFSA, 
2005). The Margin of Exposure (MOE) approach was recently proposed by the FAO/WHO 
Joint Expert Committee on Food Additives (JECFA) and the European Food Safety 
Authority (EFSA) as an alternative approach for the risk assessment of compounds that are 
both genotoxic and carcinogenic (EFSA, 2005). The MOE is based on the available animal 
dose-response data, without extrapolation outside the experimental data range, and on 
human intake data. The MOE approach needs a reference point which can be taken from 
the dose response data of the animal experiments and should represent a dose causing a low 
but measurable cancer response. The MOE can be calculated as the ratio between the 
reference point (e.g. BMDL10) (the lower confidence limit of the benchmark dose causing 
10% extra tumor incidence above background levels (BMD10)) and the estimated daily 
dietary human intake (EDI). An MOE of 10,000 or higher is considered as a low priority 
for risk management (EFSA, 2005). This MOE of 10,000 is applied to adequately allocate 
various uncertainties; taking into account a factor 100 for species differences and human 
variability in the basic processes of toxico-kinetics and toxico-dynamics, a factor 10 for 
  
 
interindividual human variability in cell cycle control and DNA repair, and a factor 10 for 
uncertainties in the shape of the dose-response curves outside the observed dose range 
(EFSA, 2005). 
Overall, it is important to note that the MOE does not provide a quantitative risk 
assessment, but especially provides a tool to set priorities in risk management. This implies 
that new approaches for risk assessment of compounds that are both genotoxic and 
carcinogenic are required. Quantitative risk assessment of a compound that is genotoxic and 
carcinogenic requires extrapolation from high to low dose, from one exposure route to 
another and from one exposure duration to another which can all be performed using a 
physiologically based biokinetic (PBBK) approach. In addition, extrapolation from animal 
toxicity data cannot assure human safety without understanding of the species dependent 
differences in kinetics of absorption, distribution, metabolism and excretion (ADME) of the 
compound of interest. PBBK modeling provides a powerful method for increasing the 
accuracy of the extrapolation because it facilitates extrapolation from animal species to 
human, from high doses to low doses and from one exposure route or time frame to another 
(Clewell, 1995). An accurate assessment of risk associated with exposure to a hazardous 
chemical should be based on all the biologically relevant mechanistic data (Andersen and 
Krishnan, 1994). Biologically based PBBK models provide a method for increasing the 
accuracy of these extrapolations (Clewell, 2010). 
Physiologically based biokinetic (PBBK) modeling 
Physiologically based biokinetic (PBBK) models are mathematical descriptions of the 
ADME characteristics of a chemical and its metabolites in the species and organs of 
interest. The mathematical descriptions include physiological (e.g. blood flow), 
physicochemical (e.g. partition coefficients) and biochemical (e.g. metabolic rates) 
parameters. PBBK models consist of many compartments representing individual target 
tissues (e.g. liver, kidney, lung) or non-target tissues lumped together in one compartment 
(e.g. slowly perfused tissues such as muscle and skin or richly perfused tissues such as 
brain and spleen) (Punt et al., 2007).  
  
 
Exposure to carcinogenic compounds leads to absorption and distribution of the compounds 
or their reactive metabolites to the target tissues. These reactive metabolites may alter the 
chemical structure of the DNA of the target tissues which may initiate tumor formation. 
Using the PBBK models, the dose of the reactive metabolites reaching the target tissues can 
be predicted. Quantitative information on the concentration of the reactive form of a 
compound in the target tissue of interest in different species provides a better basis for 
species dependent extrapolation in risk assessment (Andersen and Krishnan, 1994). PBBK 
models have been used in risk assessment of various carcinogenic compounds. One 
example of the application of PBBK models in risk assessment is the development of a 
PBBK model for inhaled styrene by Ramsey and Andersen (Ramsey and Andersen, 1984). 
The model was evaluated with a set of data of rats and human and used for dose route, dose 
level and interspecies extrapolation for time dependent changes in tissue and blood levels of 
styrene. The obtained PBBK models adequately described the blood and organ 
concentrations of styrene for intravenous (iv), inhalation and intragastric doses of styrene 
and this information was subsequently used for route to route extrapolations in the risk 
assessment. Another example of the application of a PBBK model in risk assessment is the 
PBBK model for vinyl chloride (Clewell et al., 1995). The PBBK models developed 
described the uptake, distribution and metabolism of vinyl chloride in mouse, rat, hamster 
and human following inhalation or oral exposure. The mode of action for carcinogenicity of 
vinyl chloride appears to be DNA adduct formation by its reactive metabolite 
chloroethylene epoxide. The results showed that the PBBK model based predictions for 
vinyl chloride were in good agreement with risk estimates based on inhalation studies with 
mice and rats facilitating dose-response extrapolation across species. Furthermore, the risks 
estimated from dietary administration were in accordance with those derived from the 
inhalation route (Clewell et al., 1995).  
Food matrix effects  
Another factor that should be take into account in risk assessment for food-born compounds 
that are genotoxic and carcinogenic is the effect of the food matrix. Safrole has been 
demonstrated to be carcinogenic in in vivo studies. However, all of these studies have been 
done using high doses of the pure compound without taking matrix effects into 
  
 
considerations. In a realistic human situation, exposure to safrole occurs mainly via 
consumption of nutmeg, mace and their essential oils and/or food products containing these 
spices or essential oils (SCF, 2002). Possible modulating effects of other compounds 
present in the herbs or spices or in other parts of the diet on the bioavailability and/or on the 
cytochrome P450 and or SULT-catalyzed bioactivation of safrole may occur and may have 
to be taken into account in the risk assessment.  
Some spices were found to inhibit cytochrome P450 2C9, one of the cytochrome isoforms 
found to be involved in the metabolism of safrole to 1′-hydroxysafrole (Jeurissen et al., 
2004; Kimura et al., 2010; Ueng et al., 2004). Furthermore for the related alkenylbenzene 
estragole present in basil it was recently demonstrated that a methanolic basil extract and its 
isolated constituent nevadensin inhibited the sulfation and resulting DNA adduct formation 
of the proximate carcinogenic 1′-hydroxyestragole metabolite in studies using rat and 
human S9 protein, the hepatoma cell line HepG2 and/or rat hepatocytes (Alhusainy et al., 
2010; Jeurissen et al., 2008). Moreover, an in vivo study with Sprague-Dawley rats showed 
that co-administration of estragole with nevadensin, at dose levels with a ratio reflecting 
their actual presence in basil, resulted in a significant 36% reduction in the levels of N2-
(trans-isoestragol-3′-y1)-2′-deoxyguanosine (E-3′-N2-dGuo) DNA adducts formed in the 
liver (Alhusainy et al., 2013). Thus matrix effects should preferably be taken into account 
in the risk assessment and studies on bioactivation and detoxification of safrole.  
Objective and outline of this thesis 
The aim of this thesis was to obtain insight into the effects of dose-, species-, 
interindividual- and matrix dependent differences on the bioactivation and detoxification of 
safrole using PBBK modeling.  
This chapter, chapter 1, presents an introduction to the bioactivation and detoxification of 
safrole, safrole DNA adduct formation and the resulting tumor incidence, PBBK modeling, 
the importance of the matrix effects in the risk assessment of food-borne chemicals and the 
aim and the content of this thesis. In chapter 2, a PBBK model for safrole bioactivation and 
detoxification in rats is defined. Chapter 3 defines the PBBK model for safrole 
bioactivation and detoxification in human with a Monte Carlo simulation to predict 
  
 
interindividual variation in the population as a whole. To investigate whether the food 
matrix modulates sulfotransferase (SULT)-catalyzed bioactivation of safrole, in chapter 4 
the safrole containing spice mace is analysed for possible ingredients that may modulate 
safrole bioactivation. The kinetic data for interference with safrole bioactivation obtained 
for the thus identified mace ingredient are incorporated into the PBBK model to predict the 
effect of this matrix ingredient on formation of 1′-sulfooxysafrole in rat and human. An in 
vivo validation study in rats to evaluate the PBBK model based predictions for the effect of 
the mace ingredient on safrole bioactivation and DNA adduct formation in vivo is presented 
in chapter 5. Finally, chapter 6 summarizes the results obtained, and presents an overall 
discussion including future perspectives to be addressed. 
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Abstract 
A physiologically based biokinetic (PBBK) model for alkenylbenzene safrole in rats was 
developed using in vitro metabolic parameters determined using relevant tissue fractions. 
The performance of the model was evaluated by comparison of the predicted levels of 1,2-
dihydroxy-4-allylbenzene and 1′-hydroxysafrole glucuronide to levels of these metabolites 
reported in the literature to be excreted in the urine of rats exposed to safrole, and by 
comparison of the predicted amount of total urinary safrole metabolites to the reported 
levels of safrole metabolites in the urine of safrole exposed rats. These comparisons 
revealed that the predictions adequately match observed experimental values. Next, the 
model was used to predict the relative extent of bioactivation and detoxification of safrole 
at different oral doses. At low as well as high doses, P450 mediated oxidation of safrole 
mainly occurs in the liver in which 1,2-dihydroxy-4-allylbenzene was predicted to be the 
major P450 metabolite of safrole. A dose dependent shift in P450 mediated oxidation 
leading to a relative increase in bioactivation at high doses was not observed. Comparison 
of the results obtained for safrole with the results previously obtained with PBBK models 
for the related alkenylbenzenes estragole and methyleugenol revealed that the overall 
differences in bioactivation of the three alkenylbenzenes to their ultimate carcinogenic 1′-
sulfooxy metabolites are limited. This is in line with the generally less than 4-fold 
difference in their level of DNA binding in in vitro and in vivo studies and their almost 
similar BMDL10 values (lower confidence limit of the benchmark dose that gives 10% 
increase in tumor incidence over background level) obtained in in vivo carcinogenicity 
studies. It is concluded that in spite of differences in the rates of specific metabolic 
conversions, overall the levels of bioactivation of the three alkenylbenzenes are comparable 
which is in line with their comparable carcinogenic potential. 
  
  
 
Introduction 
Safrole (1-allyl-3,4-methylenedioxybenzene) is an alkenylbenzene that is recognized to be a 
genotoxic carcinogenic agent in rodents (Borchert et al., 1973; Miller and Miller, 1983; 
Phillips et al., 1981). In rats, its hepatocarcinogenicity was reported to correlate closely 
with its DNA adduct formation in the liver (Miller and Miller, 1983; Phillips et al., 1981). 
Safrole is the main component of sassafras oil, and it occurs as a trace constituent in star 
anise, nutmeg and black pepper and can be found in food containing these herbs such as 
pesto sauce, cola beverages, Bologna sausages and Vienna sausages (Siano et al., 2003). 
The habit of chewing a betel quid which contains leaves of Piper betle (15 mg/g fresh 
weight of safrole) have been reported to result in safrole concentrations of up to 420 µM in 
saliva during chewing (Hwang et al., 1992).  
Safrole and sassafras oil were banned as food additives and flavoring agents by the FDA in 
1960 because of their carcinogenic potential. The European Council Directive on food 
flavoring 88/388/EEC, amended by Commission Directive 91/71/EEC, limited safrole in 
foodstuff and beverages to 1 ppm. In 1997, the Committee of Experts on Flavoring 
Substances (CEFS) of the Council of Europe evaluated safrole and concluded that safrole is 
a weak hepatocarcinogen in experimental animal studies but also a genotoxic and a 
transplacental carcinogen, and that efforts should be made to reduce its consumption 
through foods and beverages as far as possible.  
The Scientific Committee for Food of the European Union (SCF, 2002) estimated the 
average daily intake of safrole to be 0.3 mg/day equivalent to 5 µg/kg bw/day for a 60 kg 
person while the Joint FAO/WHO Expert Committee on Food Additives (JECFA) 
estimated the maximum dietary exposure to safrole to amount to 879 µg/person/day 
equivalent to 14.6 µg /kg bw/day for a 60 kg person.  
The genotoxic and hepatocarcinogenic action of safrole has been correlated to the 
formation of its proximate carcinogenic metabolite 1′-hydroxysafrole followed by sulfation 
to the ultimate carcinogenic metabolite 1′-sulfooxysafrole (Borchert et al., 1973; Wislocki 
et al., 1976; Wislocki et al., 1977). A second pathway for bioactivation to an electrophilic 
metabolite consists of the formation of 1,2- dihydroxy-4-allylbenzene, which can 
  
subsequently be oxidized to an o-quinone leading to an electrophilic p-quinone methide 
intermediate (Bolton et al., 1994). Figure 2.1 gives a schematic overview of the metabolism 
of safrole presenting these pathways for bioactivation as well as the relevant detoxification 
pathways. Bioactivation of safrole to 1′-hydroxysafrole is catalyzed by cytochromes P450, 
with P450 2A6, P450 D6.1, P450 2C9, P450 2C19 and P450 2E1 being the main P450 
enzymes involved in humans (Jeurissen et al., 2004; Liu et al., 2004; Ueng et al., 2004). 
Sulfation by sulfotransferases (SULTs) converts 1′-hydroxysafrole to 1′-sulfooxysafrole 
which is unstable and spontaneously decomposes to produce an electrophilic carbonium 
cation which can form covalent adducts with cellular macromolecules (Borchert et al., 
1973; Ioannides et al., 1981; Wislocki et al., 1977). A major detoxification pathway of 1′-
hydroxysafrole in rats is the conjugation of 1′-hydroxysafrole with glucuronic acid 
catalyzed by UDP-glucuronosyltransferases (UGTs) resulting in a stable metabolite which 
is excreted in the urine (Benedetti et al., 1977; Stillwell et al., 1974). In humans, however, 
oxidation of the 1′-hydroxy metabolite of the related alkenylbenzene estragole appeared to 
be the major pathway for detoxification of 1′-hydroxyestragole (Punt et al., 2009) and it 
remains to be established whether this species difference in detoxification of the 1′-hydroxy 
metabolite also occurs for safrole. In rats, the oxidation of the 1′-hydroxy metabolite may 
be a minor pathway (Punt et al., 2008).  
Small amounts of 3′-hydroxysafrole as conjugated form have also been detected in the urine 
of rats exposed to safrole, but not in humans (Benedetti et al., 1977). The occurrence of this 
metabolite may arise from isomerization of 1′-hydroxysafrole during glucuronidase 
hydrolysis (Borchert et al., 1973; Stillwell et al., 1974) although others have questioned 
this isomerization and pointed at direct 3′-hydroxylation as a minor metabolic pathway, on 
the basis of the detection in urine of 3,4-methylenedioxybenzoyl glycine and 3,4-
methylenedioxycinnamoyl glycine which would result from oxidation of the side chain of 
3′-hydroxysafrole (Boberg et al., 1986). Swift detoxification of 3′-hydroxysafrole via these 
pathways may explain that the levels of hepatic nucleic acid and protein adducts formed in 
mice upon administration of 3′-hydroxysafrole were much lower than those obtained upon 
administration of 1′-hydroxysafrole (Boberg et al., 1986). 
  
 
 
Figure 2.1. Proposed biotransformation pathways of safrole. 
  
Oxidative dealkylation of the methylenedioxy group of safrole results in the formation of 
1,2-dihydroxy-4-allylbenzene as a major metabolite in rats, guinea pigs and humans 
(Benedetti et al., 1977; Chang et al., 2002; Klungsøyr and Scheline, 1982; Stillwell et al., 
1974), which may be converted by oxidation to quinone metabolites such as 4-allyl-o-
quinone which isomerizes nonenzymatically to a more electrophilic p-quinone methide 
(Bolton et al., 1994). In vitro studies showed that 1,2-dihydroxy-4-allylbenzene induced 
chromosome aberration in Chinese hamster ovaries (CHO-K1) in a dose dependent manner 
(10-50 µM) and increased the frequency of micronuclei up to 3 times at concentration of 40 
µM (Lee-Chen et al., 1996). However, 1,2-dihydroxy-4-allylbenzene can be excreted 
following conjugation at its hydroxyl moieties prior to oxidation to the quinone/quinone 
methide or upon GSH conjugation of its quinone/quinone methide which has been observed 
to occur in rat hepatocytes (Nakagawa et al., 2009). Thus, bioactivation of 1,2-dihydroxy-4-
allylbenzene to its quinone/quinone methide metabolites may be observed especially in 
systems without adequate conjugation possibilities. When such conjugation reactions are 
adequate, such as in vivo, possible adverse effects of 1,2-dihydroxy-4-allylbenzene are 
likely to be limited.  
Another metabolic pathway of safrole is epoxidation of the double bond in the allyl side 
chain yielding 2′,3′-safrole epoxide which is susceptible to hydrolysis by microsomal 
epoxide hydrolase forming 2′,3′-dihydroxysafrole (Ioannides et al., 1981; Klungsøyr and 
Scheline, 1983).  
To predict the extent of bioactivation and detoxification of safrole at low dose levels based 
on experimental data obtained at relatively higher dose levels, it is important to take 
nonlinear effects in toxicokinetics into account when extrapolating from high to low doses. 
The objective of the present study was to build a physiologically based biokinetic (PBBK) 
model providing insight into possible dose dependent changes in safrole metabolism with 
emphasis on detoxification and bioactivation pathways. Kinetics for relevant P450 
mediated oxidation reactions of safrole and conjugation reactions of 1′-hydroxysafrole were 
determined in vitro using tissue fractions of organs that were found to be capable of 
metabolizing safrole or 1′-hydroxysafrole. The kinetic data obtained in vitro were used to 
build a PBBK model for rats which was used to estimate the time and dose dependent 
  
 
formation of the proximate and ultimate carcinogenic metabolites of safrole, 1′-
hydroxysafrole and 1′-sulfooxysafrole in vivo. The performance of the model was 
evaluated by comparison of the predicted level of metabolites formation to the reported 
levels of metabolites excreted in the urine of Wistar rats (Klungsøyr and Scheline, 1983) 
and male Sprague-Dawley rats exposed at different levels of safrole (Benedetti et al., 
1977). The metabolites included in this comparison were 1,2-dihydroxy-4-allylbenzene, 1′-
hydroxysafrole glucuronide and the total urinary excretion of safrole metabolites. 
Materials and methods 
Caution : Safrole, 1′-hydroxysafrole, 1,2-dihydroxy-4-allylbenzene and 1′-oxosafrole are 
carcinogenic compounds which should be treated carefully.  
Materials. Pooled male rat liver microsomes and S9 from Sprague-Dawley were purchased 
from BD Gentest (Worburn,U.S.). Pooled male rat lung, kidney and small intestinal 
microsomes (Sprague-Dawley) were obtained from BioPredic International (Rennes, 
France). Safrole (purity 97%), 2′,3′-dihydroxysafrole (purity 99%), Tris 
(hydroxymethyl)aminomethane, alamethicin (from Trichoderma viride), L-ascorbic acid, 
uridine 5′-diphosphoglucuronide acid (UDPGA) and 3,4-(methylenedioxy) cinnamic acid 
were purchased from Sigma-Aldrich (Steinheim, Germany). β-Glucuronidase and reduced 
(NADPH) and oxidized (NAD+) β-nicotinamide adenin dinucleotide phosphate were 
obtained from Roche Diagnostics (Mannheim, Germany). Glutathione reduced (GSH) and 
dimethyl sulfoxide (DMSO) were purchased from Acros Organic (New Jersey, U.S.). 3′-
Phosphoadenosine-5′-phosphosulphate (PAPS) was obtained from Fluka (Buchs, 
Switzerland). Potassium dihydrogen phosphate, dipotassium hydrogen phosphate 
trihydrate, acetic acid (glacial) and magnesium chloride were purchased from VWR Merck 
(Darmstadt, Germany). Chromatography grade acetonitrile was purchased from Biosolve 
(Valkenswaard, The Netherlands). 1′-Hydroxysafrole was synthesized as described 
previously (Jeurissen et al., 2004) and purified using a preparative thin-layer 
chromatography method with a mobile phase system of a mixture of petroleumbenzene and 
ethylacetate (50:50). The purity of 1′-hydroxysafrole was determined by HPLC to be about 
99%. 3′-Hydroxysafrole was synthesized from 3,4-(methylenedioxy)cinnamic acid as 
  
described previously (Angle et al., 2008) and purified using a preparative thin-layer 
chromatography method with a mobile phase system of petroleumbenzene and ethylacetate 
(50:50). The purity of 3′-hydroxysafrole was determined by HPLC and amounted to about 
97%. 1′-Oxosafrole was synthesized from 1′-hydroxysafrole on the basis of the method 
used for 1′-oxoestragole (Wislocki et al., 1976). 1,2-Dihydroxy-4-allylbenzene was 
synthesized as described previously (Bolton et al., 1994). The purity of 1,2-dihydroxy-4-
allylbenzene was determined by HPLC to be about 95%. 
P450 mediated oxidation of safrole 
Metabolites formed during P450 mediated oxidation of safrole were identified and 
quantified upon the incubation of safrole with pooled male rat (Sprague-Dawley) liver, lung 
and kidney microsomes in the presence of NADPH. The incubations were performed at 
37°C containing 1 mg/mL of microsomal protein, 3 mM NADPH, 1 mM ascorbic acid in 
0.2 M Tris-HCl pH 7.4. After 1 min of preincubation at 37°C the reactions were started by 
adding safrole from a 100 times concentrated stock solutions in DMSO. To identify which 
organs were involved in safrole metabolism the incubations were first performed at 
concentration of 1000 µM. After 20 min the reactions were terminated by adding 40 µL of 
ice-cold acetonitrile to the total incubation volume of 160 µL. All samples were centrifuged 
for 5 min at 16000 g and frozen at -20°C until analysis by HPLC. For determination of the 
kinetic constants for formation of the various P450 mediated oxidation products of safrole 
the same conditions were used, with the final concentration of safrole ranging from 10–
1000 µM, and the final concentration of DMSO being kept constant at 1%. Blank 
incubations were performed without the cofactor NADPH. Under these conditions the 
formation of the different metabolites of P450 mediated oxidation appeared to be linear 
with time and microsomal protein concentration (data not shown). Each experiment 
consisted of three replicates. 
Determination of kinetic constants for glucuronidation of 1′-hydroxysafrole  
Incubations with pooled male rat S9 protein (Sprague-Dawley) were performed to 
determine the kinetic constants (Vmax and Km) for glucuronidation of 1′-hydroxysafrole. The 
  
 
incubation mixtures contained (final concentrations) 10 mM UDPGA, 0.2 mg S9 
protein/mL, 0.2 M Tris-HCl (pH 7.4) and 10 mM MgCl2. Preincubation of the mixture with 
0.025 mg/mL alamethicin added from a 200 times concentrated stock in methanol during 
15 min on ice was applied in order to obtain maximal glucuronidation activity (Fisher et al., 
2000). Preincubation at 37°C for 1 min was performed prior to addition of the substrate 1′-
hydroxysafrole from a 200 times concentrated stock solution in DMSO. After 10 min at 
37°C the reaction was terminated by adding 50 µL of cold acetonitrile to the total 
incubation volume of 200 µL. The samples were centrifuged for 5 min at 16000 g and 
frozen at -20°C until analysis by HPLC. Blank incubations were performed without the 
cofactor UDPGA. Three replicates of each experiment were performed. Formation of 1′-
hydroxysafrole glucuronide was confirmed by performing additional incubations in which 
the samples obtained were treated with β-glucuronidase. For these incubations, 90 µL of 
the sample of a reaction mixture that has not been terminated by the addition of acetonitrile 
was added to 10 µL of 1M potassium phosphate (pH 6.2) and 2 µL of β-glucuronidase 
solution (0.3 units), followed by incubation for 1 h at 37°C. 
Determination of kinetic constants for oxidation of 1′-hydroxysafrole  
The kinetic constants for conversion of 1′-hydroxysafrole to 1′-oxosafrole were analyzed by 
incubations of pooled male rat liver microsomes (Sprague-Dawley) with concentrations of 
1′-hydroxysafrole ranging from 10-4000 µM. The incubation mixtures contained (final 
concentrations) 3 mM NAD+, 2 mM GSH, and 1 mg/mL microsomes in 0.2 M Tris HCl 
(pH 7.4). GSH was added as an agent to trap the formed 1′-oxosafrole and NAD+ was used 
as a cofactor (Punt et al., 2009). Preincubation at 37°C for 1 min was performed prior to 
addition of the substrate 1′-hydroxysafrole. After 10 min at 37°C the reaction was 
terminated by adding 25 µL of cold acetonitrile to the total incubation volume of 100 µL. 
The samples were centrifuged for 5 min at 16000 g and frozen at -20°C until analysis by 
HPLC. Three replicates of each experiment were performed. 
  
Determination of kinetic constants for sulfation of 1′-hydroxysafrole 
The sulfation of 1′-hydroxysafrole was performed using incubations of 1′-hydroxysafrole 
with male rat liver S9 protein of Sprague-Dawley in the presence of GSH as a scavenger of 
the reactive carbocation formed upon decomposition of the unstable 1′-sulfooxysafrole (Al-
Subeihi et al., 2011). The incubation mixtures of 100 µL contained (final concentrations) 
10 mM GSH, 3 mg S9 protein/mL and 0.2 mM PAPS in 0.1 M potassium phosphate (pH 
8.0). Preincubation at 37ºC for 1 min was performed prior to addition of 1′-hydroxysafrole 
from a 100 times concentrated stock solution in DMSO (final concentration 1% DMSO). 
The incubation was terminated after 2 h by addition of 25 µL cold acetonitrile. The samples 
were centrifuged for 5 min at 16000 g and frozen at -20°C until analysis by HPLC. Under 
these condition the formation of the glutathione adduct of the carbocation derived from 1′-
sulfooxysafrole appeared to be linear with time and S9 protein concentration (data not 
shown). Determination of the kinetic constants for the formation of 1′-sulfooxysafrole from 
1′-hydroxysafrole was performed with the same conditions as those described above, with 
the final concentration of 1′-hydroxysafrole ranging from 25-600 µM. Blank incubations 
were performed without GSH or male rat liver S9 protein. Three replicates of each 
experiment were performed. 
Identification and quantification of metabolites of P450 mediated oxidation of safrole, 
and of 1′-hydroxysafrole glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole 
For the quantification of metabolites of P450 mediated oxidation of safrole, aliquots of 50 
µL were analyzed on a Waters M600 HPLC equipped with photodiode array detector 2996 
using an Alltima column C18 5 µm, 150 x 4.6 mm (Grace Alltech, Breda,The Netherlands). 
The gradient was made with ultrapure water and acetonitrile. The flow rate was 1 mL/min, 
starting at 100% ultrapure water and increasing to 15% acetonitrile in 5 min, after which 
the percentage of acetonitrile was increased to 30% and 38% in 20 min and 10 min 
respectively and kept at 38% for 10 min and then increased to 100% over 10 min and kept 
at this level for 5 min, after which the column was re-equilibrated in ultrapure water for 10 
min. Quantification of 2′,3′-dihydroxysafrole and 1′-hydroxysafrole was achieved by 
comparison of the peak areas obtained at a wavelength of 286 nm to the calibration curve of 
  
 
the corresponding synthesized reference compounds. The same method was used for the 
quantification of 3′-hydroxysafrole and 1,2-dihydroxy-4-allylbenzene at a wavelength of 
266 nm and 280 nm respectively.  
For the quantification of 1′-hydroxysafrole glucuronide, aliquots of 50 µL were analyzed on 
a Waters M600 HPLC equipped with a photodiode array detector 2996 using an Alltima 
column C18 5 µm, 150 x 4.6 mm (Grace Alltech, Breda, The Netherlands). The gradient 
was made with ultrapure water containing 0.1% (v/v) acetic acid and acetonitrile. The flow 
rate was 1 mL/min and a gradient was applied from 10% to 25% acetonitrile in 30 min, 
increased to 100% acetonitrile in 2 min and maintained at 100% acetonitrile for 1 min, after 
which acetonitrile was decreased to 10% within 2 min and maintained at this level for 10 
min. Because 1′-hydroxysafrole glucuronide has the same UV spectrum as 1′-
hydroxysafrole it was assumed that it has the same molar extinction coefficient as 1′-
hydroxysafrole. Therefore, quantification was done by comparison of the peak area of 1′-
hydroxysafrole glucuronide obtained at a wavelength of 286 nm to the calibration curve of 
the synthesized 1′-hydroxysafrole at the same wavelength.  
For the quantification of 1′-oxosafrole, aliquots of 50 µL were analyzed on a Waters M600 
HPLC equipped with photodiode array detector 2996 using an Alltima column C18 5 µm, 
150 x 4.6 mm (Grace Alltech, Breda,The Netherlands). The mobile phase was made with 
ultrapure water containing 0.1% (v/v) acetic acid and acetonitrile. The flow rate was 1 
mL/min and a gradient was applied from 0% to 25% acetonitrile over 5 min after which the 
percentage of acetonitrile was kept at 25% for 5 min and then increased to 100% over 3 min 
and kept at 100% for 3 min, after which the column was re-equilibrated in ultrapure water 
containing 0.1% (v/v) acetic acid for 10 min. Detection was performed at 312 nm. 
Quantification of 1′-oxosafrole was performed by means of a calibration curve obtained as 
described previously (Punt et al., 2009). A calibration curve of 1′-oxosafrole was prepared 
by incubating 60 µM synthesized 1′-oxosafrole with increasing concentrations of GSH (0–
20 µM) in 0.2 M Tris-HCl (pH 7.4). The reactions were incubated for 6 h at 37ºC resulting 
in the maximum formation of GS-1′-oxosafrole. The peak area of GS-1′-oxosafrole in the 
chromatograms of these reactions were related to the quantity of GSH used in the reactions, 
  
thus providing the curve for the GSH adduct of 1′-oxosafrole ultimately quantifying the 
formation of 1′-oxosafrole. 
For the quantification of 1′-sulfooxysafrole, aliquots of 3.5 µL were analyzed on a UPLC 
(Ultra Performance Liquid Chromatography)-DAD system consisting of a Waters (Milford, 
MA) Acquity binary solvent manager, sample manager and photodiode array detector, 
equipped with a Waters Acquity UPLC BEH RP 18 column (1.7 µm, 2.1 x 50 mm). The 
gradient eluent consisted of ultrapure water containing trifluoroacetic acid 0.1% (v/v) and 
acetonitrile and the flow rate was 0.6 mL/min. A gradient was applied from 20% to 30% 
acetonitrile over 4.5 min after which the percentage of acetonitrile was increased to 100% 
over 0.3 min and kept at 100% for 0.2 min. Thereafter, the percentage of acetonitrile was 
reduced to its initial value in 0.2 min and kept at this level for 1.5 min. Detection and 
quantification of 1′-sulfooxysafrole were performed at 266 nm. Because the UV-spectrum 
of the GSH adduct of 1′-sulfooxysafrole was similar to the UV-spectrum of 3′-
hydroxysafrole, it was assumed that it has the same molar extinction coefficient as 3′-
hydroxysafrole. Quantification of the GSH adduct of 1′-sulfooxysafrole was therefore 
achieved by comparison of the peak area of the GSH adduct of 1′-sulfooxysafrole in the 
chromatograms obtained at a wavelength of 266 nm to the calibration curve of 3′-
hydroxysafrole at the same wavelength. 
LC-MS analysis of 1′-hydroxysafrole glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole 
Formation of 1′-hydroxysafrole glucuronide in the incubations was verified by LC-MS 
which was performed on an Agilent 1200 HPLC system coupled to a Bruker MicroTOF 
mass spectrometer. Aliquots of 20 µL were separated on an Alltima C18 5 µm, 150 mm x 
2.1 mm (Grace Alltech, Breda, The Netherlands). The gradient eluent was made with 
ultrapure water containing 0.1% (v/v) formic acid (eluent A) and acetonitrile with 0.1% 
(v/v) formic acid (eluent B) and the flow rate was set to 0.2 mL/min. A linear gradient was 
applied from 10% to 25% eluent B over 30 min after which the percentage of eluent B was 
increased to 100% over 2 min and kept at 100% for 1 min. Mass spectrometric analysis was 
in the negative electrospray mode using a spray capillary voltage of 4500 V, a capillary 
temperature of 2000C and nitrogen as nebulizer gas at 8.0 L/min.  
  
 
The nature of GS-1′-oxosafrole in the incubations was verified by LC-MS, which was 
performed on an Agilent 1200 HPLC system coupled to a Bruker MicroTOF mass 
spectrometer. Aliquots of 20 µL (injected volume) were separated on an Alltima C18 5 µm 
column, 150 x 2.1 mm (Grace Altech, Breda, The Netherlands). The gradient was made 
with acetonitrile (eluent B) and ultrapure water (eluent A) both containing 0.1% (v/v) 
formic acid and the flow rate was set to 0.2 mL/min. A linear gradient was applied from 0-
25% eluent B over 5 min and was kept at 25% for 5 min, after which the percentage of 
eluent B was increased to 100% over 2 min. Mass spectrometric analysis was performed in 
positive electrospray mode using a spray capillary voltage of 4500 V, a capillary 
temperature of 2000C and nitrogen as nebulizer gas at 8.0 L/min. 
Formation of the glutathione conjugate of 1′-sulfooxysafrole was verified by LC-MS, 
which was performed on an Agilent 1200 HPLC system coupled to a Bruker MicroTOF 
mass spectrometer. Aliquots of 20 µL (injected volume) were separated on an Alltima C18 
5 µm column, 150 x 2.1 mm (Grace Altech, Breda, The Netherlands). The gradient was 
made with ultrapure water containing 0.1% (v/v) formic acid (eluent A) and acetonitrile 
with 0.1% (v/v) formic acid (eluent B) and the flow rate was set to 0.2 mL/min. The 
percentage of eluent B was kept at 0% for 5 min after which a linear gradient was applied 
from 0% to 10% eluent B over 10 min and a subsequent increase to 30% in another 10 min 
after which the percentage of eluent B was increased to 80% over 10 min and kept at 80% 
for 2 min. Mass spectrometric analysis was in the negative electrospray mode using a spray 
capillary voltage of 4500 V, a capillary temperature of 200°C and nitrogen as nebulizer gas 
at 8.0 L/min. 
Data analysis 
The apparent maximum velocity (Vmax(app)) and apparent Michaelis-Menten constant 
(Km(app)) for the formation of the different P450 mediated oxidation products of safrole, and 
for glucuronidation, oxidation and sulfation of 1′-hydroxysafrole were determined by fitting 
the data to the standard Michaelis Menten equation: v = Vmax*[S]/(Km+[S]). In this equation, 
[S] represents the substrate concentration for P450 mediated oxidation reactions or 1′-
hydroxysafrole for conjugation reactions. Fitting the data to Michaelis Menten equation 
  
was done using GraphPad Prism version 5.03 (GraphPad Software, San Diego California 
U.S.). The values of Vmax and Km were reported in nmole per min per mg microsomal or S9 
protein and µM respectively. Scaling of in vitro data, expressed as nmol/min/mg protein, to 
in vivo data, expressed as µmol/h, was performed as described below for the definition of 
the PBBK model.  
Definition of the PBBK model for safrole metabolism 
A PBBK model was developed to describe the dose dependent kinetic behavior of safrole 
and the formation of its metabolites in male rats. The model was based on a model 
previously defined for estragole (Punt et al., 2008). A schematic presentation of the PBBK 
model used to simulate the metabolism and distribution of safrole in the rat is presented in 
Figure 2.2. The model consists of eight compartments including the liver, lung, and kidney 
as metabolizing compartments, and separate compartments for fat, arterial blood, venous 
blood, richly perfused and slowly perfused tissues. Safrole is assumed to be taken up from 
the gastrointestinal tract following first order kinetics and to be absorbed by the liver 
directly with an absorption constant set at 1.0 h-1. This assumption was based on the fact 
that uptake of the related alkenylbenzene estragole from the gastrointestinal track is known 
to be rapid and complete with an absorption half-life of 0.7 h (Anthony et al., 1987; Punt et 
al., 2008). Metabolism of safrole resulting in the formation of 1′-hydroxysafrole and 3′-
hydroxysafrole was observed in the liver, lung and kidney and therefore described for these 
organs whereas the formation of 2′,3′-dihydroxysafrole (derived from safrole 2′,3′-epoxide) 
and 1,2-dihydroxy-4-allylbenzene was observed and therefore modeled only in the liver 
compartment. The mass balance equations in the PBBK model for time dependent changes 
of safrole in the liver, kidney and lung were as follows: 
Liver:   dALS/dt = dUptakeS/dt 
   +QL*(CAS–CLS/PLS) 
   -Vmax,L_DHS*CLS/PLS/(Km,L_DHS +CLS/PLS) 
   -Vmax,L_1′HS*CLS/PLS/(Km,L_1′HS+CLS/PLS) 
   -Vmax,L_3′HS*CLS/PLS/(Km,L_3′HS+CLS/PLS) 
  
 
   -Vmax,L_DHAB*CLS/PLS/(Km,L_DHAB+CLS/PLS) 
dUptakeS/dt = -dAGIS/dt = Ka*AGIS, AGIS(0)= oral dose  
   CLS = ALS/VL  
Kidney: dAKS/dt = QK*(CAS–CKS/PKS) 
  - Vmax,K_3′HS*CKS/PKS/(Km,K_3′HS+CKS /PKS) 
        CKS = AKS/VK 
Lung:  dALuS/dt = QC*(CVS – CLuS/PLuS) 
  -Vmax,K_3′HS*CLuS/PLuS/(Km,K_3′HS+CLuS/PLuS) 
  -Vmax,K_1′HS*CLuS/PLuS/(Km,K_1′HS+CLuS/PLuS) 
  CLuS = ALuS/VLu 
 
where uptakeS (in µmol) is the amount of safrole taken up from the gastrointestinal tract, 
AGIS (in µmol) is the amount of safrole remaining in the gastrointestinal tract, ATiS (in 
µmol) is the amount of safrole in a tissue (Ti= L (liver), K(kidney) or Lu (lung)). CTiS (in 
µmol/L) is the safrole concentration in a tissue. CAS and CVS are the safrole concentrations 
in the arterial and venous blood (both in µmol/L), QTi (in L/h) is the blood flow rate to a 
tissue, QC (in L/h) is the cardiac output, VTi (in L) is the volume of a tissue, PTis is the 
tissue/blood partition coefficient of safrole and Vmax,Ti_M and Km,Ti_M are the values 
representing the apparent maximum rate and Michaelis-Menten constant for the formation 
of 2′,3′-dihydroxysafrole (DHS), 1′-hydroxysafrole (1′HS), 3′-hydroxysafrole (3′HS), and 
1,2-dihydroxy-4-allylbenzene (DHAB). Formation of 2′,3′-dihydroxysafrole, 3′-
hydroxysafrole and 1,2-dihydroxy-4-allylbenzene from safrole are taken into account but 
no further reaction of these metabolites were modeled. Formation of 1′-hydroxysafrole is 
taken into account in the liver and lung but its further conversion by conjugation reactions 
was only modeled in the liver and not in the lung because formation of this metabolite in 
 
  
 
 
Figure 2.2. Schematic presentation of the physiologically based biokinetic (PBBK) model used to simulate the 
metabolism and distribution of safrole in rat. 
 
the lung was considered too low to require further modeling of its conjugation reactions 
(see Results section). The mass balance equation for 1′-hydroxysafrole in the liver is as 
follows: 
Liver: dAL1′HS /dt = Vmax,L_1′HS * CLS/PLS /(Km,L_1′HS +CLS/PLS) 
      - Vmax,L_1′HSG * CL1′HS/PL1′HS/(Km,L_1′HSG +CL1′HS/PL1′HS) 
      - Vmax,L_1′HOS * CL1′HS /PL1′HS/(Km,L_1′HOS +CL1′HS/PL1′HS) 
      - Vmax,L_1′HSS * CL1′HS /PL1′HS/(Km,L_1′HSS +CL1′HS/PL1′HS) 
   CL1′HS = AL1′HS /VL  
where AL1′HS is the amount of 1′-hydroxysafrole in the liver (in µmol), CL1′HS is the 1′-
hydroxysafrole concentration in the liver (in µmol/L), PL1′HS is the liver/blood partition 
coefficient of 1′-hydroxysafrole and Vmax,L_M and Km,L_M are the apparent maximum rate and 
  
 
Michaelis-Menten constant for the formation in the liver of the various conjugated 
metabolites, including 1′-hydroxysafrole glucuronide (1′HSG), 1′-oxosafrole (1′HOS) and 
1′-sulfooxysafrole (1′HSS).  
The metabolites 2′,3′-dihydroxysafrole, 3′-hydroxysafrole and 1,2-dihydroxy-4-
allylbenzene formed in all organs and 1′-hydroxysafrole glucuronide and 1′-oxosafrole 
formed in the liver were all assumed to be completely excreted in the urine. Transport of 
metabolites from the liver to the kidney and urine was not included in the model. PBBK 
model predictions of the dose dependent formation of the various P450 mediated oxidation 
products of safrole and of the various conjugated metabolites were performed over 72 h.  
The kinetic parameters for the formation of P450 mediated oxidation products of safrole 
and for the glucuronidation, oxidation and sulfation of 1′-hydroxysafrole were determined 
in vitro. The Vmax values for the formation of P450 mediated oxidation products and 
conjugated metabolites obtained from incubations with microsomal liver samples were 
scaled to the liver using a microsomal protein yield of 35 mg/g liver (Medinsky et al., 1994; 
Punt et al., 2008). The Vmax values for metabolites formed in the lung and kidney were 
scaled using a microsomal protein yield of 20 mg/g lung and 7 mg/g kidney (Beierschmitt 
and Weiner, 1986; Medinsky et al., 1994; Punt et al., 2008). The Vmax values for sulfation 
and glucuronidation of 1′-hydroxysafrole were scaled to the liver using an S9 protein yield 
of 143 mg/g liver. 
The physiological parameter values including organ volumes, cardiac output, and blood 
flows were taken from literature (Brown et al., 1997) and are shown in Table 2.1. Partition 
coefficients were estimated from the log Kow based on the method described previously 
(DeJongh et al., 1997). The values of C log P for safrole and 1′-hydroxysafrole were 
calculated with ChemBio3D Ultra 2010 (CambridgeSoft, U.S.) and amounted to 3.18 and 
1.62. Mass balance and differential equations of safrole metabolism were coded and 
simulated with Berkeley Madonna 8.3.14 (Macey and Oster, UC Berkeley, CA, U.S.) using 
the Rosenbrock′s algorithm for stiff system. 
 
  
Sensitivity analysis 
Sensitivity analysis was used to identify the parameters that have the greatest impact on a 
specified model output (DeWoskin, 2007). Normalized sensitivity coefficients (SC) were 
determined according to the following equation: SC = (Cʹ- C)/(P′-P)*(P/C), where C is the 
initial value of the model output, C′ is the modified value of the model output resulting 
from an increase in parameter value, P is the initial parameter value and P′ is the modified 
parameter value (Evans and Andersen, 2000; Garg and Balthasar, 2007; Tardif et al., 2002). 
On the basis of literature data (Punt et al., 2008), an increase of 5% in parameter values was 
chosen to analyze the effect of a change in parameter on the formation of 1,2-dihydroxy-4-
allylbenzene, 1′-hydroxysafrole, 1′-hydroxysafrole glucuronide, 1′-oxosafrole and 1′-
sulfooxysafrole (expressed as % of dose over 72 h). The final coefficients were calculated 
using Excel (Excel 2007, Microsoft Corporation, WA). 
Table 2.1. Parameters used in the physiologically based biokinetic model for safrole in rat  
Physiological parametersa Tissue: blood partition coefficientsb 
body weight (kg)   0.25   
percentage of body weight  safrole   
  liver   3.4   liver   2.50 
  lungs   0.5   lung   2.50 
  kidney   0.7   kidney   2.50 
  fat   7.0   fat  80.75 
  rapidly perfused   4.4   rapidly perfused   2.50 
  slowly perfused  67.6   slowly perfused   0.82 
  arterial blood   1.85 1′-hydroxysafrole   
  venous blood   5.55   liver   1.13 
                                    
cardiac output (L/h/kg bw0.74 ) 
 
15.0   
percentage of cardiac output    
liver  25.0   
kidney  14.1   
fat   7.0   
rapidly perfused  36.9   
slowly perfused  17.0   
a
 Brown et al. (1997)  
b DeJongh et al. (1997)  
  
 
Comparison of PBBK model based predictions for safrole to the PBBK model based 
predictions for the related alkenylbenzenes estragole and methyleugenol 
The PBBK model based predictions obtained for safrole were compared to those obtained 
with previously developed PBBK models for the related alkenylbenzenes estragole and 
methyleugenol (Al-Subeihi et al., 2011; Punt et al., 2008). To this end, the three PBBK 
models were run to obtain i) the predicted time dependent concentration of alkenylbenzenes 
in the liver and ii) the dose dependent formation of the respective 1′-hydroxy metabolites, 
the 1′-hydroxy glucuronide metabolites, the 1′-oxo metabolites, and the 1′-sulfooxy 
metabolites of estragole, methyleugenol, and safrole. For the dose dependent prediction of 
metabolite formation the PBBK models were run from dose levels of 0.0001 mg/kg bw up 
to 1000 mg/kg bw, and for 24 h in the case of estragole and methyleugenol and 72 h in the 
case of safrole.  
Results 
P450 mediated oxidation of safrole  
HPLC analysis of incubations with rat liver, lung, kidney and small intestine microsomes in 
the presence of safrole as substrate and NADPH as cofactor reveals that P450 mediated 
conversion of safrole only occurs in incubations with rat liver, lung and kidney (Figure 2.3), 
whereas no conversion of safrole was found in incubations with male rat small intestinal 
microsomes (data not shown). The metabolites formed in incubations with rat liver 
microsomes are 2′,3′-dihydroxysafrole, 1′-hydroxysafrole, 3′-hydroxysafrole and 1,2-
dihydroxy-4-allylbenzene (Figure 2.3A). The HPLC chromatograms of incubations of rat 
lung microsomes revealed the formation of 3′- hydroxysafrole and 1′-hydroxysafrole 
(Figure 2.3B) and those of kidney microsomes the formation of 3′-hydroxysafrole (Figure 
2.3C). These metabolites were identified on the basis of the similarity of their UV spectrum 
and retention time compared to the UV spectrum and retention time of synthesized or 
commercially available reference compounds. Under the conditions applied the retention 
time for 2′,3′-dihydroxysafrole, 1′-hydroxysafrole, 3′-hydroxysafrole and 1,2-dihydroxy-4-
allylbenzene were 17, 28, 29, and 30 min respectively. In these microsomal incubations, 
safrole 2′,3′-oxide was not detected because of its swift hydrolysis by microsomal epoxide 
  
hydrolase to 2′,3′-dihydroxysafrole (Delaforge et al., 1980; Guenthner and Luo, 2001; Luo 
et al., 1992; Stillwell et al., 1974).Formation of 3′-hydroxysafrole was shown to result 
directly from safrole metabolism and not from the isomerization of 1′-hydroxysafrole since 
incubation of 1′-hydroxysafrole with liver microsomes and the cofactor NADPH did not 
result in the formation of 3′-hydroxysafrole (data not shown). 
The formation of 1′-hydroxysafrole in incubations with liver microsomes is higher than that 
in incubations with lung microsomes while in the incubations with kidney microsomes no 
formation of 1′-hydroxysafrole was observed. The data indicate that extrahepatic P450 
mediated oxidation contributes to a minor extent to the overall P450 mediated oxidation of 
safrole. 
 
Figure 2.3. HPLC chromatograms of incubations of safrole with male rat (A) liver, (B) lung, and (C) kidney 
microsomes at a substrate concentration of 1000 µM and NADPH as a cofactor. The peaks marked with an 
asterisk were also present in the blank incubations without NADPH. 
Kinetics of P450 mediated oxidation of safrole 
Figure 2.4A shows the rate of formation of 2′,3′-dihydroxysafrole, 1′-hydroxysafrole, 3′-
hydroxysafrole and 1,2-dihydroxy-4-allylbenzene in incubations with male rat liver 
  
 
microsomes and increasing concentrations of safrole (10-1000 µm). Similar experiments 
were performed for lung and kidney microsomes (500-4000 µM) (Figure 2.4B and 2.4C). 
Table 2.2 presents the apparent Km and Vmax values obtained from these plots and the 
catalytic efficiencies (Vmax/Km) derived from them.  
 
 
Figure 2.4. Safrole concentration dependent rate of formation of P450 metabolites in incubations with rat (A) liver, 
(B) lung, and (C) kidney microsomes and NADPH as a cofactor. In the plots each point represents the mean (+ 
SD) of three replicates corresponding to the formation of 2′,3′-dihydroxysafrole (•), 1′-hydroxysafrole (), 3′-
hydroxysafrole () and 1,2-dihydroxy-4-allylbenzene (). 
 
The results obtained reveal that with male rat liver microsomes 1,2-dihydroxy-4-
allylbenzene is the major metabolite formed, followed by 1′-hydroxysafrole, 3′-
hydroxysafrole and 2′,3′-dihydroxysafrole. The catalytic efficiency for the formation of 1,2-
dihydroxy-4-allylbenzene, resulting from O-dealkylation is about 8 fold higher than that for 
the formation of 1′-hydroxysafrole. 
The results obtained with male rat lung microsomes reveal that 1′-hydroxysafrole is the 
most abundant metabolite formed in the lung (Figure 2.4B). In the lung, the apparent Vmax 
for the formation of 1′-hydroxysafrole is about 2.5 times lower than the apparent Vmax for 
  
the formation of 3′-hydroxysafrole whereas the apparent Km is about 22 times lower. 
Overall, the catalytic efficiency for the formation of 1′-hydroxysafrole by male rat lung 
microsomes is about 8 times higher than that the catalytic efficiency for the formation of 3′-
hydroxysafrole. 
The results obtained with male rat kidney microsomes reveal that only 3′-hydroxysafrole is 
formed (Figure 2.4C). The apparent Vmax, Km and catalytic efficiency calculated as the 
apparent Vmax/Km of 3′-hydroxysafrole were 3067 µM, 0.1 nmol/ min/mg microsomal 
protein and 0.03 µL/min/mg microsomal protein
 
respectively.  
The relatively large variations in the kinetic values for formation of 3′-hydroxysafrole are 
mainly caused by the fact that 3′-hydroxysafrole was also formed in the blank incubations 
without co-factor NADPH. Correcting the amount of 3′-hydroxysafrole formed in full 
incubations for the amount formed in the blank, contributed to the experimental variation.  
 
Table 2.2. The kinetic parameters for P450 mediated oxidation of safrole in incubations 
with liver, lung and kidney microsomes from male Sprague-Dawley rats 
Organ Metabolite Km (app)  
(µM)a 
Vmax (app) 
(nmol/min/mg 
microsomal 
protein)a  
  
In vitro catalytic 
efficiency 
(Vmax(app) /Km(app)) 
(µL/min/mg 
microsomal 
protein)  
Scaled 
Vmax, in vivo 
(µmol/h) 
 
In vivo 
catalytic 
efficiency 
(scaled 
Vmax, in 
vivo/Km (app) 
(L/h) 
Liver 2′,3′-
dihydroxysafrole 149 ± 46 0.12±0.02 0.81 2.14
b
  0.014 
1′-hydroxysafrole 497 ± 190  0.40 ± 0.09 0.81  7.2 b 0.015 
3′-hydroxysafrole 546 ± 370  0.33 ±0.17  0.61 5.9 b 0.011 
1,2-dihydroxy-4-
allylbenzene  313 ±27 2.1 ±0.49  6.7 37.5
b
 0.12 
Lung 1′-hydroxysafrole 159 ±66  0.04 ±0.003 0.25 0.06c 4.10-4 
3′-hydroxysafrole 3573 ±2152  0.1 ± 0.03 0.03 0.15c 4.10-5 
Kidney 3′-hydroxysafrole 3067±1966 0.1 ± 0.015  0.03 0.07d 2.10-5 
 
a
 The values are mean + SD of three independent determinations  
b Vmax (app) /(1000 nmol/µmol)*(60 min/h)*(35 mg microsomal protein/g liver)*(34 g liver/kg bw)*(0.25 kg bw) 
c
 Vmax (app) /(1000 nmol/µmol)*(60 min/h)*(20 mg microsomal protein/g lung)*(5 g lung/kg bw)*(0.25 kg bw) 
d
 Vmax (app) /(1000 nmol/µmol)*(60 min/h)*(7 mg microsomal protein/g kidney)*(7 g kidney/kg bw)*(0.25 kg bw) 
 
  
 
Comparing the in vivo catalytic efficiencies for the formation of P450 mediated metabolites 
in different organs shows that in the male rat conversion of safrole is most efficiently 
catalyzed in the liver with 1,2-dihydroxy-4-allylbenzene as the most abundant metabolite. 
The in vivo catalytic efficiency for the formation of the proximate carcinogenic metabolite 
1′-hydroxysafrole is approximately 9% of the total catalytic efficiency of the liver. 
Glucuronidation of 1′-hydroxysafrole 
An HPLC chromatogram of an incubation of male rat liver S9 with 1′-hydroxysafrole as the 
substrate and UDPGA as cofactor to study glucuronidation of 1′-hydroxysafrole is 
presented in Figure 2.5A. Formation of a single metabolite eluting at a retention time of 24 
min was observed. Treatment of the sample with β-glucuronidase resulted in complete 
elimination of this metabolite and a concomitant increase in the intensity of the peak of 1′-
hydroxysafrole, revealing that the metabolite formed corresponds to the glucuronosyl 
conjugate of 1′-hydroxysafrole.  
Furthermore, the spectrum of the metabolite obtained by LC-MS reveals a deprotonated 
molecule at m/z 353, which corresponds to the theoretically expected mass and confirms 
that the metabolite corresponds to 1′-hydroxysafrole glucuronide. 
Kinetics of glucuronidation of 1′-hydroxysafrole 
Figure 2.5B shows the rate of glucuronidation of 1′-hydroxysafrole with a substrate 
concentration increasing from 5-1000 µM. Kinetic constants obtained from this graph 
included an apparent Vmax amounting to 25 nmol/min/mg S9 protein and an apparent Km 
value of 101 µM. The catalytic efficiency for glucuronidation of 1′-hydroxysafrole 
(Vmax/Km) is 248 µL/min/mg S9 protein (Table 2.3). 
Oxidation of 1′-hydroxysafrole  
Figure 2.6A shows the HPLC chromatogram of an incubation of 1′-hydroxysafrole with 
male rat liver microsomes and NAD+ as cofactor and GSH as a trapping agent. Formation 
of a single metabolite with a retention time of 12 min was observed. On the basis of LC-MS 
analysis, the metabolite could be identified as 1′-GS-oxosafrole because the spectrum 
  
reveals a deprotonated molecule at m/z 484 which corresponds to the theoretically expected 
mass. 
Kinetics of oxidation of 1′-hydroxysafrole  
Figure 2.6B shows the rate of oxidation of 1′-hydroxysafrole with increasing substrate 
concentrations ranging from 10-4000 µM. The data obtained revealed an apparent Vmax of 
5.9 nmol/min/mg microsomal protein and an apparent Km of 1809 µM. 
Comparison of the kinetic constants for the oxidation of 1′-hydroxysafrole with those for 
the glucuronidation of 1′-hydroxysafrole that were scaled to the in vivo situation (Table 
2.3) reveals that the catalytic efficiency for the formation of 1′-oxosafrole was about 300 
times lower than those for the formation of 1′-hydroxysafrole glucuronide. 
 
Figure 2.5 HPLC chromatogram of an incubation of 1′-hydroxysafrole (1 mM) with male rat liver S9 in the 
presence of UDPGA as a cofactor (A) and 1′-hydroxysafrole concentration dependent rate of formation of 1′-
hydroxysafrole glucuronide (B). In the plot each point represents the mean (+ SD) of three replicates. 
  
 
 
Figure 2.6. HPLC chromatogram of an incubation of 1′-hydroxysafrole (1 mM) with male rat liver microsomes in 
the presence of NAD+ as a cofactor and GSH as a trapping agent (A) and 1′-hydroxysafrole concentration 
dependent rate of formation of 1′-oxosafrole (B). In the plot each point represents the mean (+ SD) of three 
replicates. 
Table 2.3. Kinetic parameters for conjugation reactions of 1′-hydroxysafrole in incubations 
with liver microsomes and S9 protein from male Sprague-Dawley rats 
 
Organ Metabolite Km (app)  
(µM)a 
Vmax (app) 
(nmol/min/
mg 
microsomal 
or S9 
protein)a 
 
In vitro catalytic 
efficiency  
(Vmax (app)/Km (app)) 
(µL/min/mg 
microsomal or S9 
protein) 
Scaled 
Vmax, invivo 
(µmol/h)  
In vivo catalytic 
efficiency (scaled 
Vmax, in vivo/Km (app)) 
(L/h) 
Liver 
1′-hydroxysafrole 
glucuronide 101±62 25±5.7 248 1823
b 18 
1′-oxosafrole  1809±87 5.9±1.4 3.2 105c 0.06 
1′-sulfooxysafrole  127±19 0.03+ 0.002 0.24 2.12b 0.017 
 
a The values are mean + SD of three independent determinations 
bVmax (app) /(1000 µmol/nmol)*(60 min/h)*(143 mg S9 protein/g liver)*(34 g liver/kg bw)*(0.25 kg bw) 
c Vmax (app) /(1000 µmol/nmol)*(60 min/h)*(35 mg microsomal protein/g liver)*(34 g liver/kg bw)*(0.25 kg bw) 
 
 
Sulfation of 1′-hydroxysafrole  
Figure 2.7A shows the UPLC chromatogram of an incubation of 1′-hydroxysafrole with 
male rat liver S9 using PAPS as cofactor and GSH as trapping agent for the reactive 
carbocation derived from the unstable 1′-sulfooxysafrole metabolite. Formation of a single 
  
metabolite with a retention time of 1.23 min was observed. HPLC analysis of incubations 
of 1′-sulfooxysafrole in the absence of GSH and in the presence of S9 protein and PAPS 
revealed no peak formation at 1.23 min (chromatogram data not shown). This argument 
was used to confirm the formation of the GSH adduct of the carbocation of 1′-
hydroxysafrole and thus an indirect detection of the formation of 1′-sulfooxysafrole in the 
complete incubation.  
Furthermore, the spectrum of the metabolite obtained by LC-MS analysis of this metabolite 
reveals a deprotonated molecule at m/z 468 which corresponds to the theoretically expected 
mass and confirms that the metabolite corresponds to the GSH adduct of the carbocation 
formed from 1′-sulfooxysafrole.  
 
 
Figure 2.7. Figure 2.7. UPLC chromatogram of an incubation of 1′-hydroxysafrole (1 mM) with male rat liver S9 
homogenates in the presence of PAPS as a cofactor and GSH as a trapping agent (A) and 1′-hydroxysafrole 
concentration dependent rate of formation of 1′-sulfooxysafrole (B). In the plot each point represents the mean (+ 
SD) of three replicates. 
Kinetics of sulfation of 1′-hydroxysafrole  
Figure 2.7B shows the rate of sulfation of 1′-hydroxysafrole with a substrate concentration 
increasing from 25-600 µM. The data obtained revealed an apparent Vmax of 0.03 
nmol/min/mg S9 protein and an apparent Km of 127 µM. The catalytic efficiency for the 
sulfation of 1′-hydroxysafrole (Vmax/Km) is 0.24 µL/min/mg S9 protein. 
  
 
Comparison of the kinetic constants for sulfation of 1′-hydroxysafrole with those for 
glucuronidation and oxidation of 1′-hydroxysafrole that were scaled to the in vivo situation 
(Table 2.3) reveals that the catalytic efficiency for formation of 1′-sulfooxysafrole was 
about 1058 times and 3.5 times lower than those for the formation of 1′-hydroxysafrole 
glucuronide and 1′-oxosafrole respectively. 
Altogether, it can be concluded that in the male rat liver, glucuronidation is the major 
pathway for the conversion of 1′-hydroxysafrole followed by oxidation and sulfation of 1′-
hydroxysafrole to 1′-sulfooxysafrole is a minor pathway. 
Performance of the PBBK model 
The PBBK model defined when incorporating all of the kinetic constants and parameters 
defined (Tables 2.1, 2.2 and 2.3) was used to predict time and dose dependent safrole 
metabolism at low and high dose levels. To this end dose levels of 0.05 and 300 mg/kg bw 
were chosen to allow for the comparison with the outcomes obtained previously using the 
PBBK model for estragole (Punt et al., 2008).  
The PBBK model predicts that at doses ranging from 0.05 to 300 mg/kg bw about 99% of 
the metabolism of safrole takes place in the liver. The major metabolites of safrole formed 
in the liver are 1,2-dihydroxy-4-allylbenzene and 1′-hydroxysafrole which were formed for 
respectively 100% and 99% in the liver amounting to ~74% and ~10% of the dose within 
the dose-range of 0.05-300 mg/kg bw. Extrahepatic conversion of safrole did not contribute 
significantly to the overall formation of these metabolites.  
Performance of the constructed PBBK model was evaluated by comparison of the predicted 
total metabolite formation to the reported total urinary excretion of safrole metabolites as a 
percentage of the dose in male Sprague-Dawley rats exposed to different levels of safrole 
(Benedetti et al., 1977) and by comparison of the percentage of the dose predicted to be 
excreted as 1′-hydroxysafrole glucuronide and 1,2-dihydroxy-4-allylbenzene in the urine as 
compared to the actual reported level of excretion of these metabolites in the urine of 
Wistar rats upon intragastrical administration of safrole at a dose level of 162 mg/kg bw 
(Klungsøyr and Scheline, 1983).  
  
Figure 2.8 shows the comparison between the PBBK predicted and the reported 
experimental data on the level of total safrole metabolites excreted in urine at different oral 
dose levels of safrole. At a dose level of 0.63 mg/kg bw, the PBBK model-predicted 
percentage of the dose excreted as metabolites and the actual percentage excreted in an in 
vivo rat experiment (Benedetti et al., 1977) are similar (Figure 2.8A). At 6 h postdosing, 
the PBBK model predicted the percentage of the dose excreted as safrole metabolites to 
amount to 51% and the experimental value reported in the literature (Benedetti et al., 1977) 
amounted to 45%, whereas at 12 hours these values amount to respectively 67 and 78% of 
the dose. At a dose of 60 mg/kg bw (Figure 2.8B) only limited experimental data are 
available, but the three data points reported amount to values of 18%, 78% and 85% of the 
dose, values that match the predicted values relatively well since these amount to 46%, 
84% and 97% of the dose. At a dose of 745 mg/kg bw, (Figure 2.8C) deviation between the 
PBBK predicted levels of excretion and the actually observed levels of excretion are 
somewhat larger especially in the first hour after dosing where the predicted levels are 6.5 
fold higher than the measured levels, although at 24 h or more upon dosing the predicted 
levels again match the experimental levels well and amount to values that were only 1.1- 
2.3 fold higher than the reported levels.  
 
 
Figure 2.8. PBBK predicted (x) and reported (•) (Benedetti et al., 1977) percentage of the safrole dose excreted as 
urinary metabolites at oral dose levels of (A) 0.63 mg/kg bw (B) 60 mg/kg bw, and (C) 745 mg/kg bw.  
  
 
The model was also evaluated by comparing the PBBK model based prediction for the 
percentage of the dose excreted as 1′-hydroxysafrole glucuronide and 1,2-dihydroxy-4-
allylbenzene to the values reported in a study in which Wistar rats were exposed to 162 
mg/kg bw safrole (Klungsøyr and Scheline, 1983). Figure 2. 9 shows that the model 
accurately predicts the percentage of 1,2-dihydroxy-4-allylbenzene excreted in urine. The 
predicted formation of 1,2-dihydroxy-4-allylbenzene 24, 48 and 72 h after oral dosing was 
60%, 72% and 74% of the dose, respectively, whereas the levels actually measured 
amounted to 58%, 70% and 72% respectively. The PBBK model prediction for the 
formation of 1′-hydroxysafrole glucuronide 24, 48 and 72 h upon dosing are 2-2.5 times 
higher than reported levels but within the same order of magnitude (Figure 2.9). Predicted 
levels of 1′-hydroxysafrole glucuronide amounted to 7.9%, 9.3% and 9.6% of the dose 
respectively whereas the reported levels amounted to 3.9%, 4.0% and 4.0%. 
 
Figure 2.9. PBBK predicted formation of 1,2-dihydroxy-4-allylbenzene (), and 1′-hydroxysafrole glucuronide 
() compared to experimental data reported for formation of 1,2-dihydroxy-4-allylbenzene (), and 1′-
hydroxysafrole glucuronide () in rats exposed to 162 mg/kg bw safrole (Klungsøyr and Scheline, 1983). 
 
 
 
 
 
  
Model predictions 
In a next step, the PBBK model was used to predict the concentration of safrole and 1′-
hydroxysafrole and the further metabolism of 1′-hydroxysafrole to 1′-hydroxysafrole 
glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole in the liver. The PBBK model-predicted 
time dependent concentration of safrole and 1′-hydroxysafrole and the formation of 1′-
hydroxysafrole glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole in male rat liver upon 
exposure to 0.05 or 300 mg/kg bw of safrole are presented in Figure 2.10. At a dose 0.05 
mg/kg bw the maximum concentration of safrole and 1′-hydroxysafrole were predicted to 
be achieved within less than 1 h while full conversion of safrole and maximal overall 
formation of 1′-hydroxysafrole glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole were 
predicted to be achieved within 48 h. The maximum concentrations of safrole and 1′-
hydroxysafrole and the overall formation of 1′-hydroxysafrole glucuronide, 1′-oxosafrole 
and 1′-sulfooxysafrole are 0.23, 0.00008, 0.8, 0.0026 and 0.0007 nmol/g liver respectively. 
Formation of 1′-hydroxysafrole glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole 
corresponds to 8.9%, 0.03% and 0.008% of the dose respectively. 
PBBK model predictions at a dose of 300 mg/kg bw reveal that safrole and 1′-
hydroxysafrole were metabolized completely after 72 h and that the maximum 
concentrations of safrole and 1′-hydroxysafrole were obtained within 1 h with values of 
1700 and 0.256 nmol/g liver, respectively (Figure 2.10B). The formation of 1′-
hydroxysafrole glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole was predicted to amount 
to 5370, 17.4 and 5.1 nmol/g liver which corresponds to 9.9%, 0.03% and 0.009% of the 
dose, respectively. These percentages were similar to the percentages of formation 
predicted at a dose level of 0.05 mg/kg bw. 
  
 
 
 
Figure 2.10. PBBK model predicted time dependent concentration (nmol/g liver) of safrole and 1′-hydroxysafrole 
and formation of 1′-hydroxysafrole glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole at a dose level of (A) 0.05 
mg/kg bw safrole and (B) 300 mg/kg bw safrole. 
The PBBK model based predictions for the percentage of safrole metabolized to the various 
P450 metabolites at increasing oral doses of safrole are presented in Figure 2.11. At a dose 
of 0.05 mg/kg bw the percentage of safrole metabolized to 2′,3′-dihydroxysafrole, 1′-
hydroxysafrole, 3′-hydroxysafrole and 1,2-dihydroxy-4-allylbenzene was, respectively, 
8.9%, 9.1%, 6.7%, and 74.5% of the dose. When the dose was increased to 300 mg/kg bw, 
approximately 6.9%, 10.0%, 7.7% and 74.0% of the dose was predicted to be metabolized 
to 2′,3′-dihydroxysafrole, 1′-hydroxysafrole, 3′-hydroxysafrole and 1,2-dihydroxy-4-
  
allylbenzene respectively. These results reveal that 1,2-dihydroxy-4-allylbenzene is the 
major metabolite at low but also at high dose levels. When the dose increases the relative 
formation of 2′,3′-dihydroxysafrole decreased only to a limited extent from 8.9% at a dose 
0.05 mg/kg bw to approximately 6.9% of the dose at a dose 300 mg/kg bw while the 
percentage formation of 1′-hydroxysafrole and 3′-hydroxysafrole tended to increase also 
only to a limited extent from values amounting to, respectively, 9.1% and 6.7% of the dose 
at 0.05 mg/kg bw to values of, respectively, 10.0% and 7.7% of the dose at 300 mg/kg 
bw/day. Overall, the results presented in Figure 2.11 reveal that for safrole a dose 
dependent shift in P450 mediated oxidation leading to a relative increase in bioactivation at 
higher dose levels, is not observed. This can be explained by the fact that for P450 
mediated oxidation of safrole no saturation of an important metabolic route occurs in a dose 
range from 0.05 up to 300 mg/kg bw/day. 
 
Figure 2.11. PBBK predicted dose dependent changes in overall formation of P450 metabolites in all organs. The 
lines correspond to 2′,3′-dihydroxysafrole (••••), 1′-hydroxysafrole (▬ ▬ ), 3′-hydroxysafrole (▬▬), and 1,2-
dihydroxy-4-allylbenzene (▬ • ▬).  
Sensitivity analysis  
A sensitivity analysis was performed to identify the key parameters that influence the 
formation of 1,2-dihydroxy-4-allylbenzene, 1′-hydroxysafrole, 1′ hydroxysafrole 
glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole.  
  
 
Figure 2.12A presents that at both dose levels analyzed, 0.05 and 300 mg/kg bw, the 
formation of 1,2-dihydroxy-4-allylbenzene is influenced by the kinetic constants for its 
formation from safrole (Vmax,L_DHAB and Km,L_DHAB).  
Figure 2.12B presents the sensitivity analysis for 1′-hydroxysafrole formation. Formation of 
1′-hydroxysafrole is predicted to be mostly affected by the kinetic constants for its 
formation from safrole (Vmax,L_1′HS and Km,L_1′HS) and kinetic constants for the formation of 
1,2-dihydroxy-4-allylbenzene (Vmax,L_DHAB and Km,L_DHAB). 
Figure 2.12C shows the results of the sensitivity analysis on the kinetic parameters which 
influence the formation of 1′-hydroxysafrole glucuronide. Glucuronidation of 1′-
hydroxysafrole was affected by the kinetic constants for formation of 1′-hydroxysafrole 
(Vmax,L_1′HS, Km,L_1′HS) and the kinetic constants for formation of 1,2-dihydroxy-4-
allylbenzene (Vmax,L_DHAB and Km,L_DHAB).  
Figure 2.12D reveals that oxidation of 1′-hydroxysafrole was affected by the kinetic 
constants for formation of 1′-hydroxysafrole (Vmax,L_1′HS and Km,L_1′HS), for glucuronidation 
of 1′-hydroxysafrole (Vmax,L_1′HSG and Km,L_1′HSG), for oxidation of 1′-hydroxysafrole 
(Vmax,L_1′HOS and Km,L_1′HOS), the kinetic constants for formation of 1,2-dihydroxy-4-
allylbenzene (Vmax,L_DHAB and Km,L_DHAB), the yield of microsomal liver protein (MPL), and 
the yield of S9 protein (S9PL). 
Figure 2.12E reveals that sulfation of 1′-hydroxysafrole was affected by the kinetic 
constants for the formation of 1′-hydroxysafrole (Vmax,L_1′HS and Km,L_1′HS), the kinetic 
constants for the formation of 1,2-dihydroxy-4-allylbenzene (Vmax,L_DHAB and Km,L_DHAB), 
for the glucuronidation of 1′-hydroxysafrole (Vmax,L_1′HSG and Km,L_1′HSG), and for the 
sulfation of 1′-hydroxysafrole (Vmax,L_1′HSS and Km,L_1′HSS).  
Comparison of the PBBK model based predictions for safrole to the PBBK model 
based predictions for the related alkenylbenzenes estragole and methyleugenol 
Figure 2.13A shows that at a dose of 0.05 mg/kg bw, safrole was metabolized within 48 h 
which is longer than the 5 and 15 h predicted previously by the related PBBK models for 
estragole and methyleugenol respectively (Al-Subeihi et al., 2011; Punt et al., 2008). At a 
  
dose of 300 mg/kg bw, safrole was predicted to be metabolized within 72 h whereas the 
corresponding values for estragole and methyleugenol amounted to respectively 15 and 20 
h (Figure 2.13B). 
Using these PBBK models for predicting bioactivation and detoxification of estragole, 
methyleugenol and safrole the relative time and dose dependent formation of the proximate 
carcinogenic 1′-hydroxy metabolites and also of the 1′-hydroxy glucuronide and the 
ultimate carcinogenic reactive and unstable 1′-sulfooxy metabolites of the three model 
alkenylbenzenes can be obtained. Figure 2.14 presents the formation of these metabolites 
for the three alkenylbenzenes as predicted by the respective PBBK models. Figure 2.14A 
and 14B show that formation of the 1′-hydroxy metabolite and 1′-hydroxy glucuronide for 
the three alkenylbenzenes are very similar. Figure 2.14C shows that the formation of 1′-
oxomethyleugenol is predicted to be approximately less than 20-fold higher than the 
formation of 1′-oxoestragole and 1′-oxosafrole. Figure 2.14D reveals that the formation of 
the unstable reactive 1′-sulfooxy metabolite in the liver of male rat is predicted to vary less 
than 6-fold for the three alkenylbenzenes, being highest for methyleugenol, mainly because 
of additional differences in the catalytic efficiency of the conversion of the 1′-hydroxy 
metabolites in the various conjugation reactions. The data obtained also reveal that for all 
three alkenylbenzenes the formation of the ultimate carcinogenic 1′-sulfooxy metabolite 
increases linearly with the dose up to dose levels of at least 100 mg/kg bw and that the 
overall conversion of safrole is slower than that of estragole and methyleugenol taking 
about 72 instead of 24 h for full conversion. This can be explained by the fact that for P450 
mediated oxidation of safrole, in contrast to that of estragole and methyleugenol, no 
saturation of an important metabolic route occurs in a dose range from 0.05 up to 300 
mg/kg bw/day. 
  
 
 
Figure 2.12. Sensitivity of the predicted formation of (A) 1,2-dihydroxy-4-allylbenzene, (B) 1′-hydroxysafrole, (C) 
1′-hydroxysafrole glucuronide, (D) 1′-oxosafrole, and (E) 1′-sulfooxysafrole to different model parameters. White 
bars correspond to the normalized sensitivity coefficients at a dose of 0.05 mg/kg bw and black bars at a dose of 
300 mg/kg bw. S9PL = Liver S9 protein yield, MPL = Liver microsomal protein yield, Vmax and Km are the 
maximum rate of formation and the Michaelis-Menten constant for the formation of the different metabolites in 
the liver: 1′-hydroxysafrole (1′HS), 1,2-dihydroxy-4-allylbenzene (DHAB), 1′-hydroxysafrole glucuronide 
(1′HSG), 1′-oxosafrole (1′HOS), and 1′-sulfooxysafrole (1′HSS). 
  
 
Figure 2.13. PBBK model predicted time dependent concentration (nmol/g liver) of estragole (▬▬), 
methyleugenol (▬ ▬ ), and safrole (••••) at a dose level of (A) 0.05 mg/kg bw and (B) 300 mg/kg bw 
 
 
Figure 2.14. PBBK predicted dose dependent formation of (A) the 1′-hydroxy metabolite, (B) 1′-hydroxy 
glucuronide, (C) 1′-oxo metabolite, and (D) 1′-sulfooxy metabolite of estragole (▬▬▬), methyleugenol (▬ ▬ 
▬), and safrole (••••) in male rat liver (Sprague-Dawley) after 24 h in case of estragole and methyleugenol and 72 
h in case of safrole (Al-Subeihi et al., 2011; Punt et al., 2008). 
  
 
Discussion 
In the present study, a PBBK model was developed that allowed for the evaluation of 
bioactivation and detoxification of safrole at different oral dose levels in male rats. The 
advantages of PBBK models over in vivo or in vitro experiments are that PBBK models 
provide more insight into which tissues are involved, provide insight into the formation and 
distribution of metabolites in the various tissues of interest, allow predictions of the 
formation of the proximate and ultimate reactive unstable carcinogenic metabolite(s) and 
provide insight into the dose levels at which deviation from linear kinetics for bioactivation 
and detoxification might occur.  
The performance of the newly developed PBBK model was evaluated by comparison of the 
predicted levels of metabolite formation to levels reported in the literature. A first 
experimental data set available reported levels for the formation of total safrole metabolites 
detected in the urine of Sprague-Dawley rats exposed to three different oral doses of safrole 
(Benedetti et al., 1977). The model predicted the time dependent formation of safrole 
metabolites relatively well especially at dose levels of 0.63 and 60 mg/kg bw. A second 
experimental data set available for the evaluation of model performance reported time 
dependent excretion of 1,2-dihydroxy-4-allylbenzene and 1′-hydroxysafrole as 1′-
hydroxysafrole glucuronide, in the urine of Wistar rats exposed to 162 mg/kg bw safrole 
(Klungsøyr and Scheline, 1983). The model predicted the formation of these two 
metabolites at levels amounting to, respectively, 74% and 10% of the dose, whereas the 
percentages experimentally observed amounted to respectively 72% and 4 % of the dose. 
Thus, the model appeared to accurately predict the biotransformation for safrole generally 
within 2-fold variation. Part of the deviations observed may be due to the fact that our 
PBBK model was developed using tissue samples from Sprague-Dawley rats, whereas the 
literature data were obtained with, respectively, Sprague-Dawley (Benedetti et al., 1977) 
and Wistar rats (Klungsøyr and Scheline, 1983). Different species may have different types 
and contents of enzymes responsible for safrole metabolism, and metabolism may vary 
depending on the rat strain used (Kishida et al., 2008). Moreover, uncertainty in the exact 
values of the model parameters for scaling up the in vitro data to the in vivo situation may 
affect the accuracy of the model as the sensitivity analysis revealed that the formation of 
  
1,2-dihydroxy-4-allylbenzene and 1′-hydroxysafrole is mostly affected by kinetic 
parameters. Altogether, the results obtained in the analysis of model performance imply 
that conclusions derived from the model should preferably not be based on absolute 
outcomes but rather on a comparison of different conditions in a relative way as done in the 
present study. 
Comparison of the PBBK model based predicted time dependent concentrations of the three 
alkenylbenzenes in the liver reveals that for safrole, in contrast to estragole and 
methyleugenol, metabolism might not be complete within 24 h upon dosing pointing at 
possibilities for accumulation upon repeated dosing especially at relatively high dose levels. 
The major detoxification route of safrole is O-demethylation resulting in 1,2-dihydroxy-4-
allylbenzene (predicted to account for 74.5% of the dose at a dose of 0.05 mg/kg bw) a 
reaction catalyzed almost entirely in the liver. This result is different from the results 
obtained for the related alkenylbenzene estragole for which at a dose of 0.05 mg/kg bw, the 
major detoxification route, resulting in 4-allylphenol upon O-demethylation, appeared to 
occur predominantly in the lung and kidney (Punt et al., 2008). Thus, at relatively low dose 
levels, extrahepatic metabolism has a role in rapid metabolism of estragole while this is not 
the case for safrole where metabolism mainly occurs in the liver, resulting in a longer time 
needed for complete conversion. 
The PBBK predictions also revealed that the relative formation of the various safrole P450 
mediated metabolites is hardly changing with the dose (Figure 2.11). The formation of the 
proximate carcinogenic metabolite 1′-hydroxysafrole is predicted to increase from 9.1% to 
10.2% of the dose when the dose increases from 0.05 mg/kg bw to 300 mg/kg bw. 
Together, these data indicate that in contrast to outcomes previously obtained from similar 
PBBK models for the related alkenylbenzenes estragole and methyleugenol (Al-Subeihi et 
al., 2011; Punt et al., 2008) for safrole a dose dependent shift in P450 catalyzed reactions 
leading to a relative increase in bioactivation at higher dose levels is not observed. 
The 1′-hydroxy metabolites of the alkenylbenzenes and their sulphate conjugates have been 
shown to form DNA adducts in vivo and in vitro in a dose dependent manner (Boberg et 
al., 1983; Daimon et al., 1998; Drinkwater et al., 1976; Miller et al., 1983; Miller and 
  
 
Miller, 1983; Phillips et al., 1984; Randerath et al., 1984; Swanson et al., 1981). It is of 
interest to compare the results for the PBBK predicted formation of the ultimate 
carcinogenic metabolites of the three alkenylbenzenes to their relative potency for DNA 
adduct formation in vitro and in vivo and even to their BMDL10 values (the lower 
confidence bound of the benchmark dose that gives 10% extra cancer incidence (BMD10)) 
for tumor formation. In HepG2 cells exposed to the alkenylbenzenes, the dose dependent 
formation of DNA adducts decreased in the order methyleugenol > estragole > safrole, but 
varied at most 3.5-fold (Zhou et al., 2007). This is similar to the earlier finding in 
experiments in vivo in mouse liver in which the formation of DNA adducts in the liver of 
mice exposed to alkenylbenzenes also varied by less than 3.4-fold being again highest for 
methyleugenol (Randerath et al., 1984). Furthermore, the estimated calculated BMDL10 
values of safrole, methyleugenol and estragole amount to approximately 3-29 mg/kg 
bw/day (calculated using BMD software based on the data from (Boberg et al., 1983; 
Miller et al., 1983)), 22-32 mg/kg bw (Rietjens et al., 2008) and 9-33 mg/kg bw/day 
(Rietjens et al., 2010), respectively. This indicates that these alkenylbenzenes have a 
comparable carcinogenic potential. 
Altogether, it is concluded that the present study describes a PBBK model to quantify the 
bioactivation and detoxification of safrole in male rats. In contrast to outcomes previously 
obtained from similar PBBK models for the related alkenylbenzenes estragole and 
methyleugenol, for safrole a dose dependent shift in P450 mediated conversion leading to a 
relative increase in bioactivation at higher dose levels is not observed. In spite of this 
difference and the fact that complete metabolism of safrole takes longer than that of 
estragole and methyleugenol, the overall differences in bioactivation of the three 
alkenylbenzenes to their ultimate carcinogenic 1′-sulfooxy metabolites are limited, which is 
in line with the generally less than 4-fold difference in their level of DNA binding in in 
vitro and in vivo studies and in their comparable BMDL10 values in in vivo carcinogenicity 
studies. It is concluded that in spite of differences in the rate of specific metabolic 
conversions, overall the levels of bioactivation of the three alkenylbenzenes is comparable, 
which is in line with their comparable carcinogenic potential. 
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Abstract 
A physiologically based biokinetic (PBBK) model for the alkenylbenzene safrole in 
humans was developed based on in vitro- and in silico-derived kinetic parameters. With the 
model obtained, the time- and dose-dependent formation of the proximate and ultimate 
carcinogenic metabolites, 1′-hydroxysafrole and 1′-sulfooxysafrole in human liver were 
estimated and compared with previously predicted levels of these metabolites in rat liver. In 
addition, Monte Carlo simulations were performed to predict interindividual variation in the 
formation of these metabolites in the overall population. For the evaluation of the model 
performance, a comparison was made between the predicted total amount of urinary 
metabolites of safrole and the reported total levels of metabolites in the urine of humans 
exposed to safrole, which adequately matched. The model results revealed no dose-
dependent shifts in safrole metabolism and no relative increase in bioactivation at dose 
levels up to 100 mg/kg body weight/day. Species differences were mainly observed in the 
detoxification pathways of 1′-hydroxysafrole, with the formation of 1′-oxosafrole being a 
main detoxification pathway of 1′-hydroxysafrole in humans but a minor pathway in rats, 
and glucuronidation of 1′-hydroxysafrole being less important in humans than in rats. The 
formation of 1′-sulfooxysafrole was predicted to vary 4- to 17-fold in the population (fold-
difference between the 95th and median, and 95th and 5th percentile respectively), with the 
median being three to five times higher in human than in rat liver. Comparison of the 
PBBK results for safrole with those previously obtained for the related alkenylbenzenes 
estragole and methyleugenol revealed that differences in 1′-sulfooxy metabolite formation 
are limited, being only twofold to fivefold. 
 
  
 
Introduction 
Safrole, a natural plant constituent, is the major component of sassafras oil and a minor 
constituent in star anise, nutmeg and black pepper. Safrole was documented to be a rodent 
carcinogen (Borchert et al., 1973; Miller et al., 1983; Wislocki et al., 1977). The 
genotoxicity and carcinogenicity of safrole has been related to the formation of DNA 
adducts (Borchert et al., 1973; Daimon et al., 1998). Studies on the bioactivation and 
detoxification of safrole in humans are limited. Chewing of betel quid, which contains 
Piper betle leaves containing 15 mg safrole/g fresh weight, has been reported to result in 
safrole concentrations of up to 420 µM in saliva (Hwang et al., 1992). A case-control study 
showed a significant correlation between the incidence of oral squamous cell carcinoma 
and chewing of betel quid in a Taiwanese population (Ko et al., 1995). This phenomenon 
was linked to a high frequency of safrole-DNA adducts in squamous cell carcinoma and 
oral submucous fibrosis tissues of betel quid users (Chen et al., 1999). 
Safrole and sassafras oil were banned as food additives in 1960 by the U.S. Food and Drug 
Administration (FDA). In Europe, a limitation of safrole in foodstuff and beverages was set 
at 1 ppm (The European Council Directive on food flavoring 88/388/EEC, amended by 
Commission Directive 91/71/EEC) (EEC, 1988). In 1997, the Committee of Experts on 
Flavoring Substances (CEFS) of the Council of Europe evaluated safrole and concluded 
that safrole is a weak hepatocarcinogen in experimental animal studies but also a genotoxic 
and a transplacental carcinogen; hence efforts should be made to reduce its consumption 
through foods and beverages as much as possible (Council of Europe, 1997). The Scientific 
Committee on Food (SCF) of the European Union concluded in their evaluation that safrole 
is genotoxic and carcinogenic and that reductions in the exposure and restriction in the use 
levels are indicated (SCF, 2002). 
Daily intakes of safrole were estimated by the SCF to amount to 0.3 mg/day equivalent to 5 
µg/kg body weight (bw)/day for a 60 kg person (SCF, 2002), and the Joint FAO/WHO 
Expert Committee on Food Additives (JEFCA) estimated the maximum dietary exposure to 
safrole to amount to 879 µg/person/day equivalent to 14.6 µg/kg bw/day for a 60 kg person 
(JECFA, 2008). Furthermore, a study performed amongst non-betel quid chewers in 
  
 
Taiwan showed that the urine of non-betel quid chewers contained 1,2-dihydroxy-4-
allylbenzene, a major metabolite of safrole pointing out that intake of safrole from common 
spices in Taiwanese foods such as ginger and black pepper results in detectable exposure 
levels (Chang et al., 2002).  
The carcinogenicity of safrole has been correlated to its metabolic conversion by 
cytochromes P450 and sulfotransferases (SULTs) to a genotoxic metabolite, 1′-
sulfooxysafrole (Borchert et al., 1973; Ueng et al., 2005; Wislocki et al., 1977). In humans, 
the first step in this bioactivation is mainly catalyzed by cytochromes P450 2A6, P450 
D6*1, P450 2C9, P450 2C19 and P450 2E1 (Jeurissen et al., 2004; Liu et al., 2004; Ueng 
et al., 2004). The proximate carcinogenic metabolite 1′-hydroxysafrole can subsequently be 
sulfonated to the ultimate carcinogenic metabolite 1′-sulfooxysafrole, which is unstable and 
spontaneously decomposes to produce an electrophilic carbonium cation forming covalent 
adducts with cellular macromolecules including DNA (Borchert et al., 1973; Ioannides et 
al., 1981; Wislocki et al., 1977). Other metabolites of safrole are presented in Figure 3.1 
and include products resulting from O-demethylation, epoxidation and 3′-hydroxylation 
being 1,2-dihydroxy-4-allylbenzene, 2′,3′-safrole oxide and 3′-hydroxysafrole, respectively. 
In rats, 1,2-dihydroxy-4-allylbenzene is the major metabolite of microsomal conversion of 
safrole and this metabolite can subsequently be oxidized to an o-quinone leading to an 
electrophilic p-quinone methide intermediate (Bolton et al., 1994). 2′,3′-Safrole oxide is 
susceptible to hydrolysis by microsomal epoxide hydrolase forming 2′,3′-dihydroxysafrole 
(Ioannides et al., 1981; Klungsøyr and Scheline, 1983). 1′-Hydroxysafrole is converted to 
the ultimate carcinogen by SULT-mediated conversion to 1′-sulfooxysafrole, but can also 
be detoxified via oxidation to 1ʹ-oxosafrole or glucuronidation to 1ʹ-hydroxysafrole 
glucuronide (Figure 3.1) (Punt et al., 2008).  
Species-dependent differences in bioactivation and detoxification of safrole have been 
reported. For example, glucuronide conjugates of 1ʹ-hydroxysafrole and 3ʹ-hydroxysafrole 
were detected in the urine of rats but not in that of humans (Benedetti et al., 1977). 
Formation of the 1′-oxo metabolites of the related alkenylbenzenes estragole and 
methyleugenol appears to be a minor detoxification pathway in rats (Al-Subeihi et al., 
2011; Martati et al., 2011; Punt et al., 2008). In humans, however, oxidation of the 1′-
  
 
hydroxy metabolite of the related alkenylbenzenes estragole and methyleugenol appeared to 
be a major pathway for detoxification of the 1′-hydroxy metabolite (Al-Subeihi et al., 2012; 
Punt et al., 2009).  
To facilitate extrapolations of high dose animal carcinogenicity data for safrole to low dose 
in human exposure scenarios, insights are required in possible dose-dependent effects, 
species differences, and interindividual human variation in bioactivation and detoxification 
of this compound. The aim of the present study was to build a physiologically based 
biokinetic (PBBK) model for safrole in humans to obtain these insights. For the model 
development, the kinetic parameters for the metabolic conversions of safrole and 1′-
hydroxysafrole were determined in vitro using tissue fractions of human organs that were 
found to be capable of metabolizing safrole or 1′-hydroxysafrole. The outcomes of the 
model were compared with those of the previously defined PBBK model for safrole in rats 
(Martati et al., 2011) to evaluate the occurrence of species differences in bioactivation and 
detoxification of safrole. In addition, Monte Carlo simulations were performed to predict 
interindividual variation in the formation of these metabolites in the population as a whole. 
Finally, the outcomes of the humans model were also compared with those obtained with 
previously defined PBBK models for the related alkenylbenzenes estragole and 
methyleugenol (Punt et al., 2010; Al-Subeihi et al., 2012).  
Materials and methods 
Materials. Pooled human liver microsomes, cytosol and S9 were purchased from BD 
Gentest (Worburn, MA). Pooled human lung and kidney microsomes were obtained from 
BioPredic International (Rennes, France). Safrole (purity 97%), 2′,3′-dihydroxysafrole 
(purity 99%), Tris(hydroxymethyl)aminomethane, alamethicin (from Trichoderma viride), 
L-ascorbic acid, uridine 5′-diphosphoglucuronic acid (UDPGA) and 3,4-(methylenedioxy) 
cinnamic acid were purchased from Sigma-Aldrich (Steinheim, Germany). β-
Glucuronidase and reduced β-nicotinamide adenin dinucleotide phosphate (NADPH) and 
oxidized (NAD+) were obtained from Roche Diagnostics (Mannheim, Germany). Reduced 
glutathione (GSH) and dimethyl sulfoxide (DMSO) were purchased from Acros Organics 
(New Jersey). 3′-Phosphoadenosine-5′-phosphosulphate (PAPS) was obtained from Sigma-
  
 
Aldrich (Zwijndrecht, The Netherlands). Potassium dihydrogen phosphate, dipotassium 
hydrogen phosphate trihydrate, acetic acid (glacial) and magnesium chloride were 
purchased from VWR (Darmstadt, Germany). Chromatography grade acetonitrile was 
purchased from Biosolve (Valkenswaard, The Netherlands). 1′-Hydroxysafrole was 
synthesized and purified as described previously (Jeurissen et al., 2004; Martati et al., 
2011). 3′-Hydroxysafrole was synthesized from 3,4-(methylenedioxy) cinnamic acid as 
described previously (Angle et al., 2008) and purified as previously described (Martati et 
al., 2011). 1′-Oxosafrole was synthesized from 1′-hydroxysafrole based on the method used 
for 1′-oxoestragole (Wislocki et al., 1976). 1,2-Dihydroxy-4-allylbenzene was synthesized 
as described previously (Bolton et al., 1994).  
Determination of the kinetic constants for microsomal conversion of safrole  
Metabolites formed by microsomal conversion of safrole were identified and quantified 
upon incubation of safrole with human liver, lung, and kidney microsomes in the presence 
of NADPH. These incubations were performed as described previously for the microsomal 
conversion of safrole in rat tissue fractions (Martati et al., 2011). The incubation mixtures 
had a final volume of 160 µL and contained 1 mg/mL microsomal protein, 3 mM NADPH, 
and 1 mM ascorbic acid in 0.2 M Tris-HCl (pH 7.4). When metabolite formation was 
observed with a specific tissue fraction, the kinetic constants for the formation of this 
metabolite were determined by performing incubations for 10 min at 37°C at substrate 
concentrations that ranged from 10 to 1000 µM (final concentration). The reactions were 
started after 1 min of pre-incubation by addition of the substrate and terminated by addition 
of 40 µL of cold acetonitrile. An incubation mixture without NADPH was used as the 
blank. 
 
  
 
 
Figure 3.1. Biotransformation pathways of safrole. 
  
 
Determination of kinetic constants for glucuronidation, sulfation, and oxidation of 1ʹ-
hydroxysafrole  
To determine the kinetic constants for the metabolic conversion of 1ʹ-hydroxysafrole to 1ʹ-
hydroxysafrole glucuronide, 1ʹ-sulfooxysafrole, and 1ʹ-oxosafrole, incubations were 
performed with human liver S9 (in case of glucuronidation and sulfonation) or human liver 
microsomes (in case of oxidation) in the presence of the relevant cofactors. The choice of 
the tissue fractions was based on our previous works on the related alkenylbenzene 
estragole (Punt et al., 2008; Punt et al., 2009) in order to make the results comparable. 
Incubations for glucuronidation and sulfonation were, for instance, performed with S9 
fractions and not with microsomes and cytosol separately to allow for direct comparison of 
the kinetic constants obtained for these reactions (Punt et al., 2007; Punt et al., 2008). All 
the reactions were performed as described previously for the metabolic conversion of 1ʹ-
hydroxysafrole by rat tissue fractions (Martati et al., 2011). In case of glucuronidation, the 
incubation mixtures had a final volume of 200 µL and contained (final concentrations) 10 
mM UDPGA, 0.2 mg S9 protein/mL in 0.2 M Tris-HCl (pH 7.4) and 10 mM MgCl2. These 
incubation mixtures were first pre-treated on ice with 0.025 mg/mL alamethicin for 15 min 
to obtain maximum glucuronidation activity (Fisher et al., 2000). The reactions were 
carried out for 360 min at 37°C at a substrate concentration that ranged from 100 to 4000 
µM (final concentration). In case of sulfonation of 1ʹ-hydroxysafrole the incubation 
mixtures had a final volume of 100 µL, containing (final concentrations) 0.2 mM PAPS, 2 
mg S9 protein/mL, and 10 mM GSH in 0.1 M potassium phosphate (pH 8.0). These 
incubations were carried out for 120 min at 37°C at a substrate concentration that ranged 
from 250 to 4000 µM (final concentration). For oxidation of 1ʹ-hydroxysafrole, initial 
incubations were performed to determine the subcellular distribution and enzyme 
specificity of this enzymatic reaction. These reactions were carried out for 10 min at a 
substrate concentration of 1000 µM with incubation mixtures that had a final volume of 100 
µL, containing (final concentrations) 3 mM NAD+, NADH, NADP+, or NADPH, 1 mg 
microsomal or cytosolic protein/mL, and 2 mM GSH in 0.2 M Tris-HCl (pH 7.4). Based on 
these incubations, the oxidation reaction of 1ʹ-hydroxysafrole was observed to mainly occur 
in incubations with microsomes and NAD+ as cofactor (data not shown) and the kinetic 
  
 
constants were determined for this reaction only. For the determination of these kinetic 
constants, incubations were carried out for 10 min at 37°C at the same conditions as 
described above and a substrate concentration that ranged from 10 to 4000 µM (final 
concentration).  
All of the above reactions were started after pre-incubation at 37°C for 1 min by addition of 
the substrate 1ʹ-hydroxysafrole diluted in DMSO and terminated by addition of cold 
acetonitrile amounting to 25% (v/v) of the incubation volume. The final concentration of 
DMSO in the incubation mixtures was kept constant at 1%. Incubation mixtures without the 
specific cofactors were used as blanks. 
Samples and data analysis 
For the determination of kinetic constants for each metabolite, three replicates were always 
performed. All samples were centrifuged for 5 min at 16000 g and the supernatants were 
frozen at -20°C until analysis by high performance liquid chromatography (HPLC) or ultra 
performance liquid chromatography (UPLC). Analysis of the samples resulting from the 
microsomal conversion of safrole as well as the oxidation and glucuronidation of 1′-
hydroxysafrole was performed on a Waters M600 HPLC equipped with a photodiode array 
detector as previously described (Martati et al., 2011). Quantification and detection of the 
GSH conjugate of 1′-sulfooxysafrole were performed on a Waters UPLC equipped with a 
photodiode array detector system as described previously (Martati et al., 2011). The 
different metabolites of safrole and 1′-hydroxysafrole were identified and quantified on the 
basis of the similarity of their UV spectrum and retention time and compared with the UV 
spectrum and retention time of synthesized or commercially available reference compounds 
as described previously (Martati et al., 2011). In the microsomal incubations, safrole 2′,3′-
oxide was not detected because of its swift hydrolysis by microsomal epoxide hydrolase to 
2′,3′-dihydroxysafrole (Guenthner and Luo, 2001; Luo et al., 1992; Stillwell et al., 1974).  
The safrole concentration-dependent rate of formation of different products of microsomal 
conversion of safrole, and the 1′-hydroxysafrole concentration-dependent rate of 
glucuronidation, oxidation and sulfation were fitted to the standard Michaelis-Menten 
equation: v = Vmax*[S]/(Km+[S]). In this equation, [S] represents the substrate concentration 
  
 
of the respective reaction. The apparent maximum velocity (Vmax(app)) and apparent 
Michaelis-Menten constant (Km(app)) were determined using GraphPad Prism version 5.03 
(GraphPad Software, San Diego CA). The values of Vmax and Km were reported in 
nmol/min/mg microsomal or S9 protein and µM, respectively. Scaling of in vitro data, 
expressed as nmol/min/mg protein, to in vivo data, expressed as µmol/h/g tissue, was 
performed as described below.  
Definition of the PBBK model for safrole metabolism  
A PBBK model describing the dose-dependent kinetic behavior of safrole and formation of 
its metabolites in humans was developed based on the model previously defined for safrole 
in male rats (Martati et al., 2011), and for the related alkenylbenzene estragole in rats (Punt 
et al., 2008) and in humans (Punt et al., 2009). Figure 3.2 presents a schematic overview of 
the PBBK model used to simulate the metabolism and distribution of safrole in humans. 
The following compartments were included in the model: (1) liver and kidney as 
metabolizing compartments, and (2) lung, fat, blood, richly perfused tissue and slowly 
perfused tissue as separate compartments. No parallel model describing the distribution of 
1′-hydroxysafrole over the body was included, because a near quantitative intrahepatic 
conversion of 1′-hydroxysafrole was assumed. This assumption was based on the findings 
(see Results section) that the overall catalytic efficiency for the reactions converting 1′-
hydroxysafrole was higher than the catalytic efficiency for the formation of 1′-
hydroxysafrole.  
The uptake of safrole from the gastrointestinal tract was assumed to follow first-order 
kinetics, assuming safrole to be absorbed directly to the liver with an estimated absorption 
constant set at 1.0 h-1. This assumption was based on the fact that uptake of the related 
alkenylbenzene estragole from the gastrointestinal track is known to be rapid and complete 
with an estimated absorption half-life of 0.7 h (Anthony et al., 1987; Punt et al., 2008). 3′-
Hydroxysafrole formation was modeled in the liver and kidney. Microsomal metabolism of 
safrole resulting in 1′-hydroxysafrole, 2′,3′-dihydroxysafrole (derived from safrole 2′,3′-
oxide) and 1,2-dihydroxy-4-allylbenzene was only observed in the liver and therefore 
modeled only in the liver compartment. Formation of 1′-hydroxysafrole in the liver was 
  
 
followed by its further conversion to 1′-hydroxysafrole glucuronide, 1′-sulfooxysafrole, and 
1′-oxosafrole. The mass balance equations in the PBBK model for time-dependent changes 
of safrole in the liver and kidney were essentially the same as previously described for the 
rats PBBK model (Martati et al., 2011).  
The urinary excretion of safrole metabolites was considered rapid and complete based on 
the literature data of Benedetti et al. (1977) indicating that 14C-safrole administered to 
humans was excreted almost completely in the urine within 5 days, and that only a limited 
percentage of the dose (< 2.25%) was found in feces. Based on this consideration, the 
transport of metabolites from liver to the kidney and urine was not included in the model. 
Instead, the metabolites 2′,3′-dihydroxysafrole, 1,2-dihydroxy-4-allylbenzene, 1′-
hydroxysafrole glucuronide and 1′-oxosafrole formed in liver and 3′-hydroxysafrole formed 
in the liver and kidney were assumed to be all completely excreted in the urine.  
 
 
Figure 3.2. Schematic presentation of the physiologically based biokinetic (PBBK) model used to simulate the 
bioactivation and detoxification of safrole in humans. 
  
 
The kinetic parameters for the product formation upon by microsomal conversion of safrole 
and for the glucuronidation, oxidation and sulfation of 1′-hydroxysafrole were determined 
in vitro. The Vmax values for the formation of microsomal safrole metabolites and of 
conjugated metabolites obtained from incubations with microsomal liver samples were 
scaled to the liver using a microsomal protein yield of 32 mg/g liver (Barter et al., 2007). 
The Vmax values for the formation of metabolites formed in the kidney were scaled using a 
microsomal protein yield of 7 mg/g kidney (Beierschmitt and Weiner,1986; Medinsky et 
al., 1994; Punt et al., 2008). The Vmax values for the sulfation and glucuronidation of 1′-
hydroxysafrole were scaled to the liver using an S9 protein yield of 143 mg/g liver 
(Medinsky et al., 1994; Punt et al., 2008; Al-Subeihi et al., 2012). 
The physiological parameter values including organ volumes, cardiac output, and blood 
flows were taken from literature (Brown et al., 1997) and are shown in Table 3.1.  
Table 3.1. Parameters used in the physiologically based biokinetic model for safrole in 
humans. 
Physiological Parametersa 
 
Tissue : Blood Partition Coefficientsb 
Body Weight (kg)  60   
Percentage of Body Weight  Safrole   
 Liver  2.6   Liver  6.7 
 Kidney  0.4   Kidney  6.7 
 Fat  21.4   Fat  106 
 Rapidly Perfused  4.6   Rapidly Perfused  6.7 
 Slowly Perfused  51.7   Slowly Perfused  4.2 
 Blood  7.9 1′-Hydroxysafrole   
    Liver  1.7 
     
Cardiac Output (L/h/kg bw0.74 ) 
 
15.0   
Percentage of Cardiac Output    
Liver  22.7   
Kidney  17.5   
Fat  5.2   
Rapidly Perfused  29.8   
Slowly Perfused  24.8   
a
 Brown et al. (1997) 
b DeJongh et al. (1997)  
  
 
 
Partition coefficients for safrole and 1′-hydroxysafrole were estimated from the ClogP 
values (DeJongh et al., 1997). ClogP values were calculated with ChemBio3D Ultra 2010 
(CambridgeSoft, MA) and were 3.18 and 1.62 for safrole and 1′-hydroxysafrole, 
respectively. Mass balance and differential equations of safrole metabolism were coded and 
simulated with Berkeley Madonna 8.3.14 (Macey and Oster, UC Berkeley, CA) using the 
Rosenbrock′s algorithm for stiff system. PBBK model predictions of the dose-dependent 
formation of the various products of microsomal conversion of safrole and of the various 
conversion products of 1′-hydroxysafrole were performed over 120 h. In our PBBK model 
predictions, 120 h was selected because for this time point in vivo human experimental data 
that could be used for model evaluation were available (Benedetti et al., 1977). 
Sensitivity analysis 
Sensitivity analysis was used to identify the parameters that have the greatest impact on a 
specified model output (DeWoskin, 2007). Normalized sensitivity coefficients (SC) were 
determined according to the following equation: SC = (C′- C)/(P′-P)*(P/C), where C is the 
initial value of the model output, C′ is the modified value of the model output resulting 
from an increase in parameter value, P is the initial parameter value and P′ is the modified 
parameter (Rietjens et al., 2011). The effect of a 5% change in each parameter on the 
formation of 1′-hydroxysafrole and 1′-sulfooxysafrole (expressed as percentage of dose 
over 120 h) was analyzed. The final coefficients were calculated using Excel (Excel 2007, 
Microsoft Corporation, WA). 
Evaluation of interindividual variability on population level using Monte Carlo 
simulation 
To predict the influence of interindividual variability on the model outcomes, a Monte 
Carlo simulation was performed. For this simulation, a total number of 10,000 simulations 
were run. The parameters that significantly affect the outcomes as indicated by the 
normalized SC values higher than |0.1| were included in the Monte Carlo simulations. For 
these simulations, the mean µw and standard deviation σw describing the log-normal 
  
 
distribution of each parameter were derived from the mean µx and coefficient of variation of 
the non-ln-transformed data using the following equation (Zhang et al., 2007) : 
    
                                                   
 
Meanwhile, the values of the parameters that have normalized SC values lower than |0.1| 
were kept at their mean values. The coefficients of variation (CVs) of the distribution of the 
yield of S9 protein (S9PL), microsomal protein yield of the liver (MPL), and volume of the 
liver (VL) were collected from the literature and corresponded to 46% (Barter et al., 2007), 
46% (Barter et al., 2007), and 5% (EPA, 2000), respectively. For the kinetic constants of 
the different metabolic reactions included in the Monte Carlo simulations, general CVs of 
30% were used to represent a moderate level of uncertainty and variability (Covington et 
al., 2007). The outputs were then analyzed statistically to calculate the different percentiles 
of the distribution of the model outcomes using GraphPad Prism version 5.03 (GraphPad 
Software, San Diego CA).  
Comparison of PBBK model-based predictions for safrole with the PBBK model-
based predictions for the related alkenylbenzenes estragole and methyleugenol 
The PBBK model-based predictions obtained for safrole were compared with those 
obtained with previously developed PBBK models for the related alkenylbenzenes 
estragole and methyleugenol (Al-Subeihi et al., 2012; Punt et al., 2009). To this end, the 
three PBBK models were run to obtain the dose-dependent formation of the respective 1′-
hydroxy metabolites, 1′-hydroxy glucuronide metabolites, 1′-oxo metabolites, and 1′-
sulfooxy metabolites. The PBBK models were run from dose levels of 10-6 mg/kg bw to 
100 mg/kg bw for 120 h. The lowest dose level of 10-6 mg/kg bw was chosen to ascertain 
that the modeling would include realistic human dietary intake levels and the high dose 
levels of 100 mg/kg bw was chosen to make sure the evaluation would include dose levels 
known to cause tumors in in vivo rodent studies. 
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Results 
Microsomal conversion of safrole 
HPLC analysis of incubations with pooled human liver, kidney and lung microsomes in the 
presence of safrole as substrate and NADPH as cofactor reveals that conversion of safrole 
only occurs in incubations with pooled human liver and kidney microsomes, whereas no 
conversion of safrole occurs in incubations with human lung microsomes (data not shown). 
The metabolites formed in incubations with human liver microsomes are the same as those 
previously shown to be formed in incubations with rat liver microsomes (Martati et al., 
2011). Incubations of safrole with human kidney microsomes revealed the formation of 
only 3′-hydroxysafrole (chromatogram not shown). Altogether the data indicate that 
extrahepatic microsomal conversion of safrole contributes to a minor extent to the overall 
microsomal conversion of safrole.  
Kinetics of microsomal conversion of safrole 
Figure 3.3A shows the rate of formation of 2′,3′-dihydroxysafrole, 1′-hydroxysafrole, 3′-
hydroxysafrole and 1,2-dihydroxy-4-allylbenzene in incubations with pooled human liver 
microsomes and increasing concentrations of safrole from 10 to 1000 µM. Similar 
experiments were performed with kidney microsomes using substrate concentrations 
ranging from 250 to 4000 µM (Figure 3.3B). Table 3.2 presents the apparent Km and Vmax 
values obtained from these plots and the catalytic efficiencies (Vmax/Km) derived from them.  
The results obtained reveal that with pooled human liver microsomes 1,2-dihydroxy-4-
allylbenzene is the major metabolite formed, followed by 1′-hydroxysafrole, 2′,3′-
dihydroxysafrole and 3′-hydroxysafrole. The catalytic efficiencies of the major metabolites 
1,2-dihydroxy-4-allylbenzene and 1′-hydroxysafrole, were 4.9 and 4.3 µL/min/mg 
microsomal protein,
 
respectively. 
The results obtained with human kidney microsomes reveal that only 3′-hydroxysafrole is 
formed. The apparent Vmax, Km and catalytic efficiency calculated as the apparent Vmax/Km 
for the formation of 3′-hydroxysafrole were 0.03 nmol/min/mg microsomal protein, 1054 
µM, and 0.03 µL/min/mg microsomal protein,
 
respectively (Figure 3.3B). In the kidney, 3′-
  
 
hydroxysafrole was also formed in the blank incubations without NADPH. Correcting the 
amount of 3′-hydroxysafrole formed in the complete incubation for the amount of 3′-
hydroxysafrole formed in the blank incubation contributed to the relatively large 
experimental variation in the Km value revealing a coefficient variation of 80%. 
Glucuronidation of 1′-hydroxysafrole 
Formation of the glucuronosyl conjugate of 1′-hydroxysafrole was analyzed in incubations 
with pooled human liver S9 and UDPGA as cofactor. Formation of the glucuronosyl 
conjugate of 1′-hydroxysafrole eluting at a retention time of 24 min was observed 
(chromatogram not shown). This metabolite was previously identified as 1′-hydroxysafrole 
glucuronide by liquid chromatography-mass spectrometry (LC-MS) (Martati et al., 2011). 
Treatment of the sample with β-glucuronidase resulted in complete elimination of this 
metabolite and a concomitant increase in the intensity of the peak of 1′-hydroxysafrole, 
corroborating that the metabolite formed corresponds to the glucuronosyl conjugate of 1′-
hydroxysafrole. 
 
  
 
 
Figure 3.3. Safrole concentration dependent rate of formation of microsomal conversion of safrole in incubations 
with human (A) liver and (B) kidney microsomes and NADPH as a cofactor. In the plots each point represents the 
mean (+ SD) of three replicates corresponding to the formation of 2′,3′-dihydroxysafrole (•), 1′-hydroxysafrole 
(), 3′-hydroxysafrole () and 1,2-dihydroxy-4-allylbenzene (). 
  
  
 
Table 3.2. The kinetic parameters for microsomal conversion of safrole in incubations with liver and kidney microsomes and for  
conversion of 1′-hydroxysafrole in incubations with liver microsomes or S9 protein from humans and the cofactor for the respective conversions. 
 
Organ Metabolite Km (µM)a Coefficient 
Variation of Km 
Vmax (nmol/min/mg 
microsomal protein or S9 
protein)a 
Coefficient 
Variation of Vmax 
In vitro catalytic efficiency 
(Vmax(app) /Km) (µL/min/mg 
microsomal protein or S9 
protein)  
Microsomal conversion of safrole      
Liver 2′,3′-dihydroxysafrole 41 ± 10 24% 0.07 ± 0.004 6% 1.7 
1′-hydroxysafrole 35 ± 10  29% 0.15 ± 0.008 5% 4.3 
3′-hydroxysafrole 255 ± 99  39% 0.11 ± 0.01 9% 0.4 
1,2-dihydroxy-4-allylbenzene  172 ± 30 17% 0.85 ± 0.05  6% 4.9 
Kidney 3′-hydroxysafrole 1054 ± 843 80% 0.03 ± 0.008  27% 0.03 
Conversion of 1′-hydroxysafrole      
Liver  1′-hydroxysafrole 
glucuronideb 1322 ± 208 
16% 0.1 ± 0.006  6% 0.08 
 1′-oxosafrole c 549 ± 84 15% 7.5 ± 0.4 5% 13.7 
 1′-sulfooxysafrole b 3828 ± 1801 47% 0.017 ± 0.005 29% 0.004 
 
a
 The values are mean + SD of three independent determinations; b Incubation with S9 protein; c Incubation with microsomal protein  
 
  
 
Figure 3.4A shows the rate of glucuronidation of 1′-hydroxysafrole with a substrate 
concentration increasing from 100 to 4000 µM. The apparent Vmax and Km values derived 
from these data amounted to 0.1 nmol/min/mg S9 protein and 1322 µM, respectively, 
resulting in an apparent catalytic efficiency (Vmax/Km) of 0.08 µL/min/mg S9 protein (Table 
3.2). 
Oxidation of 1′-hydroxysafrole  
Formation of the glutathione adduct with 1′-oxosafrole (GS-1′-oxosafrole) was analyzed in 
incubations with pooled human liver microsomes and NAD+ as cofactor and GSH as a 
trapping agent for the 1′-oxosafrole formed. Formation of a single metabolite with a 
retention time of 12 min was observed (chromatogram not shown). This metabolite was 
previously identified by LC-MS as GS-1′-oxosafrole (Martati et al., 2011).  
Figure 3.4B shows the rate of oxidation of 1′-hydroxysafrole with increasing substrate 
concentrations ranging from 10 to 4000 µM. The apparent Vmax obtained from this graph 
amounted to 7.5 nmol/min/mg microsomal protein and the apparent Km value to 549 µM, 
resulting in an apparent catalytic efficiency (Vmax/Km) of 13.7 µL/min/mg microsomal 
protein (Tabel 3.2).  
Sulfation of 1′-hydroxysafrole  
Formation of the glutathione adduct with 1′-sulfooxysafrole (GS-1′-sulfooxysafrole) was 
analyzed in incubations with human liver S9 using PAPS as cofactor and GSH as trapping 
agent for the reactive carbocation derived from the unstable 1′-sulfooxysafrole metabolite. 
A single metabolite was formed which eluted at a retention time of 1.2 min (chromatogram 
not shown). This metabolite was previously identified as GS-1′-sulfooxysafrole by LC-MS 
(Martati et al., 2011). UPLC analysis of incubations of 1′-sulfooxysafrole in the absence of 
GSH and in the presence of S9 protein and PAPS revealed no peak formation at 1.2 min 
(chromatograms not shown).  
 
 
  
 
Figure 3.4. 1′-Hydroxysafrole concentration dependent rate of formation of (A) 1′-hydroxysafrole glucuronide 
with pooled human liver S9 in the presence of UDPGA as a cofactor, (B) GS-1′-oxosafrole with pooled human 
liver microsomes in the presence of NAD+ as a cofactor and GSH as a trapping agent and (C) GS-1′-
sulfooxysafrole with pooled human liver S9 homogenates in the presence of PAPS as a cofactor and GSH as a 
trapping agent. In the plot each point represents the mean (+ SD) of three replicates 
 
Figure 3.4C shows the rate of the formation of GS-1′-sulfooxysafrole with a substrate 
concentration increasing from 250 to 4000 µM. Based on these data the Km for formation of 
1′-sulfooxysafrole by human liver S9 protein was determined to be 3828 µM and the Vmax 
0.017 nmol/min/mg S9 protein resulting in a catalytic efficiency (Vmax/Km) of 0.004 
µL/min/mg S9 protein (Table 3.2). 
  
 
Table 3.3. Scaled kinetic parameters for safrole metabolism by human and male rat tissue fractions as used in the PBBK models. 
Metabolite Organ Humansa,b   Male Ratsa,c    
Scaled Vmax, in 
vivo
 (µmol/h/g 
tissue)d 
Km  
(µM) 
Catalytic 
efficiency 
(mL/h/g 
tissue)e 
Scaled Vmax, in 
vivo
 (µmol/h/g 
tissue)d 
Km  
(µM) 
Catalytic 
efficiency 
(mL/h/g 
tissue)e 
Microsomal conversion of safrole        
2′,3′-dihydroxysafrole Liver 0.1 41 2.4 0.20  149 1.3 
1′-hydroxysafrole Liver  0.3 35 8.6  0.8 497  1.6 
 Lung n.d n.d - 0.05 159  0.3 
3′-hydroxysafrole Liver 0.2 255 0.8 0.7 546  1.1 
 Lung  n.d n.d - 0.1 3573  0.03 
 Kidney 0.01 1054 0.01 0.04 3067 0.01 
1,2-dihydroxy-4-allylbenzene  Liver  1.6 172 9.3 4.0 313  13.0 
Conversion of 1′-hydroxysafrole        
1′-hydroxysafrole glucuronide Liver  0.90 1322 0.7 215 101 2124 
1′-oxosafrole Liver 16.0 549 29 11.0 1809 6.3 
1′-sulfooxysafrole Liver  0.15 3828 0.04 0.26 127 2.0 
 
a
 The values are mean + SD of three independent determinations  
b
 data obtained from present study 
c
 data obtained from previous study 
d Scaled Vmax were converted from in vitro Vmax based on microsomal protein yield of 32, 20 and 7 mg/g tissue for liver, lung and kidney, respectively, and S9 protein 
yield of 143 mg/g liver 
e
 Catalytic efficiency (scaled Vmax/Km ) 
 n.d : not detected  
  
Comparison of kinetic data for safrole bioactivation and detoxification by humans 
and male rats  
Table 3.3 presents a summary of the kinetic parameters for safrole bioactivation and 
detoxification by human tissue fractions compared to the kinetic parameters previously 
reported for male rat tissue fractions (Martati et al., 2011). The Vmax values expressed as 
µmol/h/g tissue were obtained by scaling the in vitro Vmax values to Vmax values expressed 
per g liver using microsomal or S9 protein yields from the different organs that were 
obtained from literature (Medinsky et al., 1994). This conversion allowed comparison of 
the kinetic constants obtained with different tissue fractions.  
In the human liver, the scaled Vmax for formation of 1′-hydroxysafrole is about 2.5-fold 
lower than that for rat liver, whereas the apparent Km is 14-fold lower than that for rat liver. 
Overall, the catalytic efficiency (scaled Vmax/Km) for formation of the proximate 
carcinogenic metabolite 1′-hydroxysafrole in human liver is 5 times higher than that in rat 
liver. The catalytic efficiency for formation 1,2-dihydroxy-4-allylbenzene is 1.3-fold lower 
in human than in male rat liver. The catalytic efficiency for formation of 2′,3′-
dihydroxysafrole in human liver is 2.0-fold higher than that in rat liver. The catalytic 
efficiencies for formation of 3′-hydroxysafrole are similar for human and male rat liver. 
Comparison of the catalytic efficiency for glucuronidation of 1′-hydroxysafrole by human 
and male rat liver reveals that this conversion is more than 3200 times less efficient in 
human liver which is due to a 250-fold lower scaled Vmax and a 13-fold higher Km for 
glucuronidation in human liver. Comparison of oxidation of 1′-hydroxysafrole in human 
liver to that in male rat liver reveals that this metabolic pathway is four times more efficient 
in human liver due to a 1.3-fold higher scaled Vmax value and a 3.3-fold lower Km value for 
1′-hydroxysafrole oxidation in human liver as compared to rat liver. The catalytic efficiency 
for formation of 1′-sulfooxysafrole was 50-fold lower in human liver than in rat liver due to 
a 2-fold lower Vmax value and a 30-fold higher Km value. 
 
  
 
Sensitivity analysis of the PBBK model developed 
To identify the key parameters that affect the levels of the proximate carcinogenic 
metabolite 1′-hydroxysafrole and the ultimate carcinogenic metabolite 1′-sulfooxysafrole, a 
sensitivity analysis was performed. Normalized SC values (sensitivity coefficients) were 
calculated at a dose 0.005 mg/kg bw and only parameters that had a normalized SC higher 
than 0.1 (in absolute value) are presented (Figure 3.5). Formation of 1′-hydroxysafrole is 
predicted to be mostly affected by the kinetic constants for its formation from safrole 
(Vmax,L_1′HS and Km,L_1′HS), the kinetic constants for formation for 2′,3′-dihydroxysafrole 
(Vmax,L_DHS and Km,L_DHS), the kinetic constants for formation of 1,2-dihydroxy-4-
allylbenzene (Vmax,L_DHAB and Km,L_DHAB), microsomal protein yield of the liver (MPL), and 
the volume of the liver (VL). The predicted formation of 1′-sulfooxysafrole was mostly 
affected by the kinetic constants for formation of 1′-hydroxysafrole (Vmax,L_1′HS and 
Km,L_1′HS), for oxidation of 1′-hydroxysafrole (Vmax,L_1′HOS and Km,L_1′HOS) and for sulfation of 
1′-hydroxysafrole (Vmax,L_1′HSS and Km,L_1′HSS) and to a minor extent by the kinetic constants 
for formation of 1,2-dihydroxy-4-allylbenzene (Vmax,L_DHAB and Km,L_DHAB), for formation of 
2′,3′-dihydroxysafrole (Vmax,L_DHS and Km,L_DHS), the yield of S9 protein (S9PL), the yield of 
microsomal protein of the liver (MPL), and the volume of the liver (VL). 
Based on the sensitivity analysis probability distributions were assigned to the model 
parameters to which the model outcome is most sensitive, thereby allowing to perform 
Monte Carlo simulations to see the effect of uncertainty and variability on the PBBK based 
predictions for the total amount of metabolites excreted in the urine, for the formation of 
microsomal metabolites of safrole (2′,3′-dihydroxysafrole, 1′-hydroxysafrole, 3′-
hydroxysafrole and 1,2-dihydroxy-4-allylbenzene), for the conversion of 1ʹ-hydroxysafrole 
(1′-hydroxysafrole glucuronide, 1′-oxosafrole and 1′-sulfooxysafrole), for concentration of 
safrole in liver and blood and for the concentration of 1′-hydroxysafrole in the liver, and the 
predicted formation of 1′-sulfooxysafrole at different oral doses. 
 
  
 
Figure 3.5. Sensitivity analysis showing the sensitivity of the predicted formation of 1′-hydroxysafrole (white bars) 
and 1′-sulfooxysafrole (black bars) to different model parameters. VL= volume of the liver, S9PL= liver S9 
protein yield, MPL= microsomal protein yield of the liver and Vmax and Km are the maximum rate and the 
Michaelis-Menten constant for the formation of the different metabolites in the liver, respectively, 2′,3′-
dihydroxysafrole (DHS), 1′-hydroxysafrole (1′HS), 1,2-dihydroxy-4-allylbenzene (DHAB), 1′-oxosafrole 
(1′HOS), and 1′-sulfooxysafrole (1′HSS). 
Model simulation of total metabolites formed 
Performance of the PBBK model thus obtained was evaluated by comparison of the PBBK-
model based prediction for the total formation of metabolites that will be excreted in the 
urine to the reported total urinary excretion of safrole metabolites expressed as a percentage 
of the dose reported in the literature for humans exposed to dose levels of safrole of 0.163 
and 1.655 mg/subject given orally (corresponding to 0.0027 mg/kg bw and 0.0276 mg/ kg 
bw for a 60 kg person) (Benedetti et al., 1977). The metabolites to be excreted were 
calculated as the sum of 2′,3′-dihydroxysafrole, 1,2-dihydroxy-4-allylbenzene, 1′-
hydroxysafrole glucuronide and 1′-oxosafrole formed in liver and 3′-hydroxysafrole formed 
in the liver and kidney. 
  
 
The results of the Monte Carlo simulations show that at a dose of 0.163 mg/subject (Figure 
3.6A), the PBBK model predicted percentage excreted as metabolites and the actual 
percentage excreted in human experiments are comparable. The simulation shows that at 6 
h upon oral administration of 0.163 mg/subject, the 5th, median and 95th percentile of the 
predicted percentage of the dose excreted as safrole metabolites were 37%, 59% and 78% 
of the dose, respectively, whereas the experimental value reported in the literature 
amounted to 55 + 15.6% (Benedetti et al., 1977). Upon 12 h of exposure, the reported value 
is 86 + 1.3% of the dose and the predicted percentage of 5th, median, and 95th percentile 
were 46%, 68% and 84% of the dose, respectively.  
At a dose of 1.655 mg/subject (Figure 3.6B), upon 6 h of exposure the percentage of the 
dose excreted as safrole metabolites is reported to be 70% (standard deviation not given) 
(Benedetti et al., 1977), whereas the predicted values of the simulation were 37%, 59%, and 
77% of the dose for the 5th, median and 95th percentile, respectively.  
 
Figure 3.6. PBBK model and Monte Carlo simulation based predictions for interindividual variability in urinary 
safrole metabolite excretion (expressed as percentage of the dose administered) as compared to reported values 
(mean + SD) (•) (Benedetti et al., 1977) at oral dose levels of (A) 0.163 mg/subject (corresponding to 0.0027 
mg/kg bw for a 60 kg person) and (B) 1.655 mg/subject (corresponding to 0.0276 mg/kg bw for a 60 kg person in 
the PBBK model). The solid line corresponds to the predicted median value and the dashed lines to the 5th, and 
95th percentiles. Note that for several reported data points, the standard deviation is so small that they are not 
visible.  
  
Model simulation of the concentration of safrole in the liver and blood and the 
concentration of 1′-hydroxysafrole in the liver 
In a next step, the PBBK model was used to make predictions for the time- and dose-
dependent bioactivation and detoxification of safrole in humans. Figure 3.7 presents the 
time-dependent predictions for the concentration of safrole in human blood and liver and 
the concentration of 1′-hydroxysafrole in human liver upon oral exposure to 0.005 mg 
safrole/kg bw, which is the estimated dietary human intake reported by the SCF (2002). At 
a dose of 0.005 mg/kg bw, the maximum liver concentrations of safrole and 1′-
hydroxysafrole were predicted to be achieved within less than 0.5 h upon dosing. Although 
safrole and 1′-hydroxysafrole concentrations in the liver are low after 12 h, full conversion 
is not yet reached at this time point. Only after 120 h a more complete conversion is 
achieved, with 88% of the dose being metabolized to the different microsomal metabolites 
of safrole and almost full conversion of the 1′-hydroxysafrole formed. The PBBK model-
predicted levels of the different safrole metabolites formed after 120 h are displayed in 
Table 3.4. The major metabolites are 1,2-dihydroxy-4-allylbenzene and 1′-hydroxysafrole, 
which are predicted to amount to ~38 and ~36% of the dose, respectively. 1′-
Hydroxysafrole was mostly converted to 1′-oxosafrole at a dose 0.005 mg/kg bw (10.8 
nmol/kg bw, corresponding to 35% of the dose, and to 98% of the 1′-hydroxysafrole 
formed), whereas formation of the ultimate carcinogenic metabolite 1′-sulfooxysafrole was 
predicted to amount to 0.04% of the dose and to 0.1% of the amount of 1′-hydroxysafrole 
formed. Formation of 1′-hydroxysafrole glucuronide was predicted to amount to 0.8% of 
the dose and to 2.0% the amount of 1′-hydroxysafrole formed. 
  
  
 
Table 3.4. PBBK model predicted quantities of metabolites formed during 120 h upon an 
oral dose of 0.005 mg/kg bw (equivalent to 31 nmol/kg bw) 
Metabolite 
 
Amount formed  
(nmol/kg bw)a 
Percentage  
of the dosea 
Percentage of  
1′-hydroxysafrole 
Microsomal conversion of safrole     
  2′,3′-dihydroxysafrole 3 (2, 7) 11 (6, 23)  
  1′-hydroxysafrole 11 (5, 17) 36 (16, 55)  
  3′-hydroxysafrole 1 (0.6, 1.0) 3 (2, 4)  
  1,2-dihydroxy-4-allylbenzene 12 (6, 17) 38 (19, 56)  
Conversion of 1′-hydroxysafrole    
  1′-hydroxysafrole glucuronide 0.2 (0.06, 0.6) 0.8 (0.2, 2.0) 2.0 
  1′-oxosafrole 10.8 (5, 16)  35 (16, 53) 98 
  1′-sulfooxysafrole 0.01 (0.0027, 
0.04) 
0.04 (0.01, 0.13) 0.1 
a
 Values between the parentheses represents the 5th and 95th percentiles. 
 
Figure 3.7. Monte Carlo simulation for the time-dependent concentration of safrole in A) liver and B) blood and 
C) time-dependent concentration of 1′-hydroxysafrole in the liver, upon oral exposure to 0.005 mg/kg bw safrole. 
No experimental data were available for comparison. The solid line indicates the predicted median value and the 
dashed lines the 5th and 95th percentile values. 
  
The PBBK model-based predictions for the percentage of safrole metabolized to the various 
microsomal metabolites at increasing oral doses of safrole are presented in Figure 3.8. At a 
dose of 0.005 mg/kg bw the percentage of safrole metabolized to 2′,3′-dihydroxysafrole, 1′-
hydroxysafrole, 3′-hydroxysafrole and 1,2-dihydroxy-4-allylbenzene was, respectively, 11, 
36, 3, and 38% of the dose. When the dose was increased to 100 mg/kg bw, approximately 
8, 21, 4, and 39% of the dose was predicted to be metabolized to 2′,3′-dihydroxysafrole, 1′-
hydroxysafrole, 3′-hydroxysafrole and 1,2-dihydroxy-4-allylbenzene, respectively. These 
results reveal that 1,2-dihydroxy-4-allylbenzene is the major metabolite at low but also at 
high dose levels. When the dose increases the relative formation of 2′,3′-dihydroxysafrole 
and 1′-hydroxysafrole decreased only to a limited extent from 11 and 36% of the dose at 
0.005 mg/kg bw to approximately 8 and 21% of the dose at 100 mg/kg bw, whereas the 
percentage formation of 1,2-dihydroxy-4-allylbenzene and 3′-hydroxysafrole tended to 
increase to a limited extent from values amounting to, respectively, 38 and 3% of the dose 
at 0.005 mg/kg bw to values of 39 and 4% of the dose at 100 mg/kg bw/day. Overall the 
results reveal that for safrole a dose-dependent shift in microsomal conversion of safrole 
leading to a relative increase in bioactivation at higher dose levels, is not observed. This can 
be explained by the fact that for microsomal conversion of safrole no saturation of an 
important metabolic route occurs in a dose range from 0.005 to 100 mg/kg bw/day. 
 
Figure 3.8. PBBK model based predicted dose-dependent changes in overall formation of microsomal safrole 
metabolites in all organs. The lines correspond to 2′,3′-dihydroxysafrole (••••), 1′-hydroxysafrole (▬ ▬ ), 3′-
hydroxysafrole (▬▬), and 1,2-dihydroxy-4-allylbenzene (▬•▬).  
  
 
Model simulations of the formation of different metabolites of safrole and 1′-
hydroxysafrole and comparison of those metabolites between humans and male rats 
To obtain insight in possible species differences in metabolic activation and detoxification 
of safrole between humans and male rats, the results obtained with the PBBK model for 
safrole in humans were compared with those obtained by the previously defined PBBK 
model for safrole in male rats (Martati et al., 2011). First, a comparison is made with 
respect to the possible species differences in the formation of various microsomal 
metabolites of safrole and in the formation of 1′-hydroxysafrole metabolites. This 
comparison was made at a dose level of 0.005 mg/kg bw, which is a dose level reflecting 
realistic daily human intakes. The second comparison focuses on the formation of 1′-
sulfooxysafrole in human and male rat liver at dose levels varying from high doses 
representing dose levels causing liver tumors in long-term rodent bioassays, down to dose 
levels reflecting realistic human exposure.  
Results from a Monte Carlo simulation of the formation of microsomal metabolites of 
safrole and of the conversion of 1ʹ-hydroxysafrole and comparison of those metabolites 
between humans and rats are presented in Figure 3.9. Differences between humans and 
male rats mainly occur in the formation of 1′-hydroxysafrole and 1,2-dihydroxy-4-
allylbenzene (Figure 3.9A) with the median formation of 1′-hydroxysafrole being fourfold 
higher in humans and the median formation 1,2-dihydroxy-4-allylbenzene being twofold 
lower in humans. The median formation of 2′,3′-dihydroxysafrole is 1.3- fold higher in 
humans than in male rats. The median formation of 3′-hydroxysafrole is twofold lower in 
humans than in male rats (Figure 3.9A). In humans, 1′-hydroxysafrole is mostly oxidized to 
1′-oxosafrole (Figure 3.9B), which is due to the relative high efficiency for oxidation of 1′-
hydroxysafrole in comparison with glucuronidation and sulfonation. Predicted formation of 
1′-oxosafrole in humans is 98% of the 1′-hydroxysafrole formed while in rats this 
metabolite only accounts for 0.3% of the 1′-hydroxysafrole formed (Martati et al., 2011). In 
male rats, 1′-hydroxysafrole is mostly converted to 1′-hydroxysafrole glucuronide 
corresponding to 99.5% of the 1′-hydroxysafrole formed (Martati et al., 2011), a value that 
is predicted to amount to only 2% in human liver. Formation of the ultimate carcinogen 1′-
sulfooxysafrole in humans was predicted to range between 0.128% (95th percentile) and 
  
0.01% (5th percentile) of the dose with the median being fivefold higher in human than in 
rat liver (Figure 3.9B).  
Figure 3.9. PBBK model and Monte Carlo simulation based prediction of (A) the formation of microsomal 
conversion of safrole in humans (indicated with H) and male rat (indicated with R) liver following an oral dose of 
0.005 mg/kg bw safrole and (B) the cumulative levels of metabolites formed from 1′-hydroxysafrole in humans 
(indicated with H) and male rat liver (indicated with R) at this oral dose. Results of the Monte Carlo simulation 
obtained with the PBBK model for humans were presented as box-plots. The bottom and top of the boxes 
represent the 25th and 75th percentile, respectively and the the middle of the box is the 50th percentile (the median). 
The ends of the whiskers attached to the box represent the the 5th and 95th percentile. For the rat model only the 
average predicted formation of different metabolites is displayed.  
To see the possible dose-dependent changes in the formation of 1′-sulfooxysafrole in 
different species, the dose-dependent predicted formation of 1′-sulfooxysafrole in humans 
was compared with that predicted for rats. The predicted formation of 1′-sulfooxysafrole 
from a dose as low as 10-6 mg/kg bw to a dose as high as 100 mg/kg bw is presented in 
Figure 3.10. From these results it can be derived that the formation of 1′-sulfooxysafrole in 
human and rat liver is predicted to be linear up to doses as high as the benchmark dose 
(BMD10) that gives 10% extra cancer incidence (Filipsson et al., 2003) amounting to 5-39 
mg/kg bw (calculated based on data from Boberg et al. (1983) and Miller et al. (1983)) 
when plotted on a log-log scale (Figure 3.10) as well as on linear scale (data not shown). 
Over the whole dose range the median formation of 1′-sulfooxysafrole is three to fivefold 
higher in human than in rat liver, with the 5th percentile being equal to the formation of 1′-
sulfooxysafrole in rat liver and the 95th percentile being 12- to 19-fold higher. 
  
 
                
Figure 3.10. PBBK model-predicted dose-dependent formation of 1′- sulfooxysafrole in the liver of human, 
corresponding to the median or 50th percentile ( ▬▬ ), the 5th and 95th percentiles ( ▬ ▬ ) and rat (▬ ▬ ). Note 
that the lines of the 5th percentile of 1′-sulfooxysafrole formation in humans and the mean of those in rats overlap. 
Comparison of PBBK model-based predictions for safrole with the PBBK model-
based predictions for the related alkenylbenzenes estragole and methyleugenol in 
humans 
With the present PBBK model for safrole and the PBBK models for the related 
alkenylbenzenes estragole and methyleugenol previously developed (Al-Subeihi et al., 
2012; Punt et al., 2009), comparisons can be made for the dose-dependent formation of the 
proximate carcinogenic 1′-hydroxy metabolites and also of the 1′-hydroxy glucuronide, 1′-
oxo, and 1′-sulfooxy metabolites. Figure 3.11 presents the formation of these metabolites 
for the three alkenylbenzenes as predicted by the respective human PBBK models. Figure 
3.11A shows that the predicted formation of 1′-hydroxysafrole is 12-fold lower than 
formation of 1′-hydroxyestragole and fivefold higher than formation of 1′-
hydroxymethyleugenol. Figure 3.11B shows that the predicted formation of 1′-hydroxy 
glucuronide is very similar for the three alkenylbenzenes. Figure 3.11C shows that the 
predicted formation of 1′-oxosafrole is approximately twofold lower than formation of 1′-
oxoestragole and 10-fold higher than formation of 1′-hydroxymethyleugenol. Figure 3.11D 
reveals that the formation of the unstable reactive 1′-sulfooxy metabolite in the human liver 
  
is predicted to vary less than fivefold for the three alkenylbenzenes, being highest for 
estragole. The data obtained also reveal that for all three alkenylbenzenes the formation of 
the ultimate carcinogenic 1′-sulfooxy metabolite increases linearly with the dose up to dose 
levels of at least 10 mg/kg bw and that the overall conversion of safrole is slower than that 
of estragole and methyleugenol taking about 120 h instead of 24 h for full conversion.  
 
 
 
Figure 3.11. PBBK model based prediction of the dose-dependent formation of (A) the 1′-hydroxy metabolite, (B) 
the 1′-hydroxy glucuronide metabolite, (C) the 1′-oxo metabolite, and (D) the 1′-sulfooxy metabolite of estragole 
(▬▬▬), methyleugenol (▬ ▬ ▬), and safrole (…..) in pooled human liver after 120 h. The human PBBK 
models used for estragole and methyleugenol were previously described (Al-Subeihi et al., 2012; Punt et al., 
2009). 
  
 
Discussion 
In the present study, a PBBK model was developed to provide possibilities for the 
evaluation of the relative extent of bioactivation and detoxification of safrole in humans at 
dose levels relevant for human dietary intake. 
The performance of the developed PBBK model was evaluated by comparison of the 
predicted levels of urinary metabolite formation with the literature reported levels of the 
total safrole metabolites detected in the urine of humans exposed to two different oral doses 
of safrole (Benedetti et al., 1977). The model predicted the time-dependent formation of 
safrole urinary metabolites reasonably well at the two dose levels of 0.0027 mg/kg bw for a 
60 kg person (corresponding to 0.163 mg/subject) and 0.0276 mg/kg bw for a 60 kg person 
(corresponding to 1.655 mg/subject). The PBBK model-based prediction for the formation 
of safrole urinary metabolites at these dose levels amounted to 88% of the dose, whereas 
the percentage experimentally reported amounted to 97 and 96% of the dose, respectively. 
Based on results of a Monte Carlo simulation the differences observed were found to be 
partly due to uncertainty and variability in rates of formation of different metabolites and/or 
in other parameters shown in the sensitivity analysis to influence the modeling outcomes to 
the largest extent. 
Benedetti et al. (1977) revealed that treatment of the urine of humans exposed to 1.655 
mg/subject with β-glucuronidase resulted in extracted safrole metabolites at levels that were 
lower than those obtained for the urine of a rat exposed to safrole. This correlates with the 
finding of the present study that the glucuronidation of 1′-hydroxysafrole is a minor 
pathway in humans when compared with rats, leaving the possibility for other conversions 
of 1′-hydroxysafrole in humans. Although the extent of oxidation of 1′-hydroxysafrole to 
1′-oxosafrole could not be evaluated against human in vivo data, the present study reveals 
that in human liver oxidation of 1′-hydroxysafrole is the main detoxification route of 1′-
hydroxysafrole and this is in line with what was observed before for detoxification of 1′-
hydroxyestragole and 1′-hydroxymethyleugenol in human liver (Al-Subeihi et al., 2012; 
Punt et al., 2009).  
  
The PBBK model-predictions revealed that the relative formation of the various metabolites 
of microsomal conversion of safrole as well as the formation of the different 1′-
hydroxysafrole metabolites is hardly changing at dose levels up to 100 mg/kg bw in 
humans (Figure 3.8). The PBBK model for safrole previously developed for male rats 
revealed similar results, showing also no dose-dependent effects on the relative extent of 
bioactivation and detoxification (Martati et al., 2011). The PBBK model-predictions on 
species differences and interindividual human variation in formation of 1′-sulfooxysafrole 
can be used to derive so-called chemical-specific adjustment factors (CSAFs), which allow 
to evaluate the appropriateness of the default uncertainty factors used in risk assessment for 
species differences and interindividual human variation in kinetics (Meek et al., 2003). 
Comparison of the median 1′-sulfooxysafrole up to dose levels of 100 mg/kg bw between 
rats and humans, revealed that species differences are moderate, amounting to only three- to 
fivefold. Species-dependent differences in the bioactivation of safrole to 1ʹ-sulfooxysafrole 
are thus in line with the default factor of 4 generally assumed to reflect interspecies 
variation in kinetics (assuming that the default factor of 10 can be divided into a factor of 4 
for kinetics and 2.5 for dynamics) (IPCS, 2010). Monte Carlo simulations were performed 
to evaluate the effect of uncertainty and variability on the predicted formation of 1ʹ-
sulfooxysafrole in the liver. Based on these results a CSAF for interindividual differences 
in kinetics can be calculated by dividing the parameter estimate at the 95th percentile by the 
parameter estimate at the median (IPCS, 2005). The CSAF obtained in this way for the 
predicted formation of 1ʹ-sulfooxysafrole is 3.9. Comparison of the CSAF with the default 
uncertainty factor of 3.16 for human variability in biokinetic reveals that the default 
uncertainty factor adequately protects 95% of the population. 
Different approaches worldwide exist to assess the risk of compounds that are both 
genotoxic and carcinogenic. Numerical estimates of the risk associated with human 
exposure might be derived by extrapolation of carcinogenicity data obtained in animals at 
high to low dose levels relevant for the human situation. Linear extrapolation is the simplest 
form by which such extrapolations below the available experimental data set can be 
performed (COC, 2004). This approach is, however, much debated, because it is not known 
whether linear extrapolation actually reflects the underlying biological processes. In 
  
 
addition, it is argued that species differences are not taken into account in this approach 
(EFSA, 2005). The results of the PBBK models for rats (Martati et al., 2011) and humans 
obtained in the present study, however, indicate that the kinetic data do not provide a reason 
to argue against such a linear extrapolation from the rat tumor data to the human situation. 
As illustrated in Figure 3.10, the dose-dependent formation of 1ʹ-sulfooxysafrole in the 
liver of rat and human is linear from doses as high as the BMD10 down to dose levels as low 
as the virtual safe dose (VSD) that gives one additional cancer risk in a million upon life 
time exposure) amounting to 0.046-0.39 µg/kg bw when plotted on a log-log scale as done 
in Figure 3.10 and also when plotted on a linear scale (Figure not shown). Because the 
BMD10 appears to be located within the linear part of the curves and the rat and human 
curves do not differ substantially, the PBBK results of the present study support that 
possible non-linear kinetics and species differences in kinetics should not be used as an 
argument against using a linear low dose cancer risk extrapolation from animal data to the 
low dose human situation. This illustrates that PBBK models provide a useful tool in risk 
assessment of food-borne chemicals when evaluating human risks. 
The 1ʹ-hydroxy metabolites of the alkenylbenzenes safrole, methyleugenol, and estragole 
and their sulphate conjugates have been shown to form DNA adducts in vivo and in vitro in 
a dose-dependent manner. It is of interest to compare the results for the PBBK predicted 
formation of the ultimate carcinogenic metabolites of the three alkenylbenzenes with their 
relative potency for DNA adduct formation in vitro and in vivo and even with their BMD10 
values for tumor formation. In human liver, the differences in the level of the predicted 
formation of the ultimate carcinogenic 1′-sulfooxy metabolite formed from the three 
alkenylbenzenes were less than fourfold, the formation being highest for estragole. For rat 
liver, we have previously reported similar (fivefold) differences in bioactivation of the three 
alkenylbenzenes to their ultimate carcinogenic 1′-sulfooxy metabolites (Martati et al., 
2011). In HepG2 cells exposed to the alkenylbenzenes, the dose-dependent formation of 
DNA adducts decreased in the order methyleugenol > estragole > safrole but varied at most 
3.5-fold. Furthermore, the estimated calculated BMDL10 values of safrole, methyleugenol, 
and estragole, amount to approximately 3-29 mg/kg bw/day (calculated using BMD 
software based on the data from Boberg et al. (1983) and Miller et al. (1983)), 22-32 mg/kg 
  
bw (Rietjens et al., 2008), and 9-33 mg/kg bw/day (Rietjens et al., 2010), respectively. 
These results together indicate that in both rats and humans the level of bioactivation of the 
three alkenylbenzenes is comparable, which is in line with their comparable carcinogenic 
potential.  
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Abstract 
Safrole, a natural constituent of mace, causes liver tumors in rodent bioassays at high dose 
levels. This is ascribed to formation of DNA reactive 1′-sulfooxysafrole. The present paper 
identifies malabaricone C as a mace constituent able to inhibit safrole DNA adduct 
formation at the level of sulfotransferase (SULT)-mediated bioactivation. The SULT 
inhibition was incorporated into the physiologically based biokinetic (PBBK) rat and 
human models for safrole to investigate the possible in vivo effect of co-administration of 
safrole and malabaricone C-containing mace extract. At a dose of 50 mg/kg body weight 
(bw), assuming 100 or 1% uptake of malabaricone C and a ratio of malabaricone C-
containing mace extract to safrole similar to what is found in mace, inhibition of 1′-
sulfooxysafrole formation by malabaricone C-containing mace extract for rats and humans 
amounts to 90 and 100% or 61 and 91%, respectively. Altogether these data suggest a 
potential reduction of the cancer risk when safrole exposure occurs via mace within its 
normal food matrix compared to what is observed upon exposure to safrole as a pure 
compound. 
 
 
 
 
 
 
 
  
  
 
Introduction 
Myristica fragrans Houtt. belongs to the family Myristicaceae and is the source for two 
important spices produced from different parts of the plant: nutmeg which originates from 
the seeds and mace which is made from the dried aril cover of the seeds. Mace and its 
essential oils are most widely used as flavouring agents for sauces, meat and other food 
products. However, mace as well as nutmeg are known to contain so-called 
alkenylbenzenes including safrole (Archer, 1988) which has been recognized to be DNA 
reactive and carcinogenic in rodent bioassays when given at high dose levels (Daimon et 
al., 1997; Daimon et al., 1998). In addition, the habit of chewing betel quid in the 
Taiwanese population was reported to result in safrole concentrations up to 420 µM in 
saliva during chewing and has been linked to the increased incidence of oral squamous cell 
carcinoma (Hwang et al., 1992; Ko et al., 1995). Furthermore, safrole-like DNA adducts 
were detected with high frequency in oral tissues from oral cancer patients (Chen et al., 
1999).  
The DNA reactive and hepatocarcinogenic effects of alkenylbenzenes have been linked to 
their bioactivation via the formation of a 1′-hydroxy metabolite catalyzed by cytochromes 
P450 followed by sulfation resulting the ultimate reactive 1′-sulfooxy metabolite that forms 
covalent adducts with cellular macromolecules including DNA, RNA and proteins 
(Borchert et al., 1973a; Wislocki et al., 1977). Figure 4.1 schematically presents the 
pathway for bioactivation of safrole and the nature of the DNA adducts formed. The DNA 
adducts found in hepatic tissue of rats exposed to safrole were identified as N2-(trans-
isosafrol-3′-yl)-2′-deoxyguanosine (S-3′-N2-dGuo), N2-(safrol-1′-yl)-2′-deoxyguanosine (S-
1′-N2-dGuo) and N6-(trans-isosafrol-3′-yl)-2′-deoxyadenosine (S-3′-N6-dAdo) (Randerath et 
al., 1984). The S-3′-N2-dGuo and S-1′-N2-dGuo were the major adducts found in patients 
with oral squamous cell carcinoma resulting from the habit of betel quid chewing (Chen et 
al., 1999).  
The Committee of Experts on Flavouring Substances (CEFS) of the Council of Europe 
evaluated safrole and concluded that safrole is a weak hepatocarcinogen and that efforts 
should be made to reduce its consumption through foods and beverages as much as possible 
  
(Council of Europe, 1997). Safrole and sassafras oil were banned as food additives in 1960 
by the U.S. Food and Drug Administration (FDA). The Scientific Committee on Food 
(SCF) concluded that safrole is genotoxic and carcinogenic and that reduction in exposure 
and restriction in the use levels are indicated (SCF, 2002). Human exposure to safrole is 
mainly via consumption of herbs and spices mostly nutmeg, mace and their essential oils 
(SCF, 2002). One may argue that risk assessment resulting from consumption of herbs and 
spices that contain safrole should take into account the possible modulating effects of other 
compounds present in these herbs or spices on the cytochrome P450 and/or sulfotransferase 
(SULT)-catalyzed bioactivation of safrole. Some spices were found to inhibit cytochrome 
P450 2C9, one of the cytochrome isoforms found to be involved in the metabolism of 
safrole to 1′-hydroxysafrole (Jeurissen et al., 2004; Kimura et al., 2010; Ueng et al., 2004). 
Furthermore for the related alkenylbenzene estragole present in basil, it was recently 
demonstrated that a methanolic basil extract and its isolated constituent nevadensin 
inhibited the sulfation and DNA adduct formation of the proximate carcinogenic 1′-
hydroxyestragole metabolite in studies using rat and human S9 protein, the hepatoma cell 
line HepG2 and/or rat hepatocytes (Alhusainy et al., 2010; Jeurissen et al., 2008). 
Therefore, the objective of the present study was to investigate whether safrole containing 
spices contain ingredients that may inhibit the SULT mediated bioactivation of safrole. 
Mace was chosen as the model spice of interest because it contains significant levels of 
safrole (0.43-1.99%) (Archer, 1988). Upon identifying a major mace ingredient able to 
inhibit SULT mediated bioactivation and DNA adduct formation of 1′-hydroxysafrole in in 
vitro model systems, the possible effect of combined in vivo exposure was investigated by 
incorporating the kinetics for SULT inhibition into our recently developed physiologically 
based biokinetic (PBBK) models for formation of 1′-sulfooxysafrole in the rat and human 
liver.  
  
 
 
 
Figure 4.1. Bioactivation pathways of safrole and the structure of DNA adducts as identified by (Chung et al., 
2008; Daimon et al., 1998; Randerath et al., 1984; Phillips et al., 1981). S-3′-N2-dGuo = N2-(trans-isosafrol-3′-yl)-
2′-deoxyguanosine, S-1′-N2-dGuo = N2-(safrol-1′-yl)-2′-deoxyguanosine and S-3′-N6-dAdo= N6-(trans-isosafrol-3-
yl)-2′-deoxyadenosine.  
  
Materials and methods 
Caution : The following chemicals are hazardous and should be handled carefully: 1′-
hydroxysafrole and 1′-acetoxysafrole. 
Powder dried mace was obtained from a local supermarket. Pooled human and male rat 
liver S9 (Sprague-Dawley) were purchased from BD Gentest (Worburn, U.S.). The HepG2 
cell line was purchased from American type culture collection (Manassas, Virginia). 
Culture medium DMEM/F12 (L-glutamine, 15 mM HEPES) and phosphate buffer saline 
(PBS, pH 7.4) were purchased from GIBCO (Paisley, UK). The chemical compounds were 
obtained with highest purity available. 7-Hydroxycoumarin (7HC), 7-hydroxycoumarin 
sulphate potassium salt (7HCS), 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium 
bromide (MTT), ammonium bicarbonate, Tris(hydroxymethyl)aminomethane, uridine 5′-
diphosphoglucuronic acid (UDPGA), 3′-phosphoadenosine-5′-phosphosulphate (PAPS), 2′-
deoxyguanosine (2′dGuo), pentachlorophenol (PCP), glutathione reduced (GSH), 
phosphodiesterase I from Crotalus adamenteus (venom phosphodiesterase, VPDE), 
phosphodiesterase II from bovine spleen (spleen phosphodiesterase, SPDE), alkaline 
phosphatase from Escherichia coli, and nuclease P1 from Penicillium citrinum were 
obtained from Sigma-Aldrich (Steinheim, Germany). Oxidized β-nicotinamide adenine 
dinucleotide phosphate (NAD+) was obtained from Roche Diagnostics (Mannheim, 
Germany). Methanol and ethanol (pro analysis), hydrochloric acid, acetic acid glacial, 
formic acid, ethylenediaminetetraacetic acid (EDTA), sodium phosphate, zinc sulphate 
(ZnSO4.7H2O), pyridine and trifluoroacetic acid (Uvasol) were purchased from VWR 
(Darmstadt, Germany). Dimethyl sulfoxide (DMSO) and dichloromethane were purchased 
from Acros Organic (New Jersey, U.S.). Acetic anhydride was supplied by J.T. Baker 
(Deventer, The Netherlands). Chromatography grade acetonitrile and methanol were 
purchased from Biosolve BV (Valkenswaard, The Netherlands). 1′-Hydroxysafrole was 
synthesized and purified as described previously (Jeurissen et al., 2004; Martati et al., 
2011). 1′-Acetoxysafrole was synthesized from 1′-hydroxysafrole as described previously 
for synthesis of 1′-acetoxyestragole from the related alkenylbenzenes estragole (Borchert et 
al., 1973b; Punt et al., 2007). 
  
 
Preparation of mace extract 
A methanolic mace extract was prepared as previously described for preparation of 
methanolic extracts from basil (Alhusainy et al., 2010). The extraction yield was 
approximately 32% (w/w). The mace extract obtained was subsequently diluted with 
methanol, to a concentration of 150 mg/mL. Methanolic mace extract and its stock of 150 
mg/mL were kept at -20°C until usage.  
Fractionation of mace extract  
Mace extract was fractionated using preparative HPLC using a Waters 600 controller liquid 
chromatography system with Waters 2996 PDA-detector (Waters, Milford, MA). To this 
end, 50 µL of a solution of 150 mg methanolic mace extract/mL was injected onto a 
preparative column Sunfire C18 (5 µm, 10 x 250 mm). The mobile phase was made with 
ultrapure water containing 0.1 % (v/v) acetic acid and methanol. The flow rate was 4 
mL/min and a gradient was applied from 0 % to 100% methanol in 80 minutes, and kept at 
100% for 10 minutes, after which the column was re-equilibrated with the initial condition 
for 10 minutes. A total of 37 fractions were collected. Methanol was subsequently 
evaporated under nitrogen stream. Prior to freeze drying, the fractions were kept overnight 
at -80°C. The freeze drying was performed using an Alpha 1-2 LDplus freeze dryer 
(Salmenkipp BV, The Netherlands) at approximately 0.63 mbar. The samples thus obtained 
were dissolved in 100 µL methanol and kept at -80°C until further analysis for SULT 
inhibiting activity using the SULT activity assay. 
Measurement of SULT activity  
The effect of the methanolic mace extract and its isolated freeze dried fractions on SULT 
activity was investigated using the substrate 7HC and performed as previously described 
(Alhusainy et al., 2010). For quantification of 7HCS in the incubations for SULT activity, 
aliquots of 3.5 µL of the incubation mixtures were analyzed on a Waters UPLC/DAD 
system consisting of a Waters Acquity binary solvent manager, sample manager and 
photodiode array detector (Waters, Milford, MA), equipped with a Waters Acquity UPLC 
BEH C18 column (1.7 µm, 2.1 x 50 mm). Quantification of 7HCS was achieved by 
  
comparison of the peak area of the 7HCS in the chromatograms obtained at wavelength of 
280 nm to the calibration curve of a commercially available of reference compound. 
Determination of IC50  
The IC50 for the mace extract mediated inhibition of SULT was determined in incubation 
with rat or pooled human S9 based on incubation for SULT activity performed as described 
above, with 25 µM 7HC and concentration of mace extract ranging from 0.01 to750 mg/L 
The IC50 values of mace extract were determined by fitting the data to the standard enzyme 
hyperbolic inhibition equation: y = Vmax * (1 - (x /(IC50 +x))) + Y2, using the Life Science 
Workbench (LSW) data analysis toolbox (version 1.1.1, MDL information system, San 
Leandro, CA). In this equation, Y represents the percentage of inhibition of 7HCS 
formation compared to control, Y2 is the lowest value of Y, Vmax refers to the velocity 
observed in the absence of mace extract and x is the concentration of mace extract. 
Determination of the inhibition constant  
The inhibition constant for SULT inhibition was determined in incubations with rat or 
pooled human S9 by the mace extract based on incubations for SULT activity performed as 
described above, with concentrations of 7HC increasing from 0 to 25 µM in the absence or 
presence of mace extract at the concentration close to the IC50 for the respective S9 
preparation. The type of inhibition by mace extract was determined with SigmaPlot 
Enzyme Kinetics Module (Systat Software, Inc, San Jose, CA). The initial velocities 
observed in the presence or absence of mace extract were automatically fitted to the 
equations and the best fitting inhibition model was selected. Mace extract appeared to 
exhibit a mixed-type inhibition of SULT catalyzed formation of 7HCS with rat and human 
liver S9 protein (see Results section). The inhibition constant (Ki) and the factor alpha 
describing this type of inhibition were obtained. The factor alpha reveals the effect of 
inhibitor on the binding of the enzyme for its substrate as well as the effect of the substrate 
on the binding of the enzyme for its inhibitor (Copeland, 2000). 
  
 
1
 H-NMR analysis 
The fraction showing the most potent SULT-inhibiting activity was analyzed by 1H-NMR 
to identify the compound(s) present. To this end, the methanol was evaporated under a 
nitrogen flow, followed by freeze drying and the sample was dissolved in 200 µL 
deuterated methanol in a 3 mm NMR tube (Bruker match system). 1H-NMR analysis was 
performed using a Bruker Avance III 600 MHz NMR spectrometer (Bruker Ettlingen, 
Germany) equipped with a cryoprobe. A Noesygppr1d pulse sequence with a 3 s delay, 0.1 
s mixing time and a 1.8 s acquisition time were used (18,028 Hz sweep width, 64 K data 
points). Spectra were obtained at 300 K. Resonances were reported relative to deuterated 
methanol at 3.34 ppm. In addition 2D 1H-1H NMR data were acquired (COSY and 
TOCSY) as well as 1H-13C HSQC data.  
Cytotoxicity test  
Cytotoxicity of 1′-hydroxysafrole and the mace extract towards HepG2 cells was 
determined using the MTT test (Jeurissen et al., 2008). The optical density of each well was 
measured with a plate reader (Molecular Devices, Sunnyvale, CA) at a wavelength 562 and 
620 nm for the colour intensity and background, respectively. The cell viability was defined 
as the ratio between the absorbance of exposed cells as compared to the absorbance for 
untreated controls. 
Formation of S-3′-N2-dGuo in HepG2 cells exposed to 1′-hydroxysafrole and mace 
extract  
HepG2 cells were grown in culture medium (DMEM/F12 with glutamine containing 10% 
foetal calf serum) in a 75 mL flask. Cell confluence of 90% was required prior to exposure. 
At 90% confluence, the growth medium was removed and the cells were exposed to fresh 
medium containing the test compounds. 1′-Hydroxysafrole was added from a 1000 times 
concentrated stock solution in DMSO to give a final concentration of 100 µM. Mace extract 
(final concentrations of 0, 5, 25, and 100 mg/L) was added from 1000 times concentrated 
stock solutions in methanol. After exposure for 14 hours at 37°C and 5% CO2, the cells 
were scrapped in PBS (pH 7.4) and collected in a 1.5 mL Eppendorf tube and centrifuged at 
  
1500 rpm for 5 min. The pellets were stored at -20°C until DNA isolation. Isolation of 
DNA from HepG2 cells exposed to the test compounds was performed as described 
previously (Paini et al., 2010). 
Synthesis of S-3′-N2-dGuo 
S-3′-N2-dGuo was prepared as described previously for synthesis of the N2-(trans-
isoestragol-3′-yl)-2′-deoxyguanosine (E-3′-N2-dGuo) adduct of the related alkenylbenzene 
estragole (Punt et al., 2007). To obtain pure synthesized S-3′-N2-dGuo, the reaction mixture 
was purified using HPLC-UV (Waters 600 controller liquid chromatography system) 
equipped with an Alltima C18 column of 5 µm, 150 x 4.6 mm (Grace Alltech, Breda, The 
Netherlands). The flow rate was set at 1 mL/min. The gradient was made with ultrapure 
water and acetonitrile. A gradient was applied from 20% to 26% acetonitrile over 40 min 
after which the percentage of acetonitrile was increased to 100% in 2 min and kept at 100% 
for 1 min. The initial condition was reached within 2 min and kept for 15 min. Under these 
conditions, the peak corresponding to S-3′-N2-dGuo eluted at a retention time of 22.6 min. 
Collected fractions were pooled and the acetonitrile was evaporated under nitrogen. Freeze 
drying was performed after the collected fractions were kept overnight at -80°C. 
Quantification DNA adducts by LC-MS  
Quantification of S-3′-N2-dGuo was performed using LC-ECI-MS/MS on a Perkin Elmer 
200 series HPLC System (Perkin Elmer, Waltham, MA) coupled to an API 3000 system 
(Applied Biosystem, Foster city, CA) as previously described for detection of E-3′-N2-dGuo 
(Paini et al., 2012; Punt et al., 2007). To this end, an aliquot of 10 µL was injected on an 
Agilent Zorbax Extend-C18 column, 2.1×50 mm, 3.5 Micron 80 Å (Basel, Switzerland), 
with a Zorbax guard column. The gradient was made with ultrapure water containing 0.1% 
(v/v) formic acid and acetonitrile. The flow rate was set at 0.3 mL/min and a gradient was 
applied from 20% to 70% acetonitrile over 8 min, after which the percentage of acetonitrile 
was brought to 100% in 1 min and kept at 100% acetonitrile for 2 min. The initial condition 
was restored in 1 min and the column was equilibrated at this condition for 8 min. Under 
these conditions S-3′-N2-dGuo eluted at 2.7 min. The mass spectrometric analysis was done 
  
 
in positive ion mode. The ion spray voltage was set at 4 kV and the ion source temperature 
was set at 250°C. The nebulizer gas (air), curtain (nitrogen) and collision gas (nitrogen) 
were set to 15, 10 and 5 psi respectively. A divert valve was used in order to discard the 
eluent during the first 2 min and the gradient after elution of the peak. Sample analysis was 
carried out using the selected reaction monitoring (SRM) mode and characteristic 
transitions were recorded. The most intense transition was used as quantifier and 
subsequent transitions as qualifiers, for S-3′-N2-dGuo these transitions were as follows: 428 
→ 312 m/z (quantifier), 428 → 164 m/z (qualifier), 428 → 161 m/z (qualifier).  
Effect of mace extract on 1′-hydroxysafrole glucuronidation and oxidation 
To determine the inhibiting potency of mace extract on glucuronidation and oxidation of 1′-
hydroxysafrole, incubations were performed with human or rat liver S9 protein (for 
glucuronidation) or human or rat liver microsomes (for oxidation). The incubations were 
performed as described previously (Martati et al., 2011; Martati et al., 2012) in the absence 
or presence of 100 mg/L of mace extract added from a 200 times concentrated stock 
solution of mace extract in methanol. The type of inhibition by mace extract was 
determined with SigmaPlot Enzyme Kinetics Module (Systat Software, Inc, San Jose, CA). 
The initial velocities observed in the presence or absences of mace extract were 
automatically fitted to the equations and the best fitting inhibition model was selected and 
the values of Ki (the inhibition constants) are also obtained. 
Safrole PBBK models 
The PBBK models used to predict the effect of the SULT inhibition by mace extract on 
safrole bioactivation in vivo were based on the PBBK models previously described for 
safrole in rats (Martati et al., 2011) and humans (Martati et al., 2012). The values of the 
apparent maximum velocity (Vmax(app)) for formation of microsomal safrole metabolites and 
of 1′-oxosafrole were scaled to the liver using a microsomal protein yield of 32 mg/g liver 
(Barter et al., 2007). The Vmax(app) values for sulfation and glucuronidation of 1′-
hydroxysafrole were scaled to liver using an S9 protein yield of 143 mg/g liver (Medinsky 
et al., 1994).  
  
Safrole was assumed to be absorbed directly from the gastrointestinal tract to the liver 
following first order kinetics with a default absorption constant set at 1.0 h-1. In this study, 
the inhibition of SULT-mediated formation of 1′-sulfooxysafrole by the mace extract was 
included in the PBBK model with a function for mixed inhibition. The resulting modified 
Michaelis-Menten equation for the formation of 1′-sulfooxysafrole that was incorporated in 
the model was as follows:  
 
dAMHSS/dt=Vmax,HSS/(1+I/(alpha*Ki,HSS))*CLHS/PLHS/(Km,HSS*(1+I/Ki,HSS)/ (1+I*(alpha*Ki,HSS))+(CLHS/PLHS) 
 
In this equation, Ki,HSS and alpha*Ki,HSS are the dissociation constants of the enzyme-
inhibitor complex and of enzyme-substrate-inhibitor complex for the sulfation reaction, 
respectively. Ki,HSS and alpha*Ki,HSS were expressed as mg/L. Vmax,HSS and Km,HSS are the 
values representing the maximum rate and Michaelis-Menten constant for sulfonation of 1′-
hydroxysafrole, expressed as nmol/min/mg S9 protein and µM, respectively. CLHS is the 
concentration of 1′-hydroxysafrole in the liver (µM), PLHS is the liver/blood partition 
coefficient of 1′-hydroxysafrole.  
In incubation with rat tissue fractions, mace extract also exhibited competitive inhibition of 
oxidation of 1′-hydroxysafrole and non-competitive inhibition of glucuronidation of 1′-
hydoxysafrole. These reactions were not inhibited in incubations with human liver 
fractions. To this end, only in the rat PBBK model the Michaelis-Menten equations 
describing oxidation and glucuronidation were modified as follows: 
 
dAMHOS/dt = Vmax,HOS *CLHS/PLHS/((Km,HOS)*(1+(I/Ki,HOS)+CLHS/PLHS) 
dAMHSG/dt= Vmax,HSG/(1+I/Ki,HSG)*CLHS/PLHS/(Km,HSG+CLHS/PLHS) 
 
In this equations, Ki,HOS and Ki,HSG represent the dissociation constants of the enzyme-
inhibitor complex for oxidation and glucuronidation. Both Ki,HOS and Ki,HSG were expressed 
  
 
as mg/L. Vmax,x and Km,x are the values representing the maximum rate and Michaelis-
Menten constant, respectively, for oxidation (x=HOS) and glucuronidation (x=HSG) of 1′-
hydroxysafrole (expressed as nmol/min/mg protein and µM, respectively). CLHS is the 
concentration of 1′-hydroxysafrole in the liver (µM), PLHS is the liver/blood partition 
coefficient of 1′-hydroxysafrole.  
In the PBBK model, mace extract was assumed to undergo the same fate as safrole in the 
liver as described by the following the equation: [I] = CL * f, where [I] is the concentration 
of mace extract (mg/L), CL is the concentration of safrole in the liver (µmol/L), and f is the 
ratio mace extract (mg) and safrole (µmol). To see the possible difference in kinetics and 
bioavailability of safrole and mace extract the model was run with a variable ratio between 
these compounds (expressed as mg/µmol). The ratio was varied from 0 (no mace extract) to 
44 (representing an amount of mace extract (expressed as mg) that is 44 times higher than 
safrole (expressed as µmol). From this simulation formation of 1′-sulfooxysafrole, 1′-
oxosafrole and 1′-hydroxysafrole glucuronide were calculated after 72 h (for rat model) 
(Martati et al., 2011) or 120 h (for human model) (Martati et al., 2012) representing time 
points at which safrole conversion appeared to be complete. The dose of safrole used for 
the PBBK modeling was 0.005 mg safrole/kg body weight (bw) which is the dose 
representing human daily intake (SCF, 2002).  
Statistical Analysis 
A t-test was performed using Excel (Microsoft Office 2010) to evaluate whether the 
differences between treatments were statistically significant. Variances equality were tested 
with Levene's test (SPSS 15.0 for Windows, SPSS Inc. Chicago, IL). 
Results 
Inhibition of SULT activity by mace extract 
Figure 4.2A shows the inhibition of SULT activity by increasing concentrations of the 
methanolic mace extract. Increasing concentrations of the mace extract inhibited SULT 
activity  in a dose-dependent manner. For comparison the figure also shows the effect of 25 
µM of the well-known SULT inhibitor PCP. Incubations without co-factor PAPS did not 
  
show any formation of 7HCS, whereas, control incubations with methanol or DMSO 
elicited no inhibition of SULT mediated 7HCS formation (data not shown).  
SULT inhibition by different fractions of mace extract 
Figure 4.2B shows the SULT inhibiting potency of each of the 37 mace fractions collected 
upon HPLC fractionation of the methanolic mace extract. The fractions with the most 
potent SULT inhibiting activity were fractions 23 (with approximately 91% inhibition), 
followed by fraction 18 (88%) and fraction 19 (57%). The most potent mace fraction, 
fraction number 23, was analyzed using HPLC revealing that it contained one major 
compound (chromatogram not shown) and subsequently analyzed using 1H-NMR and 13C-
NMR in order to identify this compound. 
 
Figure 4.2. Inhibition by mace extract of the SULT mediated conversion of 7HC to 7HCS by pooled rat liver S9 
protein in the presence of (A) an increasing concentration of mace extract or 25 µM PCP or (B) collected mace 
fractions. Data points represent mean ± SD of three independent measurements. An asterisk (*) indicates a 
significant inhibition compared to the incubation without inhibitor (* p < 0.05, ** p<0.01, *** p< 0.001).  
  
 
Identification of a potent inhibitor in mace extract 
1H-NMR and 13C-NMR characteristics of the compound present in fraction 23 perfectly 
matched the molecule no 7 (malabaricone C) reported by (Pham et al., 2000). Figure 4.3 
presents the structure of this newly identified SULT inhibitor from mace. 
 
 
 
Figure 4.3. Chemical structure of malabaricone C, the newly identified SULT inhibitor in mace extract 
Effect of mace extract on the kinetics of SULT activity  
Inhibition of SULT activity by mace extract indicated that the inhibition was dose 
dependent (Figure 4.4). The IC50 values of mace extract derived from these curves are 41 
and 3.2 mg/L for rat and human liver S9 protein, respectively. For determination of the Ki 
values for the SULT inhibition by mace extract, 7HC concentration-dependent SULT 
activity was measured in the absence (uninhibited) or presence of 50 mg/L or 3 mg/L of 
mace extract for respectively rat and pooled human S9. Figure 4.5 presents the formation of 
7HCS by pooled rat and human liver S9 versus the 7HC substrate concentration in the 
presence and absence of mace extract. The apparent Kmax and Vmax values derived from the 
curve obtained in the absence of inhibitor are presented in Table 4.1. The catalytic 
efficiency (Vmax/Km) for SULT-dependent formation of 7HCS was about three times higher 
for male rat liver S9 protein than that for human liver S9 protein. In rats, the apparent Vmax 
for sulfation was two times lower and the Km increased three times in the presence of 50 
mg/L mace extract. Whereas in humans, in the presence of 3 mg/L of mace extract the 
apparent Vmax was 1.7 times lower than the Vmax obtained in the absence of mace extract and 
the Km values was 2.3 times higher. These results indicate that both Vmax as well as Km are 
  
affected to a similar extent upon addition of the mace extract pointing at a mixed-type 
inhibition for both rat and human SULT activity in the liver by mace extract. The Ki values 
for inhibition of SULT activity were 8.3 and 1.0 mg/L for rat and human liver S9, whereas 
the alpha*Ki derived from these curves amounted to 41.5 and 4 mg/L. 
Table 4.1. Kinetic parameters of SULT-dependent formation of 7HCS by pooled rat and 
human liver S9 protein in the absence and presence of mace extract.  
 Without mace extract With mace extract1 
Species  Apparent Vmax 
(pmol/min/mg 
S9 protein  
Apparent Km 
of 7HC (µM) 
Apparent Vmax 
(pmol/min/mg 
S9 protein 
Apparent 
Km of 7HC 
(µM) 
Ki 
(mg/L)
 
alpha*Ki 
(mg/L) 
Rat 1341 ± 53 3.0 ± 0.4 622 ± 49 8.8 ± 1.7 8.3 41.5 
Human  301 ± 14 2.2 ± 0.4 174 ± 11 5.0 ± 0.9 1.0 4.0 
 
 
1
 Concentration of mace extract used were 50 and 3 mg/L for, respectively, rat and pooled human S9. 
Data represent mean ± SD of three replications (for rats) and five replications (for humans). 
Ki is a dissociation constant of the enzyme-inhibitor complex. 
alpha*Ki is a dissociation constant of the enzyme-substrate-inhibitor complex.  
 
Figure 4.4. Mace extract concentration dependent SULT inhibition in incubations with male rat liver S9 protein 
(▲) and pooled human liver S9 protein (●). 
  
 
 
Figure 4.5. 7HC concentration dependent formation of 7HCS in the absence (•) or presence () of mace extract 
(50 mg/L for rat liver S9 or 3 mg/L for pooled human liver S9) in incubation with (A) male rat liver S9 protein and 
(B) pooled human liver S9 protein. 
Inhibition of DNA adduct formation by mace extract in HepG2 cells exposed to 1′-
hydroxysafrole 
Figure 4.6 presents the formation S-3′-N2-dGuo detected in HepG2 cells exposed to 100 
µM 1′-hydroxysafrole for 14 h in the absence and presence of increasing concentrations of 
mace extract. The mace extract did not display cytotoxicity up to concentrations of at least 
100 mg/L which was the highest concentration tested. The results revealed that mace 
extract inhibited formation of S-3′-N2-dGuo in 1′-hydroxsafrole exposed HepG2 cells an 
effect that increased with the concentration of the mace extract and was statistically 
significant at concentration of 25 mg/L of mace extract and above. 
Effect of mace extract on glucuronidation and oxidation of 1′-hydroxysafrole 
Table 4.2 presents the apparent Km and Vmax for glucuronidation and oxidation of 1′-
hydroxysafrole in the absence and presence of 100 mg/L mace extract with pooled rat and 
human liver S9 or microsomal protein. In rats, the apparent Vmax for oxidation was 1.3 times 
higher and the Km increased 2.8 times in the presence of 100 mg/L of mace extract.  
  
 
Figure 4.6. S-3′-N2-dGuo formation in HepG2 cells exposed to 100 µM 1′-hydroxysafrole in the absence or 
presence of an increasing concentration of mace extract. Data points represent mean ± SD. An asterik (*) indicates 
significant inhibition (P < 0.05). 
 
Whereas for glucuronidation, the Vmax is 1.5 times lower and the Km increased 2.5 times. 
These results point at competitive inhibition type for oxidation of 1′-hydroxysafrole and 
non-competitive type inhibition for glucuronidation of 1′-hydroxysafrole. Based on data 
presented in Table 4.2, the Ki values were determined to amount to 140 mg/L and 86 mg/L 
for oxidation and glucuronidation of 1′-hydroxysafrole, respectively. In human, addition of 
100 mg/L of mace extract to the incubation has no effect in glucuronidation and oxidation 
of 1′-hydroxysafrole because the apparent Vmax and Km were not significantly different 
compared with those values in the absence of 100 mg/L of mace extract. 
PBBK-based prediction for conversion of 1′-hydroxysafrole in the presence of mace 
extract 
The PBBK model for detoxification and bioactivation of safrole in both rat and human were 
modified to take the inhibition by malabaricone C-containing mace extract into account and 
allow investigation of possible in vivo effects on safrole bioactivation to 1′-sulfooxysafrole. 
PBBK model-based predictions were made at safrole dose levels of 0.005 mg/kg bw and 50 
mg/kg bw (Figure 4.7). The dose level of 0.005 mg/kg bw was selected to take into account 
  
 
realistic human dietary exposure levels and the dose of 50 mg/kg bw was chosen to include 
dose levels known to cause tumors in in vivo rodent studies. The PBBK model revealed 
that oral administration of a dose of safrole 0.005 mg/kg bw (SCF, 2002 ) together with 
increasing dose levels of mace extract result in a decrease in formation of the ultimate 
carcinogenic metabolite 1′-sulfooxysafrole. At a ratio between mace extract and safrole of 
44 (mg/µmol) reflecting the level of these constituents in mace (as characterized by the 
extraction efficiency and the safrole content of mace quantified by HPLC analysis of the 
methanolic extracts, data not shown), the predicted inhibition of formation of 1′-
sulfooxysafrole in rat and human liver were 4 and 49%, at a dose 0.005 mg/kg bw of 
safrole, respectively, assuming 100% uptake of mace extract and its constituent, including 
malabaricone C to follow the same kinetic profile as safrole. Figure 4.7B presents the 
predicted formation of 1′-sulfooxysafrole at a dose of safrole of 50 mg/kg bw. At a ratio of 
mace extract and safrole of 44, the inhibition of 1′-sulfooxysafrole formation for rat and 
human liver are 90 and 100% or 61 and 91% assuming 100 and 1% mace extract uptake, 
respectively. 
Tables 4.2. Kinetic parameters for glucuronidation and oxidation of 1′-hydroxysafrole in 
incubations with pooled rat and human liver S9 or microsomal protein in the absence and 
presence of mace extract.  
 
Species Without mace extract With 100 mg/L mace extract   
Apparent Vmax 
(nmol/min/mg S9 
protein or microsomal 
protein) 
Apparent Km  
(µM) 
Apparent Vmax 
(nmol/min/mg S9 
protein or microsomal 
protein) 
Apparent Km 
(µM) 
 Ki (mg/L) 
Oxidation       
Rat 5.0 ± 0.4 1719 ± 293 6.7 ± 0.6 4791 ± 671 140  
Human  8.0 ± 0.3  670 ± 75 7.5 ± 0.6  911 ± 202  
Glucuronidation      
Rat 17.6 ± 1.6  224 ± 56 11.7 ± 2.0  563 ± 198  86 
Human 0.09 ± 0.02 537 ± 299 0.09 ± 0.01  565 ± 148  
 
Data represent mean ± SD of three replications. 
Ki is dissociation constant of the enzyme-inhibitor complex 
 
 
 
  
 
 
Figure 4.7. PBBK-based predictions for the dose-dependent effect of mace extract on 1′-sulfooxysafrole formation 
in the liver of rat (white bars) and human (black bars) at oral dose level of (A) 0.005 mg/kg bw and (B) 50 mg/kg. 
 
Discussion 
Safrole is an alkenylbenzene occurring in many spices. The compound was shown to be 
hepatocarcinogenic in rodents when administered at high dose levels as a pure compound 
(Borchert et al., 1973a; Borchert et al., 1973b; Daimon et al., 1997; Daimon et al., 1998). 
The aim of the present study was to investigate whether ingredients present in safrole 
containing herbs and spices, using mace as the model spice, can interact with the SULT 
mediated bioactivation of safrole pointing at a possible reduction in bioactivation when the 
compound would be dosed in its natural food matrix instead of as a pure compound. In a 
previous study, it was demonstrated that the flavonoid nevadensin, a constituent in basil, is 
a potent inhibitor of bioactivation of the related alkenylbenzene estragole at the level of the 
SULT-mediated conversion of the proximate carcinogenic 1′-hydroxy metabolite to the 
ultimate carcinogenic 1′-sulfooxy metabolite (Jeurissen et al., 2008; Alhusainy et al., 
2010). The results of the present study reveal that mace also contains a potent SULT 
inhibitor which was identified as malabaricone C. The Ki for SULT inhibition by 
malabaricone C-containing mace extract was 8.3 and 1.0 mg/L for male rat and human liver 
fractions, respectively. Given that malabaricone C was not available as a pure compound 
only an estimate of the Ki for malabaricone C can be made. Mace contains 0.53% 
malabaricone C (Orabi et al., 1991). Taking 32% extraction yield for preparation of the 
  
 
mace extract and assuming all malabaricone C to be extracted in mace extract, the content 
of malabaricone C in mace extract is 1.66%. Assuming that 50% of the inhibition observed 
with mace extract would be due to malabaricone C, these Ki values would amount to 0.19 
and 0.023 µM malabaricone C. These Ki values would be in the same range as the Ki values 
determined previously for other SULT inhibitors in the diet like kaempferol and apigenin 
which Ki values of 0.6 µM and 0.7 µM were observed (Alhusainy et al., 2012). The Ki 
values are higher than the Ki value previously identified for nevadensin for which the Ki 
value amounted to 4 nM. The mechanism of inhibition of SULT activity by malabaricone 
C-containing mace extract in this present study was mixed type inhibition resulting an 
increased apparent Km and a decreased apparent Vmax. The alpha*Ki values obtained in the 
present study for malabaricone C-containing mace extract for rat liver and human were four 
to five times higher than the Ki. This indicates that the inhibitor has higher affinity for the 
free enzyme than for the enzyme-substrate complex. In a previous study, inhibition of 
SULT activity by different flavones as well as by nevadensin was found to be non-
competitive (Alhusainy et al., 2010) and also a great volume of literature data supports the 
plausibility of non-competitive inhibition of sulfonation of various substrates by different 
flavonoids such as quercetin, genistein, daidzein, (+)-catechin, kaempferol, apigenin, and 
diadzein (Ghazali and Waring, 1999; Mesía-Vela and Kauffman, 2003; Walle et al., 1995). 
Coughtrie and Johnston (2001) showed that epicatechin gallate and epigallocatechin gallate 
showed uncompetitive inhibition to SULT1A1 but mixed type inhibition to SULT1A2-
1A3. Recently, studies using Salmonella typhimurium TA100 strains with expression of 
human SULT revealed especially human SULT1A1 and SULT1C2 to be able to activate 
the 1′-hydroxymetabolite of the related alkenylbenzene methyleugenol to DNA reactive 
metabolites (Herrmann et al., 2012). The SULT enzymes responsible for conversion of 1′-
hydroxysafrole to 1′-sulfooxysafrole remain to be established. To investigate whether the 
malabaricone C-containing mace extract would also be able to exert inhibition of the DNA 
adduct formation in an intact cell system, the effect of increasing concentrations of mace 
extract on safrole DNA adduct formation in cells from the human hepatoma cell line 
HepG2 exposed to 1′-hydroxysafrole was quantified (Brandon et al., 2003; Knasmüller et 
al., 1998). Exposure of HepG2 cells to 1′-hydroxysafrole in the presence of an increasing 
  
concentration of malabaricone C-containing mace extract revealed a dose-dependent 
inhibition of S-3′-N2-dGuo formation.  
Furthermore, the kinetics for inhibition of SULT activity by malabaricone C-containing 
mace extract were integrated into the previously defined PBBK models for safrole 
bioactivation and detoxification in male rat and human liver (Martati, et al., 2011, Martati, 
et al., 2012). The modified PBBK model allowed prediction of bioactivation and 
detoxification of safrole in the rat and human liver when safrole would be dosed in the 
presence of mace extract. At a dose of safrole 50 mg/kg bw and ratio of 44 mg mace 
extract/µmol safrole, the predicted inhibition of formation of 1′-sulfooxysafrole in male rat 
and human liver were 90 and 100% and 61 and 91% assuming 100 and 1% uptake of 
malabaricone C, respectively. Thus formation of 1′-sulfooxysafrole is predicted to be 
inhibited although not completely blocked upon co-exposure to safrole and the newly 
identified SULT inhibitor present in mace, malabaricone C. 
In conclusion, the present study identifies an important SULT inhibitor present in mace to 
be malabaricone C. This points at a possible matrix effect of combined exposure to safrole 
and malabaricone C. For the human liver samples, the SULT inhibition was shown to lead 
to the inhibition of the formation of the ultimate carcinogenic metabolite, without reducing 
the rate of detoxification of the proximate carcinogen 1′-hydroxysafrole via glucuronidation 
or oxidation. This indicate a potential reduction of the cancer risk when safrole intake via 
mace results from the food matrix containing malabaricone C or other SULT inhibitors 
presents in the regular daily diet (SCF, 2002) compared to what is observed upon exposure 
to safrole as a pure compound. Validation of the relevance of the interaction of this SULT 
inhibitor with safrole bioactivation in an in vivo study will provide further support for the 
hypothesis that this combination effect should be taken into account in risk assessment of 
alkenylbenzenes. 
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Abstract 
The present study investigated whether the malabaricone C-containing mace extract that 
was previously shown to be able to inhibit safrole DNA adduct formation in vitro can also 
inhibit safrole DNA adduct formation in vivo. To this end, mace extract and safrole were 
co-administered orally to Sprague-Dawley rats and the level of safrole DNA adduct 
formation in the liver was quantified and compared to the level of safrole DNA adducts 
detected in the liver of rats exposed to safrole only. Since the inhibition of safrole DNA 
adduct formation by malabaricone C-containing mace extract was previously shown to 
occur at the level of the sulfotransferase (SULT) -mediated bioactivation of 1ʹ-
hydroxysafrole to 1ʹ-sulfooxysafrole, a third group of rats exposed to safrole together with 
the well-known SULT inhibitor pentachlorophenol (PCP) was also included. LC-ECI-
MS/MS based quantification of DNA adduct levels in the liver of safrole exposed rats 
revealed a significant (p<0.01) 55% and 64% reduction of safrole DNA adduct formation 
when exposure to safrole occured in the presence of malabaricone-C containing mace 
extract or PCP, respectively. Given the role of DNA adduct formation in the 
hepatocarcinogenicity of safrole, the results of the present study suggest that the likelihood 
of bioactivation and subsequent adverse effects may be lower, when safrole is dosed in 
rodents bioassays within a relevant food matrix containing SULT inhibitors compared to 
dosing of pure safrole. Using the data obtained a refined risk assessment using the Margin 
of Exposure (MOE) approach was performed. The results obtained point at a potential 
reduction of the cancer risk resulting in increased MOE values and a lower priority for risk 
management when the carcinogenicity of safrole would have been tested within a relevant 
food matrix containing SULT inhibitors compared to what is observed in rodent bioassays 
upon exposure to pure safrole dosed by gavage.  
 
 
 
  
  
 
Introduction 
Some spices such as mace, nutmeg, star anise and black pepper contain the alkenylbenzene 
safrole, a compound that has been proven to be genotoxic and carcinogenic at high dose 
levels in rodent studies (Borchert et al., 1973; Miller et al., 1983; Wislocki et al., 1977; 
Daimon et al., 1998). Bioactivation of safrole is initiated by cytochromes P450 resulting in 
formation of the proximate carcinogenic metabolite 1ʹ-hydroxysafrole followed by 
sulfonation mediated by sulfotransferases (SULTs) and resulting in formation of the 
ultimate carcinogenic metabolite 1ʹ-sulfooxysafrole. 1ʹ-Sulfooxysafrole forms covalent 
adducts with cellular macromolecules including DNA (Borchert et al., 1973; 1980; 
Wislocki et al., 1977). The role of 1ʹ-sulfooxysafrole in the formation of DNA adducts in 
the liver of rat and mice dosed with safrole is supported by the observation that this DNA 
adduct formation can be inhibited by co-administration of safrole with pentachlorophenol 
(PCP), a known SULT inhibitor (Boberg et al., 1983; Daimon et al., 1997; Randerath et al., 
1984). The DNA adducts isolated from the liver of rats exposed to safrole were N2-(trans-
isosafrol-3′-yl)-2′-deoxyguanosine (S-3′-N2-dGuo), N2-(safrol-1′-yl)-2′-deoxyguanosine (S-
1′-N2-dGuo) and N6-(trans-isosafrol-3′-yl)-2′-deoxyadenosine (S-3′-N6-dAdo) (Randerath et 
al., 1984). DNA adducts identified in patients with oral squamous cell carcinoma resulting 
from the habit of betel quid chewing were S-3′-N2-dGuo and S-1′-N2-dGuo (Chen et al., 
1999).  
In the European Union, the use of safrole as such in food has been banned since 2008, 
whereas in the U.S. it was already banned since 1960. As a result, the current daily 
exposure to safrole mainly results from the intake of safrole with spices or food products to 
which safrole-containing herbs or spices or their essential oils are added including for 
example cola and alcoholic beverages and sausages (Choong and Lin, 2001; Curró et al., 
1987; Siano et al., 2003). This raises the question of whether rodent studies dosing safrole 
at high levels as a pure compound present an adequate basis for assessment of the risks 
associated with the intake of safrole in a complex food matrix.  
In a previous study, we demonstrated that mace extract and especially its constituent 
malabaricone C inhibited safrole DNA adduct formation at the level of SULT-mediated 
  
 
bioactivation and formation of S-3′-N2-dGuo in 1′-hydroxysafrole exposed HepG2 cells 
(Martati et al., 2012). A physiologically based biokinetic (PBBK) model analysis of safrole 
bioactivation and detoxification in rat, incorporating the SULT inhibition to predict the 
possible in vivo effect, predicted that administration of safrole at dose levels generally used 
in rodent cancer bioassays in the presence of malabaricone C-containing mace extract 
would significantly inhibit the 1′-sulfooxysafrole formation, thereby possibly reducing the 
cancer risk and influencing the risk assessment.  
The aim of the present study was to investigate whether the inhibition by the ingredients 
present in mace extract of SULT activity and S-3ʹ-N2-dGuo adduct formation in incubations 
with male rat liver S9 fractions and in HepG2 cells (Martati et al., 2011; Martati et al., 
2012) can also be demonstrated in vivo in a rat model. The results obtained were also used 
to make a refined risk assessment of safrole. 
Materials and methods 
Fine ground powdered mace was obtained from a local supermarket. 2′-Deoxyguanosine 
(2′dGuo), pentachlorophenol (PCP), phosphodiesterase I from Crotalus adamenteus 
(venom phosphodiesterase, VPDE), phosphodiesterase II from bovine spleen (spleen 
phosphodiesterase, SPDE), alkaline phosphatase from Escherichia coli, nuclease P1 from 
Penicillium citrinum, β-glucuronidase from Helix pomatia Type HP-2, and ethyl acetate 
were obtained from Sigma–Aldrich (Steinheim, Germany). Methanol and ethanol (pro 
analysis), hydrogen chloride, acetic acid glacial, formic acid, ethylenediaminetetraacetic 
acid (EDTA), sodium phosphate, sodium acetate, trifluoroacetic acid and ZnSO4*7H2O 
were purchased from Merck (Darmstadt, Germany). Acetic anhydride was supplied by J.T. 
Baker (Deventer, The Netherlands). Pyridine was purchased from VWR (Darmstadt, 
Germany). Chromatography grade acetonitrile and methanol were purchased from Biosolve 
BV (Valkenswaard, The Netherlands). Phosphate buffered saline (PBS, pH 7.4) was 
purchased from GIBCO (Paisley, UK). 1ʹ-Hydroxysafrole was synthesized and purified as 
described previously (Jeurissen et al., 2004; Martati et al., 2011). 1ʹ-Acetoxysafrole was 
synthesized from 1ʹ-hydroxysafrole as described previously for synthesis of 1ʹ-
  
 
acetoxyestragole from 1ʹ-hydroxyestragole for the related alkenylbenzene estragole 
(Borchert et al., 1973; Punt et al., 2007).  
S-3ʹ-N2-dGuo was prepared as described previously for synthesis of the E-3ʹ-N2-dGuo 
adduct of the related alkenylbenzene estragole (Punt et al., 2007). To obtain pure 
synthesized S-3ʹ-N2-dGuo, the reaction mixture was purified using HPLC-UV (Waters 600 
controller liquid chromatography system) equipped with an Alltima C18 column of 5 µm, 
150 x 4.6 mm (Grace Alltech, Breda, The Netherlands). The flow rate was set at 1 mL/min. 
The gradient was made with ultrapure water and acetonitrile. A gradient was applied from 
20% to 26% acetonitrile over 40 min after which the percentage of acetonitrile was 
increased to 100% in 2 min and kept at 100% for 1 min. The initial condition was reached 
within 2 min and kept for 15 min. Under these conditions, the peak corresponding to S-3ʹ-
N2-dGuo eluted at a retention time of 22.6 min. Collected fractions were pooled and the 
acetonitrile was evaporated under a stream of nitrogen. Freeze drying was performed after 
the collected fractions were kept overnight at -80°C. S-3ʹ-N2-dGuo was identified and 
quantified by LC-ESI-MS/MS as described below. 
Animals 
The animal study was performed in accordance with the Dutch Act on animal 
experimentation (Stb, 1977,67; Stb 1996, 565), revised February 5, 1997. The protocol of 
the study was approved by the ethical committee on animal experimentation of 
Wageningen University. Seven week old male Sprague-Dawley (SD) rats were obtained 
from Harlan Laboratories (The Netherlands). The rats were housed in type IV cages (three 
rats per cage) with Lignocel (Lignocel BK 8/15) bedding. Animals were kept in the 
standard animal rooms under conditions of controlled temperature (21+1°C), humidity 
(55+10%) and a 12 h light/dark schedule and were monitored daily. Animals were given 
free access to feed (Teklad 2914C pellet) and tap water during the whole study (from 
arrival at the animal facility until sacrifice). Following a 5-day acclimatization period, 
animals were housed individually in the metabolic cages 24 h before gavage and were kept 
in the metabolic cages up to time of sacrifice (48 h after gavage). 
 
  
 
Pilot Study  
The in vivo studies consisted of a range finding pilot study and a main study. For the pilot 
study, eight animals were divided into four groups of 2 animals per group. These groups 
were exposed as follows: 1) first group dosed once with 150 mg/kg bw of safrole only in 
corn oil, 2) second group dosed once with 300 mg /kg bw of safrole only in corn oil, 3) 
third group dosed once with 150 mg/kg bw of safrole together with 463 mg/kg bw of mace 
extract simultaneously in corn oil, and 4) fourth group dosed once with 300 mg/kg bw of 
safrole together with 926 mg/kg bw of mace extract simultaneously in corn oil. The ratio 
between safrole and mace extract was chosen based on PBBK model based predictions 
selecting a ratio that would result in significant SULT inhibition but would require a dose 
of mace extract below the dose level reported to be toxic (El Malti et al., 2009). For the 
pilot study further animal handling and analyses were performed as described below for the 
main study. 
Main Study 
For the main study, fifteen rats were divided into three groups of 5 rats per group and 
exposed as follows: 1) safrole only group dosed once with 150 mg/kg bw safrole only in 
corn oil, 2) safrole plus mace extract group dosed once with 150 mg/kg bw of safrole 
together with 463 mg/kg bw of mace extract dosed simultaneously in corn oil and 3) safrole 
plus SULT inhibitor control group dosed once with 150 mg/kg bw of safrole together with 
11 mg/kg bw of PCP simultaneously in corn oil. 
A control group receiving only feed and carrier/corn oil was not included in the pilot or 
main study because recent studies showed that exposure to only feed and carrier/corn oil 
did not result in alkenylbenzene DNA adduct levels above the detection limit (Paini et al., 
2012). Safrole and or mace extract were administrated simultaneously using corn oil as 
carrier by gavage with the volume of gavage not exceeding 2 mL/kg bw. Animals were 
sacrificed 48 h after gavage. Anesthesia was done with a mixture of isoflurane and oxygen 
by inhalation, blood was removed after which the liver was removed, weighed and stored at 
-80°C until further analysis. The liver was separated in the left liver lobe and the rest of the 
  
 
tissue containing the right liver lobe. For the pilot and main study, urine was collected at 0, 
6, 24, 30 and 48 h after gavage and stored at -80°C for further analysis.  
Preparation of mace extract 
A methanolic mace extract was prepared as previously described for preparation of 
methanolic extracts from basil (Alhusainy et al., 2010). Briefly, 10 g of mace and 200 mL 
of a mixture of methanol, ultrapure water and acetic acid (80:19:1) were stirred for an hour 
at room temperature. The extraction was performed twice, each time with 200 mL of 
solvent mixture. The collected extraction mixtures were filtered using a folded filter 
(Schleicher and Schuell, 150 mm). The filtrate was pooled and concentrated by evaporation 
at 35°C on a rotary evaporating system (Heidolph Laborota 4000 efficient, Metrohm U.S.). 
The extraction yield was approximately 32%. The concentrated mace extract was kept at -
20°C until usage.  
Tissue DNA extraction and digestion  
Prior to DNA extraction, tissue samples were homogenized mechanically using a cell 
homogenizer (B. Melsungen Germany). For the liver, to prepare one sample, 4 random 0.8 
g samples were taken from the left liver lobe as well as 4 random 0.8 g samples from the 
right liver lobe. Each of the samples was minced with a surgical knife and subsequently 
mashed with a mortar and pestle. Then 8 mL cold phosphate buffered saline (PBS) were 
added and samples were transferred and homogenized mechanically on ice using a cell 
homogenizer. The homogenates were transferred to a 15 mL tube and centrifuged at 3000 g 
for 5 min (Sigma centrifuge, type 4K10, Germany). The pellet was dissolved in 300 µL 
remaining supernatant and then divided into two equal parts. Each part was transferred to a 
2 mL Eppendorf tube to provide sample replicates for analysis. The pellet was extracted 
with a Get pure DNA Kit-Cell protocol to obtain DNA according the manual of the Kit. 
The DNA pellet was dissolved in 100 µL of nanopure water. The yield and purity of 
isolated DNA were determined using the Nanodrop technology by measuring the 
absorbance ratio A260/A280nm. DNA samples with an absorbance ratio of 1.8 to 2 were 
considered sufficiently pure. The DNA quantity per sample was calculated from the 
Nanodrop output in ng/mL using a molar extinction coefficient for double stranded DNA of 
  
 
50 L mol-1 cm-1 (Sambrook and Russell, 2001). The DNA obtained was digested as 
previously described (Delatour et al., 2008) to release S-3ʹ-N2-dGuo. In short, to 50 µg 
DNA in 100 µL water, 20 µL buffer P1 (300 mM sodium acetate, 1 mM ZnSO4, pH 5.3), 
11 µL SPDE solution (0.0004 U/µL in water) and 10 µL nuclease P1 (0.0005 µg/µL in 
water) were added and the mixture was incubated for 4 h at 37°C. Subsequently, 20 µL 
buffer PA (500 mM Tris-HCl, 1 mM EDTA, pH 8.0), 10 µL VPDE solution (0.00026 U/µL 
in water) and 2.6 µL alkaline phosphatase (0.764 U/µL in water) were added and the 
mixture was incubated for 3 h at 37°C. The DNA hydrolysates thus obtained were passed 
through a 5000 Nominal Molecular Weight Limit (NMWL) cut-off filter for removal of the 
enzymes and subsequently evaporated to dryness and reconstituted in 50 µL ultrapure water 
and stored at -20°C until further analysis by LC-ESI-MS/MS.  
Urine analysis 
Urine analysis was performed as previously described (Benedetti et al., 1977). De-
conjugation of conjugated metabolites in the urine was performed using β-
glucuronidase/sulfatase. Briefly, frozen urine was thawed quickly at 37°C in a waterbath. A 
sample of 5 µL urine was mixed with 45 µL 0.2 M sodium acetate pH 5 and 10 µL of β-
glucuronidase from Helix pomatia (activity of glucuronidase 198.455 U/mL and sulfatase 
813 U/mL). The mixture was incubated at 37°C for 2 h. The hydrolysate was extracted with 
250 µL ethyl acetate using vortexing and centrifugation at 15.000 rpm for 3 min. The 
extraction was repeated twice using 250 µL ethyl acetate each time. The extracts thus 
obtained were pooled and solvent was evaporated under a stream of nitrogen and the 
residue was subsequently dissolved in ultrapure water and stored at -20°C until HPLC 
analysis.  
Quantification of DNA adduct formation 
Quantification of S-3′-N2-dGuo was performed using LC-ECI-MS/MS on a Perkin Elmer 
200 series HPLC System (Perkin Elmer, Waltham, MA) coupled to an API 3000 system 
(Applied Biosystem, Foster city, CA) as previously described for detection of N2-(trans-
isoestragol-3′-yl)-2′-deoxyguanosine (E-3′-N2-dGuo) (Paini et al., 2012; Punt et al., 2007). 
To this end an aliquot of 10 µL was injected on an Agilent Zorbax Extend-C18 column, 
  
 
2.1×50 mm, 3.5 Micron 80 Å (Basel, Switzerland), with a Zorbax guard column. The 
gradient was made with ultrapure water containing 0.1% (v/v) formic acid and acetonitrile. 
The flow rate was set at 0.3 mL/min and a gradient was applied from 20% to 70% 
acetonitrile over 8 min, after which the percentage of acetonitrile was brought to 100% in 1 
min and kept at 100% acetonitrile for 2 min. The initial condition was restored in 1 min and 
the column was equilibrated at this condition for 8 min. Under these conditions S-3′-N2-
dGuo eluted at 2.7 min. The mass spectrometric analysis was done in positive ion mode. 
The ion spray voltage was set at 4 kV and the ion source temperature was set at 250°C. The 
nebulizer gas (air), curtain (nitrogen) and collision gas (nitrogen) were set to 15, 10 and 5 
psi, respectively. A divert valve was used in order to discard the eluent during the first 2 
min and the gradient after elution of the peak. Sample analysis was carried out using the 
selected reaction monitoring (SRM) mode and characteristic transitions were recorded. The 
most intense transition was used as quantifier and subsequent transitions as qualifiers, for 
S-3′-N2-dGuo these transitions were as follows: 428 → 312 m/z (quantifier), 428 → 164 
m/z (qualifier), 428 → 161 m/z (qualifier).  
Identification and quantification of urinary metabolites 
Identification and quantification of urinary metabolites obtained after enzymatic de-
conjugation was performed on a UPLC (Ultra Performance Liquid Chromatography)-DAD 
(diode array) system consisting of a Waters (Milford, MA) Acquity binary solvent 
manager, sample manager and photodiode array detector. Aliquots of 3.5 µL were injected 
on the Waters Acquity UPLC BEH RP 18 column (1.7 µm, 2.1 x 50 mm). The eluent 
consisted of ultrapure water containing trifluoroacetic acid 0.1% (v/v) and acetonitrile. At a 
flow rate of 0.6 mL/min, a gradient was applied from 10% to 40% acetonitrile over 2.9 min 
after which the percentage of acetonitrile was increased to 100% over 0.2 min and kept at 
100% for 0.2 min. Thereafter, the percentage of acetonitrile was reduced to its initial value 
in 0.1 min and kept at this level for 1.2 min. Detection and quantification of the urinary 
metabolites were performed at 280 nm. Quantification of 1′-hydroxysafrole and 1,2-
dihydroxy-4-allylbenzene was achieved by comparison of the peak areas obtained at a 
wavelength of 280 nm to the calibration curves made using the corresponding synthesized 
reference compounds.  
  
 
PBBK-model-based predictions for formation of 1ʹ-sulfooxysafrole in the liver of rat 
in the presence or absence of mace extract  
The safrole PBBK model defined previously for male rat (Martati et al., 2011) as well as 
the PBBK model defined for male rat including the SULT inhibition by malabaricone C-
containing mace extract (Martati et al., 2012) were used to obtain insight in the effects of 
SULT inhibition by malabaricone C-containing mace extract on the formation of the 
ultimate carcinogenic metabolite, 1ʹ-sulfooxysafrole, in the liver. PBBK model based 
predictions for safrole bioactivation and its inhibition by malabaricone C-containing mace 
extract were compared to the results obtained for inhibition of DNA adduct formation in the 
liver of rats exposed to safrole in the absence or presence of malabaricone C-containing 
mace extract in order to further validate the PBBK models previously defined.  
Refined risk assessment for safrole 
To estimate the possible consequences of the inhibition of safrole bioactivation and DNA 
adduct formation by malabaricone C-containing mace extract for the risk assesment of 
safrole the margin of exposure (MOE) approach was used (EFSA, 2005). The MOE is 
defined as the ratio between a point of departure derived from the tumor data, preferably 
the BMDL10 (the lower confidence limit of the benchmark dose causing 10% extra tumor 
incidence) and the estimated daily intake (EDI). An MOE of 10,000 or higher is considered 
as low priority for risk management (EFSA, 2005). 
For the refined risk assessment of safrole, an estimate was made of the tumor incidences 
that would be expected when safrole would have been tested in the presence of 
malabaricone C-containing mace extract as done in the present study. To this end the 
available data on the incidence of hepatocellular carcinoma in female mice administered 
safrole via the diet for 52 weeks were taken as the starting point (Miller et al., 1983). The 
dose levels reported in the study reported by Miller et al. (Miller et al., 1983) in mg/kg diet 
were converted to dose levels in mg/kg bw/day assuming a daily feed intake of female mice 
of 0.13 kg/kg bw/day, and adjusting for 1) 3 doses a week converted to daily administration 
(values multiplied by 3/7), 2) duration of the exposure converted to life time exposure 
(doses times 52/86) and 3) the loss of the compound on standing in open containers at room 
  
 
temperature which was reported to amount to 5%/day (Miller et al., 1983). First BMDL10 
values for safrole were calculated from this data set using the BMD software version 2.4. 
MOE values were calculated by dividing the BMDL10 values obtained by the EDI for 
regular human daily intake. 
In a subsequent step, the tumor incidences in the analysis were reduced by the percentage 
inhibition of safrole DNA adduct formation detected in the present study upon co-
administration of safrole with the malabaricone C-containing mace extract. BMD analysis 
of these refined data for hepatocellular carcinoma incidence resulted in refined BMDL10 
and MOE values that reflect the possible consequences of testing safrole carcinogenicity in 
the presence of the malabaricone C-containing mace extract for the risk assessment.  
Statistical analysis 
A t-test using Excel (Microsoft Office 2010) was performed to evaluate whether the 
differences between the treatments were statistically significant. Variances equality were 
tested with Levene's version of the F tested with SPSS 15.0 for Windows (SPSS Inc. 
Chicago, IL, U.S.).  
Results 
Pilot Study: Inhibition of DNA adduct formation by mace extract in the liver of male 
rats exposed to safrole  
In a dose-finding pilot study, safrole was given by oral gavage at a dose of 150 mg/kg bw 
or 300 mg/kg bw with or without mace extract. When safrole was dosed together with mace 
extract, a ratio of mace extract to safrole of 0.5 mg/µmol was used. At this ratio, the PBBK 
model predicted approximately 80% inhibition of 1ʹ-sulfooxysafrole formation. The level of 
DNA adduct formation was measured in the liver, 48 h after gavage. This time point was 
chosen based on a similar study with the related alkenylbenzene estragole which showed 
that at 48 h following gavage DNA adducts were significantly higher than at 24 h after 
gavage (Paini et al., 2012). Figure 5.1 shows the DNA adduct formation in the liver of rats 
dosed with 150 and 300 mg/kg bw safrole. Formation of DNA adducts in the liver of rats 
dosed with 300 mg/kg bw safrole was 2.3-fold higher than DNA adduct formation in the 
  
 
livers of rats dosed with 150 mg/kg bw safrole. Co-administration of safrole with mace 
extract resulted in a significant (p<0.05) inhibition of the formation of DNA adducts by 38 
and 20% at 150 and 300 mg/kg bw safrole respectively. Based on the results obtained, the 
dose level of safrole of 150 mg/kg bw resulted in detectable and significant formation of 
safrole DNA adducts and the largest inhibition by mace extract. Therefore, 150 mg/kg bw 
safrole dosed with or without mace extract at a ratio of mace extract to safrole of 0.5 
mg/µmol, was selected for the main study. 
 
Figure 5.1. Formation of DNA adducts in the liver of SD rats treated with safrole at 150 mg/kg bw, safrole at 150 
mg/kg bw + mace extract, safrole at 300 mg/kg bw or safrole at 300 mg/bw + mace extract. When safrole was 
dosed together with mace extract a ratio of mace extract to safrole of 0.5 mg/µmol was used. DNA adducts are 
expressed as number of adducts per 1000nt. Data represent the average and standard deviation of 2 rats. * = p 
<0.05 
Main Study: Inhibition of DNA adduct formation by mace extract in the liver of male 
rats exposed to safrole  
The main study consisted of three groups of 5 rats exposed to 1) safrole only, dosed with 
150 mg/kg bw, 2) safrole and mace extract, dosed with 150 mg/kg bw safrole and 463 
mg/kg bw mace extract, and 3) safrole and a positive control for SULT inhibition, dosed 
with 150 mg/kg bw + PCP 11 mg/kg bw. Figure 5.2 presents the levels of DNA adducts 
detected in the liver of rats exposed to safrole or safrole in the presence of mace extract or 
PCP. The formation of DNA adducts in the liver of rats exposed to 150 mg/kg bw safrole, 
150 mg/kg bw safrole + 463 mg/kg bw mace extract or 150 mg/kg bw safrole +11 mg/kg 
bw PCP amounted to 0.0240+0.0120, 0.0110+0.0045 or 0.0084+0.0018 adducts/1000nt, 
  
 
respectively. The percentage inhibition of the formation of DNA adducts upon co-
administration of safrole with mace extract or PCP was significant (p<0.01) and amounted 
to 55% and 64%, respectively.  
 
 
 
Figure 5.2. Formation of DNA adducts in the liver of rats treated with 150 mg/kg bw safrole, 150 mg/kg bw 
safrole + 463 mg/kg bw mace extract, or 150 mg/kg bw safrole + 11 mg/kg bw PCP. DNA adducts are expressed 
as number of adducts per 1000nt. Data represent the average and standard deviation of 5 rats (for the group treated 
with safrole + PCP) or 7 rats (for groups treated with safrole only and safrole + mace extract combining the data 
from the pilot and the main study) **= p < 0.01 
 
Urinary metabolites of rats exposed to safrole and mace extract 
In order to ascertain that co-exposure to safrole and mace extract or PCP did not reduce 
DNA adduct formation by affecting the bioavailability of safrole, urinary excretion of 
safrole metabolites in rats exposed to safrole with or without mace extract or PCP was 
quantified. Figure 5.3 presents the chromatogram of urinary metabolites showing that 
hydrolysis of conjugated urinary metabolites of rats exposed to safrole resulted in 5 major 
metabolites including 1ʹ-hydroxysafrole, 1,2-dihydroxy-4-allylbenzene and eugenol, which 
were identified based on a comparison to commercially available reference compounds, and 
two unidentified metabolites denoted M3 and M4.  
  
 
 
  Figure 5.3: UPLC chromatogram of (A) unhydrolyzed urine, (B) hydrolyzed urine collected before gavage and 
(C) hydrolyzed urine collected 24-48 h after gavage from a rat exposed to 150 mg/kg bw safrole.  
 
                   
Figure 5.4. Cumulative (0-48 hours) excretion of the two major urinary safrole metabolites 1ʹ-hydroxysafrole 
(1ʹHS) and 1,2-dihydroxy-4-allylbenzene (DHAB) following administration of 150 mg/kg bw safrole, 150 mg/kg 
bw safrole + 463 mg/kg bw mace extract, or 150 mg/kg bw safrole + 11 mg/kg bw PCP to rats.  
 
Figure 5.4 shows the cumulative excretion (0-48 h after gavage) of the two major safrole 
metabolites 1ʹ-hydroxysafrole and 1,2-dihydroxy-4-allylbenzene. The total percentage of 
the dose of safrole excreted in the 0-48 h urine as 1ʹ-hydroxysafrole and 1,2-dihydroxy-4-
allylbenzene amounted to 61.0+10.0%, 78.0+14.6% and 58.2+11.0% of the dose for rats 
dosed with 150 mg/kg bw safrole, 150 mg/kg bw safrole + 463 mg/kg bw mace extract or 
150 mg/kg bw safrole + 11 mg/kg bw PCP, respectively. These data indicate that urinary 
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excretion of the major safrole metabolites is not significantly reduced when safrole is dosed 
in the presence of mace extract or PCP. This indicates that the reduction in DNA adduct 
formation is not due to a reduced bioavailability of safrole. 
Refined risk assessment for safrole  
The BMDL10 values for safrole were calculated using BMD software version 2.4 based on 
the data from an in vivo study in female mice administered safrole via the diet for 3 days a 
week up to 52 weeks and for 86 weeks of study duration (Miller et al., 1983). Table 5.1 
presents an overview of the incidence of hepatocellular carcinomas in female mice with 
increasing doses of safrole as reported by Miller et al. (Miller et al., 1983) and Table 5.2 
presents the results of a BMD analysis of these data. The BMDL10 values obtained amount 
to 2.6 to 7.0 mg/kg bw/day (Table 5.2). Based on the estimated dietary intake (EDI) for 
safrole reported by the SCF (2002) of 5 µg/kg bw/day, these BMDL10 values result in MOE 
values that vary between 520 to 1400.  
To estimate what BMDL10 values and MOE values would have been obtained when safrole 
would have been tested in the bioassays not as a pure compound but in the presence of 
mace extract, the percentage inhibition of DNA adduct formation by mace extract defined 
in the present study was used to refine the tumor data and the resulting risk assessment. 
Table 5.1 presents the refined incidence of hepatocellular carcinomas calculated assuming 
that malabaricone C-containing mace extract would be co-administered to the mice together 
with safrole at a ratio of safrole to mace extract of 0.5 mg/µmol. These refined incidences 
of hepatocellular carcinomas at the respective dose levels of safrole were calculated using 
the reduction by 55 % in DNA adduct formation as observed in the rat study. It is noted that 
this approach assumes, as a first approximation, that a decrease in S-3′-N2-dGuo safrole 
DNA adduct formation results in a corresponding reduction in hepatocellular carcinoma 
formation and also that the matrix effects would be similar in mice and rats. Table 5.3 
presents the results of the BMD analysis of the refined tumor data. The BMD analysis of 
the newly generated refined data resulted in BMDL10 values that varied from about 17.3 to 
22.8 mg/kg bw/day. Using these newly estimated refined BMDL10 values and the EDI for 
safrole of 5 µg/kg bw/day (SCF, 2002), the MOE for safrole would amount to about 3460 
  
 
to 4560. Clearly, co-administration of safrole together with mace extract is thus predicted to 
increase the BMDL10 and MOE levels substantially pointing at a lower priority for risk 
management, than when the MOE calculation would be based on the tumor data obtained 
with pure safrole.  
Table 5.1. An overview of the incidence of hepatocellular carcinomas in female mice 
exposed to safrole as reported by Miller et al. (Miller et al., 1983) and the refined incidence 
of hepatocellular carcinomas calculated taking into account the inhibition of safrole 
bioactivation by malabaricone C-containing mace extract.  
 
Experimental 
dose (mg/kg diet) 
Duration of 
exposure/sacrifice 
(weeks) 
Time-adjusted dose 
(mg/kg bw/day)1 
No. of 
animals 
Hepatocellular 
carcinomas 
incidence 
Refined hepatocellular 
carcinomas incidence2 
0 52/86 0 50 0 0 
2500 52/86 80 47 34 15 
5000 52/86 160 49 39 18 
 
1
 Dose levels were adjusted for dosing regimen as described in Materials and methods.  
2 Incidences were refined assuming a reduction in hepatocellular carcinoma incidences of 55% in line with the 
observed reduction in safrole bioactivation. 
 
Tabel 5.2 Results from a BMD analysis of the data on the incidence of hepatocellular 
carcinomas in mice exposed to safrole (Miller et al., 1983) (Table 5.1) using BMD software 
version 2.4, a BMD of 10% extra risk and default settings. 
Model No. of 
parameters 
Log Likelihood p-value Accepted BMD10  
(mg/kg bw/day) 
BMDL10  
(mg/kg bw/day) 
Null 1 -101.20 
    
Full 3 -57.51 
    
Gamma 1 -54.25 0.17 Yes 8.6 7.0 
Logistic 2 -64.97 0.00 No - - 
LogLogistic 1 -52.69 0.83 Yes 3.9 2.6 
LogProbit 2 -52.51 1.00 Yes 0.3  ND* 
Multistage 1 -54,26 0.17 Yes 8.6 7.0 
Probit 2 -64.91 0.00 No - - 
Weibull 1 -54.26 0.17 Yes 8.6 7.0 
Quantal-linear 1 -54.26 0.17 Yes 8.6 7.0 
* Not determined. Benchmark dose computation failed. Lower limit includes zero 
  
 
Tabel 5.3. Results from a BMD analysis for the refined incidence of hepatocellular 
carcinomas in female mice (Table 5.1) using BMD software version 2.4, a BMD of 10% 
extra risk and default settings. 
Model No. of 
parameters 
Log 
Likelihood 
p-value Accepted BMD10 
(mg/kg bw/day) 
BMDL10 
(mg/kg bw/day) 
Null 1 -78.03 
    
Full 3 -61.65 
    
Gamma 1 -62.71 0.34 Yes 30.0 22.8 
Logistic 2 -67.78 0.00 No - - 
LogLogistic 1 -62.26 0.54 Yes 24.6 17.3 
LogProbit 2 -61.65 1.00 Yes 1.09 ND* 
Multistage 1 -62.71 0.34 Yes 30.0 22.8 
Probit 2 -67.19 0.00 No - - 
Weibull 1 -62.71 0.34 Yes 30.0 22.8 
Quantal-linear 1 -62.71 0.34 Yes 30.0 22.8 
*Not determined. Benchmark dose computation failed. Lower limit includes zero. 
 
Discussion 
The results of the present paper show that malabaricone C-containing mace extract is able 
to inhibit formation of S-3′-N2-dGuo safrole DNA adducts in the liver of SD rats exposed to 
safrole and mace extract simultaneously. To date only PCP, a well-known SULT inhibitor, 
demonstrated inhibition of the formation of safrole-DNA adducts in rodent liver (Boberg et 
al., 1983; Daimon et al., 1997; Randerath et al., 1984). A great number of literature studies 
reported in vitro data on dietary compounds inhibiting SULTs such as epicatechin gallate 
(ECG), epigallocatechin gallate (EGCG), quercetin, kaempferol, genistein and daidzein 
(Coughtrie and Johnston, 2001; De Santi et al., 2002; Mesia-Vela and Kauffman, 2003), 
various beverages containing flavonoids (Nishimuta et al., 2007), basil extract (Alhusainy 
al., 2010; Jeurissen et al., 2008), and malabaricone C-containing mace extract (Martati et 
al., 2012). The results of the present study demonstrate that the inhibition of safrole DNA 
adduct formation by malabaricone C-containing mace extract observed in in vitro model 
systems (Martati et al., 2012) is also observed in vivo.  
  
 
Using a previously developed PBBK model it was predicted that inhibition of the formation 
of 1ʹ-sulfooxysafrole at a ratio of mace extract and safrole of 0.5 mg/µmol would amount to 
80% under the assumption of 100% bioavailability of the mace extract constituents (Martati 
et al., 2012). The present in vivo study demonstrates that the inhibition of S-3′-N2-dGuo 
safrole DNA adduct formation in the liver of Sprague-Dawley rats by the mace extract 
amounted to 55%. The PBBK model predicted that a 55% inhibition of safrole 
bioactivation to 1ʹ-sulfooxysafrole would be obtained when the bioavailability of the SULT 
inhibitors in the malabaricone C mace extract would be 68% instead of 100%, which may 
not be unrealistic. Thus, the results of the in vivo study are in line with what would be 
expected based on the PBBK model based predictions for safrole bioactivation. 
It is important to note that the safrole DNA adduct measured in the present study is S-3′-N2-
dGuo which was shown to be the major adduct formed in vitro, in rodent studies and in oral 
cancer patients having a habit of betel quid chewing (Chung et al., 2008; Daimon et al., 
1998; Phillips et al., 1981; Randerath et al., 1984). Given that all safrole DNA adducts are 
expected to be derived from the same 1ʹ-sulfooxy metabolite it can be foreseen that the 
inhibition of the formation of this major S-3′-N2-dGuo adduct also reflects inhibition of the 
formation of possible other minor safrole DNA adducts.  
Previous in vitro studies already revealed that the inhibition of DNA adduct formation by 
malabaricone C-containing mace extract occurs at the level of the SULT mediated 
bioactivation of 1ʹ-hydroxysafrole to 1ʹ-sulfooxysafrole (Martati et al., 2012). In the present 
study, it was demonstrated that urinary excretion of the major safrole metabolites, 
(conjugated) 1ʹ-hydroxysafrole and 1,2-dihydroxy-4-allylbenzene is not significantly 
reduced when safrole is dosed in the presence of mace extract or PCP. This observation 
excludes that the reduction in DNA adduct formation is due to a reduced bioavailability of 
safrole when dosed together with malabaricone C-containing mace extract or PCP. The 
effect of PCP on safrole DNA adduct formation in the liver is in line with previous studies 
reporting a reduction in safrole DNA adduct formation upon co-administration of safrole 
with PCP, a known SULT inhibitor (Boberg et al., 1983; Daimon et al., 1997; Randerath et 
al., 1984). Although the inhibition in the formation of S-3′-N2-dGuo DNA adduct levels 
was ascribed to inhibition of the SULT mediated conversion of 1ʹ-hydroxysafrole to 1ʹ-
  
 
sulfooxysafrole, inhibition of other enzymes involved in the bioactivation or detoxification 
of safrole by mace extract constituents may also occur. In vitro tests reported by Kimura et 
al. (Kimura et al., 2010) showed that mace extract resulted in a potent inhibition of P450 
3A4 and P450 2C9 with IC50 values of 1.1-4.2 µg/mL, and that 17 compounds isolated from 
mace inhibited the activities of P450 3A4 and P450 2C9 with IC50 less than 11.2 µM. Since 
P450 2C9 was previously shown to be a major P450 enzyme involved in the 1ʹ-
hydroxylation safrole (Jeurissen et al., 2004; Ueng et al., 2004), this inhibition of P450 2C9 
may have contributed to the observed reduction in safrole bioactivation by mace extract. 
A question of interest is how to integrate the food matrix dependent modulation of safrole 
bioactivation in the risk assessment of safrole. This can be done using the so-called Margin 
of Exposure (MOE) approach and taking into account the results of the present study for the 
effect of the malabaricone C-containing mace extract on safrole bioactivation. Assuming a 
reduction in hepatocellular carcinoma incidences in line with the observed 55% reduction 
in safrole bioactivation, the incidences for hepatocellular carcinomas were refined resulting 
in BMDL10 values of 17.3 to 22.8 mg/kg bw/day instead of 2.6 to 7.0 mg/kg bw/day and in 
MOE values that amount to 3460 to 4560 instead of 520 to 1400. From this analysis, it can 
be concluded that when safrole would have been tested in rodent bioassays in the presence 
of malabaricone C-containing mace extract, increased BMDL10 and increased MOE values 
would have been obtained indicating a lower priority for risk management compared to the 
BMDL10 and MOE values derived from rodent carcinogenicity data obtained when testing 
safrole as a pure compound.  
In conclusion, the present study demonstrated that formation of safrole DNA adducts in the 
rat liver was reduced when safrole was administered in the presence of malabaricone C-
containing mace extract. The results obtained point at a potential reduction of the cancer 
risk resulting in increased MOE values and a lower priority for risk management when the 
carcinogenicity of safrole would have been tested within a relevant food matrix containing 
SULT inhibitors compared to what is observed in rodent bioassays upon exposure to pure 
safrole dosed by gavage.  
 
  
 
 References
Alhusainy, W., Paini, A., Punt, A., Louisse, J., 
Spenkelink, A., Vervoort, J., Delatour, T., Scholz, 
G., Schilter, B., Adams, T., van Bladeren, P. J. and 
Rietjens, I. M. C. M. (2010). Identification of 
nevadensin as an important herb-based constituent 
inhibiting estragole bioactivation and physiology-
based biokinetic modeling of its possible in vivo 
effect. Toxicol. Appl. Pharmacol. 245(2), 179-190. 
Benedetti, M. S., Malnoë, A. and Broillet, A. L. 
(1977). Absorption, metabolism and excretion of 
safrole in the rat and man. Toxicology 7(1), 69-83. 
Boberg, E. W., Miller, E. C., Miller, J. A., Poland, 
A. and Liem, A. (1983). Strong evidence from 
studies with Brachymorphic mice and 
pentachlorophenol that 1ʹ-sulfooxysafrole is the 
major ultimate electrophilic and carcinogenic 
metabolite of 1ʹ-hydroxysafrole in mouse liver. 
Cancer Res. 43(11), 5163-5173. 
Borchert, P., Miller, J. A., Miller, E. C. and Shires, 
T. K. (1973). 1ʹ-Hydroxysafrole a proximate 
carcinogenic metabolite of safrole in the rat and 
mouse. Cancer Res. 33(3), 590-600. 
Borchert, P., Wislocki, P. G., Miller, J. A. and 
Miller, E. C. (1973). The metabolism of the 
naturally occurring hepatocarcinogen safrole to 1ʹ-
hydroxysafrole and the electrophilic reactivity of 1ʹ-
acetoxysafrole. Cancer Res. 33(3), 575-589. 
Carcinogenic Potency Database (CPDB). Safrole. 
University of California, Berkeley, and Lawrence 
Berkeley Laboratory. Available from: 
http://toxnet.nlm.nih.gov/cpdb/ 
chempages/SAFROLE.html. Accessed 5 July, 2013. 
Chen, C. L., Chi, C. W., Chang, K. W. and Liu, T. 
Y. (1999). Safrole-like DNA adducts in oral tissue 
from oral cancer patients with a betel quid chewing 
history. Carcinogenesis 20(12), 2331-2334. 
Choong, Y.-M. and Lin, H.-J. (2001). A Rapid and 
Simple Gas Chromatographic Method for Direct 
Determination of Safrole in Soft Drinks. J. Food 
Drug Anal. 9(1), 27-32. 
Chung, Y., Chen, C., Wu, C., Chan, S., Chi, C. and 
Liu, T. (2008). Safrole-DNA adduct in 
hepatocellular carcinoma associated with betel quid 
chewing. Toxicol. Lett. 183(1/3), 21-27. 
Coughtrie, M. W. H. and Johnston, L. E. (2001). 
Interactions between Dietary Chemicals and Human 
Sulfotransferases-Molecular Mechanisms and 
Clinical Significance. Drug Metab. Disposition 
29(4), 522-528. 
Curró, P., Micali, G. and Lanuzza, F. (1987). 
Determination of β-asarone, safrole, isosafrole and 
anethole in alcoholic drinks by high-performance 
liquid chromatography. J. Chromatogr. 404, 273-
278. 
Daimon, H., Sawada, S., Asakura, S. and Sagami, F. 
(1998). In vivo genotoxicity and DNA adduct levels 
in the liver of rats treated with safrole. 
Carcinogenesis 19(1), 141-146. 
Daimon, H., Sawada, S., Asakura, S. and Sagami, F. 
(1997). Inhibition of sulfotransferase affecting in 
vivo genotoxicity and DNA adducts induced by 
safrole in rat liver. Teratog. Carcinog. Mutagen. 
17(6), 327-337. 
Daimon, H., Sawada, S., Asakura, S. and Sagami, F. 
(1998). In vivo genotoxicity and DNA adduct levels 
in the liver of rats treated with safrole. 
Carcinogenesis 19(1), 141-146. 
De Santi, C., Pietrabissa, A., Mosca, F., Rane, A. 
and Pacifici, G. M. (2002). Inhibition of phenol 
sulfotransferase (SULT1A1) by quercetin in human 
adult and foetal livers. Xenobiotica 32(5), 363-368. 
Delatour, T., Mally, A., Richoz, J., Özden, S., 
Dekant, W., Ihmels, H., Otto, D., Gasparutto, D., 
Marin-Kuan, M., Schilter, B. and Cavin, C. (2008). 
Absence of 2′-deoxyguanosine-carbon 8-bound 
ochratoxin A adduct in rat kidney DNA monitored 
by isotope dilution LC-MS/MS. Mol. Nutr. Food 
Res. 52(4), 472-482. 
European Food Safety Authority (EFSA). (2005). 
Opinion of the Scientific Committee on a request 
from EFSA related to a harmonised approach for 
risk assessment of substances which are both 
genotoxic and carcinogenic The EFSA Journal 282, 
1-31. 
Jeurissen, S. M. F., Bogaards, J. J. P., Awad, H. M., 
Boersma, M. G., Brand, W., Fiamegos, Y. C., van 
Beek, T. A., Alink, G. M., Sudholter, E. J. R., 
Cnubben, N. H. P. and Rietjens, I. M. C. M. (2004). 
Human cytochrome P450 enzyme specificity for 
bioactivation of safrole to the proximate carcinogen 
1-hydroxysafrole. Chem. Res. Toxicol. 17(9), 1245-
1250. 
Jeurissen, S. M. F., Punt, A., Delatour, T. and 
Rietjens, I. M. C. M. (2008). Basil extract inhibits 
the sulfotransferase mediated formation of DNA 
  
 
adducts of the procarcinogen 1ʹ-hydroxyestragole by 
rat and human liver S9 homogenates and in HepG2 
human hepatoma cells. Food Chem. Toxicol. 46(6), 
2296-2302. 
Kimura, Y., Ito, H. and Hatano, T. (2010). Effects of 
mace and nutmeg on human cytochrome P450 3A4 
and 2C9 activity. Biol Pharm Bul. 33(12), 1977. 
Martati, E., Boersma, M. G., Spenkelink, A., 
Khadka, D. B., Punt, A., Vervoort, J., van Bladeren, 
P. J. and Rietjens, I. M. C. M. (2011). 
Physiologically Based Biokinetic (PBBK) model for 
safrole bioactivation and detoxification in rats. 
Chem. Res. Toxicol. 24(6), 818-834. 
Martati, E., Punt, A., Boersma, M. G., Spenkelink, 
A., Boonpawa, R., Paini, A., van Bladeren, P. J., 
Vervoort, J. and Rietjens, I. M. C. M. (2012). 
Identification of malabaricone C as an important 
spice constituent inhibiting safrole bioactivation and 
physiology-based biokinetic modeling of its possible 
in vivo effect. Submitted for publication to 
Toxicology Letter. 
Mesia-Vela, S. and Kauffman, F. C. (2003). 
Inhibition of rat liver sulfotransferases SULT1A1 
and SULT2A1 and glucuronosyltransferase by 
dietary flavonoids. Xenobiotica 33(12), 1211-20. 
Miller, E. C., Swanson, A. B., Phillips, D. H., 
Fletcher, L., Liem, A. and Miller, J. A. (1983). 
Structure-Activity Studies of the Carcinogenicities 
in the Mouse and Rat of Some Naturally Occurring 
and Synthetic Alkenylbenzene Derivatives Related 
to Safrole and Estragole. Cancer Res. 43(3), 1124-
1134. 
Nishimuta, H., Ohtani, H., Tsujimoto, M., Ogura, 
K., Hiratsuka, A. and Sawada, Y. (2007). Inhibitory 
effects of various beverages on human recombinant 
sulfotransferase isoforms SULT1A1 and SULT1A3. 
Biopharm. Drug Disposition 28(9), 491-500. 
Paini, A., Punt, A., Scholz, G., Gremaud, E., 
Spenkelink, B., Alink, G., Schilter, B., van Bladeren, 
P. J. and Rietjens, I. M. C. M. (2012). In vivo 
validation of DNA adduct formation by estragole in 
rats predicted by physiologically based biodynamic 
modelling. Mutagenesis 27 (6): 653-663. 
Phillips, D. H., Miller, J. A., Miller, E. C. and 
Adams, B. (1981). N2 atom of guanine and N6 atom 
of adenine residues as sites for covalent binding of 
metabolically activated 1ʹ-hydroxysafrole to mouse 
liver DNA in vivo. Cancer Res. 41(7), 2664-2671. 
Punt, A., Delatour, T., Scholz, G., Schilter, B., van 
Bladeren, P. J. and Rietjens, I. M. C. M. (2007). 
Tandem Mass Spectrometry Analysis of N2-(trans-
Isoestragol-3ʹ-yl)-2ʹ-deoxyguanosine as a Strategy to 
Study Species Differences in Sulfotransferase 
Conversion of the Proximate Carcinogen 1ʹ-
Hydroxyestragole. Chem. Res. Toxicol. 20(7), 991-
998. 
Randerath, K., Haglund, R. E., Phillips, D. H. and 
Reddy, M. V. (1984). 32P-Postlabelling analysis of 
DNA adducts formed in the livers of animals treated 
with safrole, estragole and other naturally occurring 
alkenylbenzenes I. Adult female CD-1 mice. 
Carcinogenesis 5, 1613-1622. 
Sambrook, J. F. and Russell, D. W. (2001). 
Molecular Cloning: A Laboratory Manual (3rd ed.). 
Cold Spring Harbor Laboratory Press, New York. 
Siano, F., Ghizzoni, C., Gionfriddo, F., Colombo, E., 
Servillo, L. and Castaldo, D. (2003). Determination 
of estragole, safrole and eugenol methyl ether in 
food products. Food Chem. 81(3), 469-475. 
Ueng, Y. F., Hsieh, C. H., Don, M. J., Chi, C. W. 
and Ho, L. K. (2004). Identification of the main 
human cytochrome P450 enzymes involved in 
safrole 1ʹ-hydroxylation. Chem Res Toxicol. 17(8), 
1151-1156. 
Wislocki, P. G., Miller, E. C., Miller, J. A., McCoy, 
E. C. and Rosenkranz, H. S. (1977). Carcinogenic 
and mutagenic activities of safrole, 1ʹ-
hydroxysafrole, and some known or possible 
metabolites. Cancer Res. 37(6), 1883-1891. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
CHAPTER 6 
 
General discussion 
 
 
 
 
 
 
  
  
 
General discussion 
Safrole, 4-allyl-1,2-methylenedioxy-benzene, is a genotoxic carcinogen of which the use in 
food has been prohibited in the U.S. by FDA since 1960 and in Europe since 2008 
(European Commission, 2008). As a result, main exposure results from dietary 
consumption of safrole containing herbs and spices, such as nutmeg, mace, star anise, 
pimento, cinnamon, and black pepper, and food products containing these herbs and spices 
or their essential oils. Herbs and spices or essential oils containing safrole are used in 
various foods, including for example meat products, baked goods, alcoholic beverages, 
soups and non-alcoholic beverages such as cola drinks (SCF, 2002; Siano et al., 2003). At 
present exposure to safrole occurs primarily from (1) consumption of spices containing 
safrole especially mace or nutmeg, (2) consumption of cola beverages which may contain 
levels that are up to 3-5 times higher than the current EU regulation use limit of 1 mg/kg 
product (Choong and Lin, 2001), (3) consumption of alcoholic beverages since one out of 
sixteen tested commercial alcoholic beverages contained safrole higher than the current EU 
recommended limit of 5 mg/kg product (Curró et al., 1987), (4) consumption of food 
products with added safrole containing spices such as Bologna sausages and Vienna 
sausage which have been reported to contain 0.2-2 mg safrole/kg product (Siano et al., 
2003), (5) consumption of plant food supplements containing safrole (Berg et al., 2011) and 
(6) the habit of Piper betle chewing since betel quid may contain 15 mg/g fresh weight of 
safrole (Hwang et al., 1992).  
Various regulatory bodies have posed scientific opinions on the safety of safrole as food 
ingredient (SCF, 2002). The European Unionʹs Scientific Committee on Food (SCF) 
concluded that safrole has been demonstrated to be genotoxic and carcinogenic, and that 
therefore the existence of a threshold cannot be assumed so that the SCF could not establish 
a safe exposure limit. The SCF also indicated that consequently reductions in the exposure 
and restrictions in the use levels are indicated (SCF, 2002). The Committee of Experts on 
Flavouring Substances (CEFS) of the Council of Europe presented the same conclusion 
stating that efforts should be made to reduce the consumption of safrole via food and 
beverages as far as possible (Council of Europe, 1997). The Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) concluded at its twenty-fifth meeting that 
  
 
flavouring agents containing safrole as the principal flavour-active ingredient should not be 
used as food additives, and that it is not practicable to advocate the discontinuation of the 
use of spices containing safrole as minor constituents (e.g. nutmeg, mace and cinnamon) 
(JECFA, 1981). However, JECFA suggested that when these spices were used, the amount 
of safrole in the finished product should be kept as low as possible. The European Council 
Directive on food flavouring regulation (EC) no. 1334/2008/EEC that has been applied 
from January 20, 2011 onwards defined maximum levels of safrole, naturally present in 
flavourings that can be present in food ingredients with flavouring properties, as well as in 
certain compound food as consumed to which flavouring and/or food ingredients with 
flavouring properties have been added. The European Council defined a limit for safrole of 
1 mg/kg for non-alcoholic beverages, 5 mg/kg for alcoholic beverages with more than 25% 
alcohol by volume and 15 mg/kg for meat preparation and meat products (European 
Commission, 2008). According to the FDA (webpage last updated in 2013)1, the toxic 
effects of nutmeg and some of its active constituents such as myristicin, elemicin, and 
safrole are clearly manifested only at doses vastly greater than the realistic daily human 
intake. However, the essential oil of nutmeg contains 6% of safrole which is known as a 
weak hepatocarcinogen and a prohibited food additive in the U.S. since 1960. The intake 
level of nutmeg oil and its equivalent from nutmeg and mace, based on the total imports 
available annually for use in food in the U.S., is 0.05 mg per kg per day for adults (JECFA, 
2009). Assuming a maximum content of 6 % safrole in the oil, the daily intake of safrole 
would be about 4 µg/kg bw/day for an adult. The Select Committee on GRAS Substances 
(SCOGS) concluded 1) that the safrole and myristicin content in nutmeg products, and 
perhaps the content of related constituents such as elemicin, eugenol, and methyleugenol, 
should be further investigated to determine the range of content of these constituents in 
both nutmeg and mace originating from the East and West Indian, 2) that it would be of use 
to investigate or reinvestigate their possible mutagenic, teratogenic, and carcinogenic 
effects, and 3) that there is no evidence that nutmeg, mace, or their essential oils 
                                                          
1
 http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260910.htm 
  
 
demonstrate a hazard to the public as they are used in the manner now practiced. 
Uncertainties remain and therefore additional studies should be conducted (FDA CFR 
Section 182.10, 1973). 
At present, there is no internationally harmonised approach for the risk assessment of 
compounds that are both genotoxic and carcinogenic. Several authorities use the Margin of 
Exposure (MOE) approach. The MOE is obtained by dividing the value of a BMDL10 (the 
lower confidence bound of the benchmark dose that gives 10% extra cancer incidence 
(BMD10)) by the estimated daily intake (EDI) of the substance by the population of interest 
(EFSA, 2005; JECFA, 2005). This approach, however, does not result in a quantitative risk 
assessment at low dose levels representative for realistic daily human intake. At present, 
discussion is ongoing on how to translate the results from animal bioassays at high dose 
levels of the pure compound to the risk for the human population exposed to safrole at 
relatively low levels via dietary intake. This translation of cancer risks from the animal data 
to humans at relevant dietary intake levels needs a better understanding of species 
dependent, dose dependent, and interindividual dependent differences in bioactivation and 
detoxification of safrole and the possible influence of the food matrix on these processes. 
The aim of this thesis was to obtain insight into the dose-, species-, interindividual- and 
matrix dependent effects on the bioactivation and detoxification of safrole using 
physiologically based biokinetic (PBBK) modeling.  
After an introduction to the thesis in chapter 1, in chapter 2, a PBBK model for 
detoxification and bioactivation of safrole in male rats was developed based on the model 
for the related alkenylbenzenes estragole and methyleugenol (Al-Subeihi et al., 2011; Punt 
et al., 2007). The PBBK model consists of eight compartments which are grouped into 
metabolizing compartments including liver, kidney, and lung, other compartments 
representing either separate tissues (including fat, venous and arterial blood), or tissues 
lumped together in compartments representing richly perfused and slowly perfused tissues. 
The model was built based on in vitro and in-silico derived parameters determined in the 
present thesis. Kinetics for relevant cytochrome P450 (P450) mediated conversions of 
safrole and conjugation of 1ʹ-hydroxysafrole were determined in vitro using tissue fractions 
of organs that appeared capable of metabolizing safrole. The physiological parameter 
  
 
values (e.g. organ volumes, cardiac output, and blood flows) were taken from literature 
(Brown et al., 1997). Physico-chemical parameters (e.g. blood/tissue partition coefficients 
were obtained using in-silico models. 
The performance of the model was evaluated by comparison of predicted levels of 
formation of 1,2-dihydroxy-4-allylbenzene (DHAB), 1′-hydroxysafrole glucuronide and 
total urinary safrole metabolites to the reported levels of these metabolites in urine of 
safrole exposed rats. This evaluation revealed that the predictions adequately matched with 
observed experimental values. The rat PBBK model predicted that at a low dose of 0.05 
mg/kg bw and also at a high dose of 300 mg/kg bw, P450 mediated conversion of safrole 
mainly occurs in the liver with DHAB predicted to be the major P450 metabolite of safrole. 
A dose dependent shift in P450 mediated oxidation leading to a relative increase in 
bioactivation at high doses was not observed which is in contrast to outcomes previously 
obtained from similar PBBK models for the related alkenylbenzenes estragole and 
methyleugenol (Al-Subeihi et al., 2011; Punt et al., 2008). This can be explained by the fact 
that for P450 mediated conversion of safrole no saturation of an important metabolic route 
occurs in a dose range from 0.05 up to 300 mg/kg bw. Extrahepatic conversion of safrole 
did not contribute significantly to the overall metabolism. In male rat liver, glucuronidation 
is the major pathway for the conversion of 1ʹ-hydroxysafrole followed by oxidation, 
whereas sulfation of 1ʹ-hydroxysafrole to the ultimate carcinogenic metabolite 1ʹ-
sulfooxysafrole is a minor pathway. 
In the risk assessment, when extrapolating from animal experimental data to the human 
situation, species differences in metabolic activation and detoxification of safrole should be 
taken into account. In chapter 3, the kinetic constants for bioactivation and detoxification of 
safrole with human tissue fractions were obtained. Furthermore, with the PBBK model for 
human defined in chapter 3, the formation of the proximate carcinogenic metabolite, 1ʹ-
hydroxysafrole, and of the ultimate carcinogenic metabolite, 1ʹ-sulfooxysafrole, in human 
could be predicted.  
The PBBK model for human was evaluated by comparison of the PBBK model based 
predicted and the reported experimental data on the level of total safrole metabolites 
  
 
detected in the urine of humans exposed to dose levels of 0.0027 mg/kg bw (for a 60 kg 
person corresponding to 0.163 mg/subject) and 0.0276 mg/kg bw (for a 60 kg person 
corresponding to 1.655 mg/subject) (Benedetti et al., 1977). This comparison revealed that 
the prediction adequately matched observed experimental values.  
Results from the PBBK model based predictions for humans were compared to the PBBK 
model based predictions for rat to obtain insight in the possible interspecies differences in 
bioactivation of safrole. This comparison showed that the predicted level of formation of 1ʹ-
hydroxysafrole in human liver is fourfold higher than that for rat liver and that the predicted 
formation of 1ʹ-sulfooxysafrole in human liver is about fivefold higher than that for rat 
liver. This indicates that the interspecies differences in toxicokinetics for bioactivation of 
safrole between rat an human are in line with the uncertainty factor normally taken into 
account for interspecies differences in toxicokinetics of 4 (IPCS, 2010). Species differences 
between human and rat in the nature of the detoxification pathways of 1ʹ-hydroxysafrole 
were larger, with the formation of 1ʹ-oxosafrole being the main detoxification pathway in 
humans but a minor pathway in rats and glucuronidation of 1ʹ-hydroxysafrole being less 
important in humans than in rats.  
At a dose relevant for human dietary intake of 0.005 mg/kg bw, formation of 1ʹ-
sulfooxysafrole in human liver was predicted to amount to 0.02 nmol/kg bw and this level 
increases to 8.7 nmol/kg bw at a dose level of 3 mg/kg bw. This shows that the formation of 
1ʹ-sulfooxysafrole in percentage of the dose at the low and high dose level of safrole was 
not significantly different. Plotting the dose of safrole (mg/kg bw) vs formation of 1ʹ-
sulfooxysafrole (µmol/kg bw) on a log-log scale for human and rat liver as shown in Fig. 
6.1, shows a linear relationship over the dose range from dose levels known to cause cancer 
in rodent bioassays (for example 100 mg/kg bw) down to dose levels relevant for daily 
human intake and as low as the virtual safe dose (VSD). The VSD is a dose that is expected 
to give one additional cancer risk in a million people upon life time exposure (Edler et al., 
2002). By linear extrapolation from the BMD10 (Benchmark Dose causing 10% extra risk) 
obtained from a BMD analysis of the data from the in vivo study of Miller et al. (1983) and 
Boberg et al. (1983), amounting to 4.6-39 mg/kg bw/day, the VSD can be derived and 
amounted to 0.046-0.390 µg/kg bw/day (Martati et al., 2011). This graph supports that 
  
 
possible nonlinear kinetics and species differences in kinetics should not be used as an 
argument against using a linear low-dose cancer risk extrapolation from animal data to the 
low-dose human situation. This shows that PBBK models can evaluate the interspecies 
differences and provide a useful tool in risk assessment of food-borne chemicals when 
evaluating human risks. 
 
Figure 6.1. PBBK model-based predicted dose-dependent formation of 1ʹ-sulfooxysafrole in the liver of human, 
corresponding to the median or 50th percentile ( ▬▬ ), the 5th and 95th percentiles ( ▬ ▬ ) and rat (▬ ▬ ). Note 
that the lines of the 5th percentile of 1ʹ-sulfooxysafrole formation in humans and the mean of those in rats overlap. 
Another factor that should be taken into account in the risk assessment of safrole is the 
influence of human interindividual differences and this was studied in more detail also in 
chapter 3. Human variability may arise from a variety of sources including variation in 
physiological parameters or in the activity of metabolizing enzymes involved in safrole 
metabolism. To obtain insight in this human interindividual variability in metabolic 
activation and detoxification of safrole, Monte Carlo simulations were performed to assess 
the impact of the variability on the model predictions. For the Monte Carlo simulation, 
probability distributions were assigned to those parameters to which the model outputs for 
the predicted level of formation of the proximate carcinogenic metabolite, 1ʹ-
hydroxysafrole, and of the ultimate carcinogenic metabolite, 1ʹ-sulfooxysafrole, were 
shown to be the most sensitive in the sensitivity analysis.  
  
 
Monte Carlo simulations revealed that the formation of 1′-sulfooxysafrole was predicted to 
vary 4- to 17-fold in the population (fold-difference between the 95th and median, and 95th 
and 5th percentile respectively). Moreover, a CSAF (chemical-specific adjustment factor) 
for interindividual differences in kinetics for predicted formation of 1ʹ-sulfooxysafrole 
representing a ratio of the parameter estimate at the 95th percentile and the median is 3.9 
(IPCS, 2005). Further analysis reveals that the default uncertainty factor of 3.16 for 
interspecies variability in biokinetics (assuming that a factor of 10 is subdivided equally 
into two sub-factors each of 10-0.5 (3.16) for biokinetic and for biodynamic) (IPCS, 2010) 
adequately protects 91% of the population. It can also be concluded that for protecting 99% 
of the population a larger uncertainty factor for interindividual differences in biokinetics of 
6.8 would be required.  
It is of interest to note that the PBBK models for safrole developed in the present thesis 
describe the biokinetics of safrole. In a previous study on estragole, we extended the PBBK 
model to a so-called physiologically based biodynamic (PBBD) model describing the dose 
dependent DNA adduct formation. This was done by linking the PBBK model based 
predictions for formation of 1ʹ-hydroxyestragole to DNA adduct formation in the liver by 
using data from an in vitro hepatocyte model in which the 1ʹ-hydroxyestragole 
concentration dependent formation of DNA adducts was quantified (Paini et al., 2010). 
This PBBD model for in vivo DNA adduct formation was validated using results from an in 
vivo study in which rats were exposed to estragole (Paini et al., 2012). Performing similar 
in vitro studies to define an equation for the 1ʹ-hydroxysafrole dependent formation of 
safrole DNA adducts in rat hepatocytes would allow extension of the current PBBK models 
predicting 1ʹ-hydroxysafrole and 1ʹ-sulfooxysafrole formation to a PBBD model predicting 
DNA adduct levels in the liver of safrole exposed rats. 
A next step would be to correlate the number of DNA adducts to mutagenicity or even to 
the level of tumor formation. Such an attempt to relate the level of DNA adducts formed to 
tumor incidence in rats and mice exposed to carcinogenic compounds was reported before 
(Otteneder and Lutz, 1999). The results of this analysis revealed that the calculated adduct 
concentration responsible for a 50% hepatocellular tumor incidence appeared to vary with 
the carcinogen studied ranging from 53 to 2083 and 812 to 5543 adducts per 108 nt for rat 
  
 
liver and mice liver, respectively. Likewise Paini et al. (Paini et al., 2011) concluded that 
the number of DNA adducts estimated to be formed at the BMDL10 for tumor formation of 
a series of liver carcinogens varied orders of magnitude. Based on that result, these authors 
concluded that the quantity of DNA adducts formed by a DNA-reactive compound is not a 
carcinogenicity predictor by itself but that other factors such as type of adduct and 
mutagenic potential of the adduct or other factors contributing to the mode of action for 
tumor formation may be equally relevant. Thus, characterization of the mutagenic and 
carcinogenic potential of the safrole DNA adducts formed is a topic that remains open for 
future studies. 
The current EU Regulation No 1334/2008 prohibits addition of safrole as pure compound to 
foods in order to reduce its daily intake and increase the MOE values. As a result of these 
regulations, the current human intake of safrole mainly results from consumption of spices 
containing safrole such as mace, nutmeg, pepper, etc or from food to which those spices or 
their essential oils are added to replace the addition of pure safrole the use of which in food 
or beverages has been banned. Thus, human exposure to safrole is always within the 
context of a food matrix. In contrast to this, studies on the toxicity and carcinogenicity of 
safrole are generally performed using pure safrole. The presence of the complex food 
matrix may modulate the bioactivation and detoxification of safrole thereby influencing its 
toxicity. Therefore, risk assessment resulting from consumption of herbs and spices that 
contain safrole should preferably be performed taking into account the possible modulating 
effects of other compounds present in these herbs or spices. Previously, a scientific opinion 
on a guidance on safety assessment of botanicals and botanical preparations intended for 
use as ingredients in food supplements published by EFSA (EFSA, 2009), already indicated 
that where a matrix effect is advocated to support the safety of specific levels of substances 
(e.g. that data from a pure substance may overestimate effects of the substance in the 
botanical matrix), testing and/or other data should be provided to demonstrate the 
occurrence of the matrix effect of the preparation and its magnitude. EFSA also indicated 
that a matrix effect should be judged on a case-by-case basis (EFSA, 2009). The 
experiments described in chapter 4 of this thesis aimed at obtaining insight in possible 
matrix derived effects on the bioactivation of safrole. To this end, the inhibition of 
  
 
sulfotransferase (SULT)-mediated bioactivation of 1ʹ-hydroxysafrole by a methanolic mace 
extract was quantified. To this end the methanolic mace extract was tested for inhibition of 
SULT activity and subsequently fractionated testing also its fractions for SULT inhibition. 
In the mace fraction, the highest SULT inhibiting activity malabaricone C was identified as 
the relevant SULT inhibitor. The Ki (inhibition constant) for inhibition of SULT activity by 
the malabaricone C-containing mace extract was 8.3 and 1.0 mg/L for rat and human liver 
S9, respectively. At a methanolic mace extract concentration of 100 mg/mL, oxidation and 
glucuronidation of 1′-hydroxysafrole were not inhibited in incubations with human liver S9, 
showing that at these concentrations, the methanolic mace extract selectively inhibited only 
SULTs without modify the detoxification reactions of 1ʹ-hydroxysafrole.  
In further studies described in chapter 4, it was investigated whether the malabaricone C-
containing mace extract would be able to inhibit the SULT mediated bioactivation and 
subsequent DNA adduct formation of safrole in an intact cell system, using human HepG2 
cells. Exposure of HepG2 cells to 1′-hydroxysafrole in the presence of increasing 
concentrations of malabaricone C-containing mace extract revealed a dose-dependent 
inhibition of N2-(trans-isosafrol-3′-yl)-2′-deoxyguanosine (S-3′-N2-dGuo) formation. With 
mace extract concentrations of 25 and 100 mg/L, S-3′-N2-dGuo formation in HepG2 cells 
exposed to 1′-hydroxysafrole was inhibited by 60 and 88 %, respectively. The mace extract 
did not display cytotoxicity up to concentrations of at least 100 mg/L which was the highest 
concentration tested. 
To investigate if possible effects on safrole bioactivation to 1′-sulfooxysafrole by 
malabaricone C-containing mace extract could also be expected in vivo, the SULT 
inhibition was integrated into the PBBK model using the Ki values obtained with rat or 
human S9. The PBBK models thus obtained predicted that at a dose of 50 mg/kg bw safrole 
and at a ratio of malabaricone C-containing mace extract to safrole similar to the level of 
these constituents in mace (44 mg/µmol), inhibition of 1′-sulfooxysafrole formation by 
malabaricone C-containing mace extract for rats and humans amounts to 90 and 100% 
when the bioavailability of the mace extract ingredients would be 100%. When the 
bioavailability of the malabaricone C-containing mace extract would be 1% inhibition of 1′-
  
 
sulfooxysafrole formation was predicted to amount to 61 and 91%, for rats and humans, 
respectively.  
This result points at a potential reduction of the bioactivation and resulting cancer risk 
when safrole intake results from the food matrix containing malabaricone C or other SULT 
inhibitors present in the regular daily diet. A great number of literature studies reported 
some natural dietary compounds to also inhibit SULT activity including compounds such as 
epicatechin gallate (ECG), epigallocatechin gallate (EGCG) (Coughtrie and Johnston, 2001; 
De Santi et al., 2002), kaempferol, quercetin, genistein and daidzein (Mesia-Vela and 
Kauffman, 2003), various beverages containing flavonoids (Nishimuta et al., 2007) and 
basil extract shown to contain the flavonoid nevadensin that inhibits SULT activity with a 
Ki values of 4 nM (Alhusainy et al., 2010; Jeurissen et al., 2008).  
In additional studies of the present thesis, it was demonstrated that the inhibition of safrole 
DNA adduct formation by malabaricone C-containing mace extract observed in in vitro 
model systems can actually be demonstrated in an in vivo experiment. Chapter 5 presents 
the results of an in vivo study in which Sprague-Dawley rats were orally exposed to mace 
extract and safrole and the level of safrole DNA adduct formation in the liver was 
quantified and compared to the level of safrole DNA adducts detected in the liver of rats 
exposed to safrole only. The ratio of mace extract and safrole (mg/µmol) used in this in 
vivo study was 0.5 instead of 44 mg/µmol, the latter being the ratio mimicking the ratio of 
these constituents in mace extract. This lower dose of mace extract was chosen to avoid 
possible toxicity of the mace extract. At a dose of safrole of 150 mg/kg bw and a ratio of 
mace extract and safrole of 0.5 mg/µmol, the dose of mace extract would amount to 463 
mg/kg bw. This is lower than the dose of 3000 mg/kg bw reported by El Malti et al. (2008) 
to result in death of mice orally exposed to mace extract, whereas at the lower dose of 300 
mg/kg bw, the mice survived (El Malti et al., 2008). At a dose safrole of 150 mg/kg bw, 
and a ratio of mace extract and safrole of 0.5 mg/µmol the predicted inhibition of 1ʹ-
sulfooxysafrole was still 80% compared to 90% for the ratio of 44 mg/µmol. Based on 
these considerations, the ratio of 0.5 mg mace extract/µmol was chosen for the in vivo 
study reported in chapter 5 of this thesis. The results of the in vivo study demonstrate that 
the inhibition of S-3′-N2-dGuo safrole DNA adduct formation in the liver of Sprague-
  
 
Dawley rats by the mace extract amounted to 55%. The PBBK model predicted that a 55% 
inhibition of safrole bioactivation to 1ʹ-sulfooxysafrole would be obtained when the 
bioavailability of the SULT inhibitors in the malabaricone C-containing mace extract would 
be 68% instead of 100%, which may not be unrealistic. Thus, the results of the in vivo 
study are in line with what would be expected based on the PBBK model based predictions 
for safrole bioactivation.  
The in vivo study also revealed a 64% inhibition of the safrole DNA adduct formation in 
the liver upon co-exposure of the rats to safrole and the well-known SULT inhibitor PCP. 
This result is in line with results reported before in rats or mice exposed to safrole or 1ʹ-
hydroxysafrole in the presence of PCP (Boberg et al., 1983; Daimon et al., 1997; Randerath 
et al., 1984).  
In chapter 5, it was also demonstrated that urinary excretion of the major safrole 
metabolites, (conjugated) 1ʹ-hydroxysafrole and DHAB was not significantly reduced when 
safrole was dosed in the presence of mace extract or PCP. This observation excludes that 
the reduction in DNA adduct formation is due to a reduced bioavailability of safrole when 
dosed together with malabaricone C-containing mace extract or PCP.  
Inhibition of other enzymes involved in the bioactivation or detoxification of safrole by 
mace extract constituents may also occur. In vitro tests reported by Kimura et al. (2010) 
showed that mace extract resulted in a potent inhibition of P450 3A4 and P450 2C9 with 
IC50 values of 1.1-4.2 µg/mL, and that 17 compounds isolated from mace inhibited the 
activities of P450 3A4 and P450 2C9 with IC50 less than 11.2 µM (Kimura et al., 2010). 
Since P450 2C9 was previously shown to be a major P450 enzyme involved in the 1ʹ-
hydroxylation safrole (Jeurissen et al., 2004; Ueng et al., 2004), this inhibition of P450 2C9 
may have contributed to the observed reduction in safrole bioactivation by methanolic mace 
extract. 
It is also of interest to note that the levels of safrole DNA adducts detected in the in vivo 
study upon a dose of 150 mg/kg bw safrole amounted to 2400+1200 adducts/108nt. This 
level is in line with the level of 3700-8000 adducts/108 nt previously detected for rats 
exposed to 150 mg/kg bw estragole (Alhusainy et al., 2013; Paini et al., 2012). It is also of 
  
 
importance to note that these values are 2 orders of magnitude higher than the levels 
recently reported by Herrmann et al. (2013) for the DNA adduct levels of the related 
alkenylbenzene methyleugenol in liver samples of 30 human subjects amounting to values 
of 13 to 37 per 108 nt (for respective median and maximum values). The methyleugenol 
adducts detected in this human study are likely to result from intake of food containing 
methyleugenol. This comparison reveals that the DNA adduct levels in the liver of rats 
exposed to alkenylbenzenes at dose levels that are capable of inducing liver tumors are only 
two orders of magnitude higher than the levels apparently present due to current levels of 
dietary human exposure, suggestion in another way that the MOE values for these 
compounds that are genotoxic and carcinogenic may be (too) low and of safety concern. 
Another issue that might be raised is whether results from studies testing safrole or the 
other alkenylbenzenes as pure compounds, without the normal food matrix being present, 
provide an adequate starting point for risk assessment. Instead one may develop ways to 
integrate the food matrix dependent modulation of safrole bioactivation in the risk 
assessment of safrole. This can be done using the so-called Margin of Exposure (MOE) 
approach and taking into account the results of the in vivo study for the effect of the 
malabaricone C-containing mace extract on safrole bioactivation presented in chapter 5 of 
this thesis. Assuming a reduction in hepatocellular carcinoma incidences in line with the 
observed 55% reduction in safrole bioactivation, the incidences for hepatocellular 
carcinomas were refined resulting in BMDL10 values of 17.3 to 22.8 mg/kg bw/day instead 
of 2.6 to 7.0 mg/kg bw/day and in MOE values that amount to 3460 to 4560 instead of 520 
to 1400. From this analysis, it can be concluded that when safrole would have been tested 
in rodent bioassays in the presence of malabaricone C-containing mace extract increased 
BMDL10 and increased MOE values would have been obtained indicating a lower priority 
for risk management compared to the BMDL10 and MOE values derived from rodent 
carcinogenicity data obtained when testing safrole as a pure compound.  
It is important to note that the inhibition of safrole DNA adduct formation by malabaricone 
C-containing mace extract in the present thesis was shown at high dose levels of safrole and 
malabaricone C-containing mace extract. The PBBK models developed in the present thesis 
may also be applied to investigate to what extent the inhibition of safrole bioactivation by 
  
 
malabaricone C-containing mace extract would be observed at lower realistic levels of 
dietary intake. It could be calculated that at a dose level of 0.05 mg/kg bw safrole and 13.6 
mg/kg bw malabaricone C-containing mace extract, reflecting their ratio in mace of 44 
mg/µmol, the inhibition of 1ʹ-sulfooxysafrole formation would amount to 23% in rat and 
77% in human liver. However, at realistic human dietary intakes the food matrix is likely to 
contain also a variety of other SULT inhibitors including epicatechin gallate (ECG), 
epigallocatechin gallate (EGCG) (Coughtrie and Johnston, 2001; De Santi et al., 2002), 
kaempferol, quercetin, genistein and daidzein (Mesia-Vela and Kauffman, 2003), various 
beverages containing flavonoids (Nishimuta et al., 2007) and basil extract shown to contain 
the flavonoid nevadensin that inhibits SULT activity with a Ki values of 4 nM (Alhusainy 
et al., 2010; Jeurissen et al., 2008). It may be expected that the combined effect of all these 
SULT inhibitors may result in an inhibition of SULT mediated safrole bioactivation also at 
dose scenarios reflecting realistic human intake via food. This remains to be investigated. 
Future perspectives and conclusions  
The present thesis describes the predictions of the dose-, species, interindividual-, and 
matrix- dependent effects on the bioactivation and detoxification of safrole using PBBK 
modeling. Several issues remain to be developed to a further extent to completely 
understand the factors affecting the ultimate risk assessment of dietary human exposure to 
safrole. In this section some factors to be considered in future research and risk assessment 
of safrole are discussed in some more detail. 
1. Improving the PBBK model by incorporation of a sub-model for malabaricone C and of 
possible P450 inhibition. 
The present PBBK-based prediction for the inhibition of in vivo safrole DNA adduct 
formation by malabaricone C-containing mace extract matched relatively well with the 
values actually observed in an in vivo validation experiment. However, further optimization 
of the model, incorporating a sub-model for malabaricone C kinetics may further improve 
the predictions. This was recently shown for the inhibition of estragole DNA adduct 
formation by the basil ingredient nevadensin. Incorporation of a nevadenisin PBBK sub-
model into the estragole model significantly improved the predictions resulting in a less 
  
 
than 2-fold difference between predicted and actually observed DNA adduct levels 
(Alhusainy et al., 2013). Such studies will require purification of malabaricone C and 
testing of the pure compound which also could be an important objective for further studies.  
A further refinement of the PBBK model could be to include inhibition of P450 by mace 
extract or the newly identified SULT inhibitor since such effects may also influence the 
bioactivation of safrole. Kimura et al. (Kimura et al., 2010) showed that extracts from 25 
herbs and spices contained inhibitors of P450 3A4 and P450 2C9 and that mace extract was 
one of them resulting in approximately 95% inhibition at concentrations of mace extract of 
100 µg/mL for the P450s tested. Mace extract selectively inhibited P450 3A4 and P450 
2C9 with IC50 values of 3.9 and 1.1 µg/mL, respectively. Moreover, the seventeen isolated 
compounds from this mace extract were shown to have IC50 values for inhibition of P450 
3A4 and P450 2C9 ranging from 0.24 to >100 µM. Based on these results, it can be 
foreseen that in the presence of mace extract the inhibition of P450 mediated conversion of 
safrole may occur, which may affect the ultimate metabolite patterns. Once established the 
kinetics for inhibition of P450 activity by malabaricone C-containing mace extract and/or 
pure malabaricone C can be integrated into the PBBK model, to further improve its 
predictive power. 
2. Development of a physiologically based biodynamic (PBBD) model for safrole 
The PBBK models obtained for safrole predict the kinetic characteristics of bioactivation 
and detoxification of safrole allowing evaluation of dose-, species-, interindividual- and 
even matrix- dependent effects on the bioactivation and detoxification of the compound. 
The ultimate carcinogenic effect of safrole will depend not only on these kinetic 
characteristics but also on toxicodynamic processes, such as the formation of DNA adducts, 
as well as the nature, repair and mutagenicity of the adducts formed and the processes 
ultimately leading to cancer formation. Therefore, information related to the formation of 
DNA adducts, the biological processes of injury, DNA repair, and tumor formation, and 
development should be considered. This can be done by extending the present PBBK 
models to physiologically based bioynamic (PBBD) models for safrole. In a first step, the 
PBBK model can be extended to a PBBD model by including an equation describing the 
  
 
relationship between formation of 1ʹ-hydroxysafrole or 1ʹ-sulfooxysafrole and DNA adduct 
formation. An example of such a PBBD model can be found in the PBBD model developed 
for estragole describing the dose-dependent formation of DNA adducts of estragole using 
the PBBK model for estragole and coupling it to in vitro data obtained with rat primary 
hepatocytes (Paini et al., 2010). The predicted formation of estragole DNA adducts in the 
liver of rats was shown to match the in vivo results. Such a PBBD model for safrole is 
obviously needed to proceed at least one step beyond the bioactivation to 1ʹ-sulfooxysafrole 
and predict DNA adduct formation. As stated already above characterization of the 
mutagenic and carcinogenic potential of the safrole DNA adducts formed is a topic that 
remains open for future studies. 
3. Identification of the SULT enzymes for safrole bioactivation and their inhibition by 
malabaricone C 
Based on the results of the present study the inhibition of the formation of safrole DNA 
adducts by a methanolic mace extract was attributed to the inhibition of the SULT mediated 
conversion of 1ʹ-hydroxysafrole to 1ʹ-sulfooxysafrole. Co-administration of safrole and the 
malabaricone C-containing mace extract or the SULT inhibitor PCP to rats (present thesis) 
and of safrole and PCP to mice (Boberg et al., 1983) resulted in the reduction of DNA 
adduct formation in the liver as a result of inhibition of SULT mediated formation of 1ʹ-
sulfooxysafrole. From the sensitivity analysis of the PBBK model for rats and humans, it 
could be derived that formation of 1ʹ-sulfooxysafrole will be most affected by the kinetic 
parameters of sulfation of 1ʹ-hydroxysafrole. Human has at least 11 different SULTs 
enzymes and it would be of interest to identify the SULT enzymes involved in safrole 
bioactivation because that would allow to take consequences of possible genetic 
polymorphisms in relevant SULTs into account in the risk assessment. Identification of the 
SULTs able to activate 1ʹ-hydroxysafrole to 1ʹ-sulfooxysafrole could be performed as done 
previously for methyleugenol using Salmonella typhimurium strains expressing various 
human or rodent SULTs developed by Herrmann et al. (2012). Using these modified 
Salmonella typhimurium strains for Ames tests on 1ʹ-hydroxymethyleugenol and its 
isomers, human SULT1A1 and SULT1C2 were observed to be the most active SULTs in 
the formation of DNA reactive methyleugenol metabolites (Herrmann et al., 2013). Using 
  
 
these modified Salmonella typhimurium strains for Ames tests on 1ʹ-hydroxysafrole will 
provide information of the SULTs involved in the bioactivation and mutagenicity of 
safrole. Using 1ʹ-hydroxysafrole in incubations with SULT1A1 Chung et al. (2009) showed 
that 1ʹ-hydroxysafrole can be efficiently sulfonated by SULT1A1 (Chung et al., 2009). 
Identification of the actual SULT enzyme involved and of its possible inhibition by 
malabaricone C remains of interest for further studies.  
4. Risk assessment of the related alkenylbenzenes using read-across of the PBBK models  
It is of interest to compare the results of the PBBK model for safrole to those obtained with 
the previously developed PBBK model for the related alkenylbenzenes estragole and 
methyleugenol in rats and humans (Punt et al., 2008; Punt et al., 2009; Al-Subeihi et al., 
2011; Al-Subeihi et al., 2012). This will reveal insight in their relative bioactivation and 
chances on DNA adduct formation and can be compared to possible differences in their 
BMDL10 values for tumor formation. The comparison of the PBBK model based predicted 
formation of the ultimate carcinogenic 1ʹ-sulfooxy metabolites of safrole, methyleugenol 
and estragole appeared to vary less than 6-fold in male rat liver and to vary even less by 2- 
to 5-fold in human liver. Formation of DNA adducts in HepG2 cells exposed to the 
alkenylbenzenes varied 3.5-fold (Zhou et al., 2007). Furthermore, the calculated BMDL10 
values showed a comparable carcinogenic potency amounting to 3-29 (Martati et al., 2011) 
mg/kg bw/day, 22-32 mg/kg bw (Rietjens et al., 2008), and 9-33 mg/kg bw/day (Rietjens et 
al., 2010) for safrole, methyleugenol, and estragole, respectively. Comparison of the 
predicted level of formation of the ultimate carcinogenic 1ʹ-sulfooxy metabolites obtained 
from the developed PBBK models to the other in vitro or in vivo data available indicated 
that safrole, methyleugenol and estragole have a comparable carcinogenic potential. Taking 
this observation into account it is concluded that based on PBBK model based prediction of 
detoxification and bioactivation of related alkenylbenzenes one could apply read across and 
predict the carcinogenic potential for alkenylbenzenes for which no rodents tumor data are 
available, like for example elemicin and apiole, without the need for further animal testing. 
Thus PBBK model based predictions could facilitate risk assessment without the need for 
animal experiments. Recently, van den Berg et al. (2012) provided an example of this 
approach and performed a risk assessment of the alkenylbenzene elemicin for which in vivo 
  
 
rodent carcinogenicity data are not available using PBBK model based read-across to the 
structurally related estragole and methyl eugenol for which tumor data are reported. 
5. Formation of safrole derived quinone metabolites by further conversion of DHAB and 
their mutagenic potency 
Another issue that might be considered in future work on safrole but also on the read across 
to other alkenylbenzenes would be the role of the ortho-quinone and/or para-quinone 
methide metabolites that have been reported to be formed from the safrole metabolite 
DHAB. These reactive quinone/quinone methide electrophiles may be scavenged via a 
reaction with glutathione (GSH) but may also cause further toxicity through either their 
potential to support redoxcycling and oxidative stress or to form covalent adducts with 
cellular macromolecules (Bolton et al., 1994; O'Brien, 1991). Lee-Chen et al. (Lee-Chen et 
al., 1996) reported that DHAB induced formation of the oxidative damage DNA product 8-
hydroxy-2ʹ-deoxyguanosine (8-OH-dG) which may be responsible for the increased 
mutagenicity and cytotoxicity in CHO-K1 cells and in the S.typhimurium TA102 test. 
Sugumaran and Bolton (1995) also reported production of p-quinone methide from DHAB 
exhibiting DNA binding potency. In rats exposed to safrole at dose levels of 500 and 1000 
mg/kg bw/day for 5 days, 8-OH-dG levels increased and rapidly returned to a basal level on 
day 15 (Liu et al., 1999). This is in contrast to the safrole DNA adducts formed in mice 
exposed to safrole that can still be detected in the liver at 30 and 140 days after dosing of 10 
mg safrole/mouse (Gupta et al., 1993; Randerath et al., 1984). Based on theses observations 
one may suggest that the stable safrole DNA adducts may play a more important role in the 
initiation of cell lesions than the rapidly repaired safrole-induced 8-OH-dG although this 
remains to be investigated in more detail. The role of the DHAB derived quinone/quinone 
methide metabolites in the adverse effects of safrole may also be limited to some extent 
because DHAB can be excreted following its conjugation prior to oxidation or upon GSH 
conjugation of its quinone/ quinone methide which has been observed to occur in rat 
hepatocytes (Nakagawa et al., 2009).  
In conclusion, in the present thesis it has been shown that integrating in vitro metabolic, 
physiological, and biochemical parameters in PBBK models forms a good tool to give 
  
 
insight into the possible dose-, species-, interindividual- and matrix dependent effects on 
the bioactivation of safrole. Furthermore, given the role of the SULT-mediated formation of 
safrole DNA adduct formation in the hepatocarcinogenicity of safrole in rodents, the results 
of the present study indicate that the likelihood of bioactivation and subsequent adverse 
effects in rodent bioassays will be lower when safrole is tested in the presence of a matrix 
containing SULT inhibitors such as malabaricone C-containing mace extract, compared to 
exposure of safrole as a pure compound. This will affect the risk assessment of safrole since 
it will result in increased BMDL10 and MOE values pointing at a lower priority for risk 
management actions. 
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Summary 
Safrole is a genotoxic carcinogen the use of which in human food has already been 
prohibited since 1960 in U.S. and since 2008 in Europe (FDA Ban 21 CFR 189, 180; 
revised April 1 2008; European Commission, 2008). As a result, the main exposure to 
safrole occurs through the use of herbs and spices containing low levels of safrole, such as 
nutmeg, mace, star anise, pimento, cinnamon, and black pepper, and food products 
containing these herbs and spices or their essential oils. Some foods and beverages contain 
safrole at levels higher than the current European Union (EU) recommended limit (Siano et 
al., 2003; Choong and Lin, 2001).  
The safety of human exposure to safrole at low dietary intake levels has been assessed 
several times (Council of Europe, 1997; SCF, 2002; SCOGS, 1973). The Scientific 
Committee on Food (SCF) of the EU concluded in their evaluation that safrole is genotoxic 
and carcinogenic and that reductions in the exposure and restriction in the use levels are 
indicated (SCF, 2002). The Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) concluded at its twenty-fifth meeting that flavouring agents containing safrole as 
the principal flavour-active ingredient should not be used as food additives (JECFA, 1981). 
These opinions are all based on carcinogenicity data from rodent studies as adequate human 
data were not available. Therefore, translation from animal bioassays at high dose levels of 
the pure compound to the risk for the human population exposed to safrole at relatively low 
levels via dietary intake within the complex food matrix is obviously needed. This 
translation needs a better understanding of species-, dose-, and interindividual dependent 
differences in bioactivation and detoxification of safrole and the possible influence of the 
food matrix on these processes. The aim of this thesis was to obtain insight into the dose-, 
species-, interindividual- and matrix dependent effects on the bioactivation and 
detoxification of safrole using physiologically based biokinetic (PBBK) modeling.  
In the first chapter, background information of the topic and the aims of the thesis are 
presented. In chapter 2, a PBBK model for detoxification and bioactivation of safrole in 
male rats was developed based on in vitro metabolic parameters determined, in silico 
derived partition coefficients, and physiological parameter values taken from literature 
  
 
(Brown et al., 1997). The PBBK model consists of eight compartments including liver, 
kidney and lung as metabolizing compartments and compartments for fat, venous and 
arterial blood, richly perfused tissue and slowly perfused tissue. The performance of the 
model was evaluated by comparison of predicted levels of 1,2-dihydroxy-4-allylbenzene 
(DHAB), 1′-hydroxysafrole glucuronide (1′-HSG) and total urinary safrole metabolites to 
the reported levels of these metabolites in urine of rats exposed to safrole (Benedetti et al., 
1977; Klungsøyr and Scheline, 1983). This evaluation revealed that the predictions 
adequately matched observed experimental values. With the model obtained the relative 
extent of bioactivation and detoxification of safrole at different oral doses was examined. 
At low as well as high doses, cytochrome P450 (P450) mediated conversion of safrole 
mainly occurs in the liver in which DHAB was predicted to be the major P450 metabolite 
of safrole. A dose dependent shift in P450 mediated conversion leading to a relative 
increase in bioactivation at high doses was not observed. This can be explained by the fact 
that for P450 mediated conversion of safrole no saturation of an important metabolic route 
occurs in a dose range from 0.05 up to 300 mg/kg bw. Extrahepatic conversion of safrole 
did not contribute significantly to the overall metabolism. In male rat liver, glucuronidation 
is the major pathway for the conversion of 1ʹ-hydroxysafrole followed by oxidation, 
whereas sulfation of 1ʹ-hydroxysafrole to generate the ultimate carcinogenic metabolite 1ʹ-
sulfooxysafrole is a minor pathway.  
Chapter 3 of the present thesis describes a PBBK model for safrole in human based on in 
vitro and in silico derived parameters. The model is composed of eight compartments 
including liver, kidney and lung as metabolizing compartments and compartments for fat, 
venous and arterial blood, richly perfused tissue and slowly perfused tissue. With the model 
obtained, the time- and dose-dependent formation of the proximate and ultimate 
carcinogenic metabolites, 1′-hydroxysafrole and 1′-sulfooxysafrole in human liver were 
estimated. In addition, a Monte Carlo simulation was performed to predict interindividual 
variation in the formation of these metabolites in the population as a whole. The PBBK 
model for human was evaluated by comparison of the PBBK predicted and the reported 
experimental data on the level of total safrole metabolites detected in the urine of human 
volunteers exposed to safrole (Benedetti et al., 1977) which showed an adequately match. 
  
 
The comparison of the PBBK model for rat and human revealed that the predicted level of 
formation of 1ʹ-hydroxysafrole in human liver is fourfold higher than that for rat liver and 
the predicted formation of 1ʹ-sulfooxysafrole is about fivefold higher than that for rat liver. 
This indicates that the interspecies differences in toxicokinetics for bioactivation of safrole 
between rat an human are in line with the uncertainty factor normally taken into account for 
interspecies differences in toxicokinetics of 4 (IPCS, 2010). Species differences between 
human and rat in the nature of the detoxification pathways of 1ʹ-hydroxysafrole were larger, 
with the formation of 1ʹ-oxosafrole being the main detoxification pathway in humans but a 
minor pathway in rats and glucuronidation of 1ʹ-hydroxysafrole being less important in 
humans than in rats. The PBBK model predicted that the formation of 1ʹ-sulfooxysafrole in 
the liver of human and rat shows a linear relationship over the dose range from dose levels 
known to cause cancer in rodent bioassays (100 mg/kg bw) down to dose levels relevant for 
daily human intake and as low as the virtual safe dose (VSD). This shows that PBBK 
models can evaluate the interspecies differences and provide a useful tool in risk 
assessment of food-borne chemicals when evaluating human risks. Monte Carlo simulations 
revealed that the formation of 1′-sulfooxysafrole was predicted to vary 4- to 17-fold in the 
population (fold-difference between the 95th and median, and 95th and 5th percentile, 
respectively). Moreover, a CSAF (chemical-specific adjustment factor) for interindividual 
differences in kinetics for predicted formation of 1ʹ-sulfooxysafrole representing a ratio of 
the parameter estimate at the 95th percentile and the median is 3.9 (IPCS, 2005). 
Comparison of the CSAF with the default uncertainty factor of 3.16 for interspecies 
variability in biokinetics (assuming that a factor of 10 is subdivided equally into two sub-
factors each of 10-0.5 (3.16) for biokinetic and for biodynamic) (IPCS, 2010) reveals that the 
default uncertainty factor adequately protects 91% of the population.  
The current EU regulation No. 1334/2008 banned addition of safrole as pure compound to 
food in order to reduce its daily intake. As a result of these regulations, the current human 
intake of safrole mainly results from consumption of spices containing safrole such as 
mace, nutmeg, pepper, etc. or from food to which those spices or their essential oil are 
added. Therefore, risk assessment of safrole resulting from consumption of herbs and spices 
containing safrole should be performed taking into account the possible modulating effect 
  
 
of other compounds present in these herbs or spices. The consequences of possible matrix 
dependent effects on the bioactivation and detoxification of safrole was investigated in 
chapter 4. Since mace is known to contain relatively high levels of safrole (Archer, 1988), 
methanolic mace extract and its fractionated samples were tested for inhibition of SULT 
activity, thereby inhibiting the final step in the bioactivation of safrole. The mace fraction 
containing malabaricone C showed the highest SULT inhibiting activity. The Ki (inhibition 
constant) for inhibition of SULT activity by the malabaricone C-containing extract was 8.3 
and 1.0 mg/L for rat and human liver S9, respectively. Inhibition by mace extract of 
oxidation and glucuronidation of 1ʹ-hydroxysafrole was not observed at a mace extract 
concentration of 100 mg/L showing that mace extract inhibited selectively SULTs. In 
chapter 4, further studies using human HepG2 cells exposed to 1ʹ-hydroxysafrole and in the 
presence of mace extract showed that formation of the DNA adduct N2-(trans-isosafrol-3′-
yl)-2′-deoxyguanosine (S-3ʹ-N2-dGuo) was inhibited by 60 and 80% at mace extract 
concentrations of 25 and 100 mg/L, respectively. The mace extract did not display 
cytotoxicity up to concentrations of at least 100 mg/L which was the highest concentration 
tested. 
To investigate if possible effects on safrole bioactivation to 1′-sulfooxysafrole by 
malabaricone C-containing mace extract could also be expected in vivo, the SULT 
inhibition was integrated into the PBBK model using the Ki values obtained with rat or 
human S9. The PBBK models thus obtained predicted that at a dose of 50 mg/kg bw safrole 
and a ratio of malabaricone C-containing mace extract to safrole similar to the level of these 
constituents in mace (44 mg/µmol), inhibition of 1′-sulfooxysafrole formation by 
malabaricone C-containing mace extract for rats and humans amounts to 90 and 100%, 
respectively, when bioavailibility of the mace extract ingredients would be 100%. When 
bioavailibility of the mace extract ingredients would be 1%, the inhibition of 1ʹ-
sulfooxysafrole formation would be 61 and 91%, respectively. This indicates a potential 
reduction of the bioactivation and of the cancer risk when safrole intake results from the 
food matrix containing malabaricone C or other SULT inhibitors presents in the regular 
daily diet as compared to results obtained when dosing safrole as a pure compound.  
  
 
In chapter 5, it was demonstrated that the inhibition of safrole DNA adduct formation by 
malabaricone C-containing mace extract observed in the in vitro model systems is also 
observed in an in vivo experiment. To this end Sprague-Dawley rats were orally exposed to 
mace extract and safrole and the level of safrole DNA adducts formed in the liver was 
quantified and compared to the level of safrole DNA adducts detected in the liver of rats 
exposed to safrole only. The results obtained demonstrate that safrole DNA adduct 
formation in the liver of Sprague-Dawley rats by the mace extract was reduced by 55%. 
The PBBK model predicted that a 55% inhibition of safrole bioactivation to 1ʹ-
sulfooxysafrole would be obtained when the bioavailability of the SULT inhibitors in the 
malabaricone C-containing mace extract would be 68% instead of 100%, which may not be 
unrealistic. Thus, the results of the in vivo study are in line with what would be expected 
based on the PBBK model based predictions for safrole bioactivation. The in vivo study 
also revealed a 64% inhibition of the safrole DNA adduct formation in the liver upon co-
exposure of the rats with the well-known SULT inhibitor PCP. This result is in line with 
results reported before in rats or mice exposed to safrole or 1ʹ-hydroxysafrole in the 
presence of PCP (Boberg et al., 1983; Daimon et al., 1997; Randerath et al., 1984). It was 
also demonstrated in chapter 5 that urinary excretion of the major safrole metabolites, 
(conjugated) 1ʹ-hydroxysafrole and DHAB was not significantly reduced when safrole was 
dosed in the presence of mace extract or PCP. This observation excludes that the reduction 
in DNA adduct formation is due to a reduced bioavailability of safrole when dosed together 
with malabaricone C-containing mace extract or PCP. 
Chapter 6 of the thesis presents a general discussion of the results obtained. With the PBBK 
models developed for rats and humans, the time- and dose-dependent formation of the 
proximate and ultimate carcinogenic metabolites, 1ʹ-hydroxysafrole and 1ʹ-sulfooxysafrole 
in rat and human liver can be predicted. Human interindividual differences in bioactivation 
of safrole can be simulated using Monte Carlo simulation. Moreover, the predictions by the 
PBBK models for rat and human were compared to evaluate the occurrence of species 
differences in bioactivation and detoxification of safrole. The results of the in vitro and in 
vivo studies that demonstrated inhibition of the formation of safrole DNA adducts by mace 
extract, support that combination effects should be taken into account in the risk assessment 
  
 
when safrole is tested in the presence of a relevant food matrix. To integrate the food matrix 
dependent modulation of safrole bioactivation in the risk assessment of safrole, the so-
called Margin of Exposure (MOE) approach can be used. This revealed that when safrole 
would be tested in rodent bioassays in the presence of a matrix containing SULT inhibitors 
the MOE values would be higher and the need for risk management actions would be 
lower. Finally, chapter 6 presents also some issues of interest for further research on 
bioactivation and risk assessment of safrole.  
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Samenvatting 
Safrol is een genotoxisch carcinogeen waarvan het gebruik in voedingsmiddelen in de V.S. 
al sinds 1960 is verboden en sinds 2008 ook in Europa (FDA Ban 21 CFR 189, 180; revised 
April 1 2008; European Commission, 2008). Als gevolg daarvan vindt blootstelling aan 
safrol hoofdzakelijk plaats door het gebruik van kruiden en specerijen die lage doses safrol 
bevatten, zoals nootmuskaat, foelie, steranijs, piment, kaneel en zwarte peper en 
voedingsproducten die deze kruiden en specerijen of de essentiële oliën daarvan bevatten. 
Sommige voedingsmiddelen en dranken bevatten hogere niveaus safrol dan de huidige 
limiet die door de Europese Unie (EU) is aanbevolen (Siano et al., 2003; Choong and Lin, 
2001). 
De veiligheid van menselijke blootstelling aan safrol bij lage innameniveaus is meerdere 
keren onderzocht (Europese Commissie, 1997; SCF, 2002; SCOGS, 1973). De Scientific 
Committee on Food (SCF) van de EU stelde in diens evaluatie vast, dat safrol genotoxisch 
en carcinogeen is en dat reductie van de blootstelling en beperking in de gebruiksniveaus 
noodzakelijk is (SCF, 2002). De Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) concludeerde in zijn 25e bijeenkomst dat smaaktoevoegingen die hoofdzakelijk 
safrol als smaakbepalend ingrediënt bevatten, niet meer als voedseladditieven gebruikt 
zouden moeten worden (JEFCA, 1981). Deze opvattingen zijn allemaal gebaseerd op 
carcinogeniteitsgegevens verkregen uit knaagdierstudies omdat adequate menselijke 
gegevens niet beschikbaar waren. Daarom is er behoefte aan een vertaling van uitkomsten 
van dierlijke bioassays, uitgevoerd bij hoge doses van de pure stof, naar het risico voor de 
mens die wordt blootgesteld aan safrol bij relatief lage doses via inname in een complexe 
voedselmatrix. Voor deze vertaling is een beter begrip nodig van de van de species-, dosis- 
en individu-afhankelijke verschillen in bioactivering en detoxificering van safrol en de 
mogelijke invloed van de voedselmatrix op deze processen. Het doel van dit proefschrift is 
om inzicht te verkrijgen in dergelijke species-, dosis- en individu-afhankelijke verschillen 
in bioactivering en detoxificering van safrol door gebruik te maken van op de fysiologie 
gebaseerde biokinetische (PBBK) modellen. 
  
 
In het eerste hoofdstuk van dit proefschrift wordt achtergrondinformatie gegeven over het 
onderwerp en worden de doelen van het proefschrift gepresenteerd. In hoofdstuk 2 wordt 
een PBPK-model ontwikkeld, dat is gebaseerd op in in vitro experimenten bepaalde 
metabole parameters, in silico bepaalde partitiecoëfficiënten, en fysiologische 
paramaterwaarden die zijn gevonden in de literatuur (Brown et al., 1997). Het PBBK-
model bestond uit 8 compartimenten waaronder lever, nier en long als metaboliserende 
compartimenten en daarnaast compartimenten voor vet, veneus en arterieel bloed, sterk 
doorbloed weefsel en zwak doorbloed weefsel. De uitkomsten van het model werden 
geëvalueerd door vergelijking van voorspelde niveaus van 1,2-dihydroxy-4-allylbenzene 
(DHAB), 1ʹ-hydroxysafrol glucuronide (1ʹ-HSG) en het totaal aan urinaire 
safrolmetabolieten met de beschreven niveaus van deze metabolieten in de urine van ratten 
die waren blootgesteld aan safrol (Benedetti et al., 1977; Klungsøyr and Scheline, 1983). 
Deze evaluatie liet zien dat de voorspellingen goed overeenkwamen met de waargenomen 
experimentele waarden. Met het verkregen model werd vervolgens onderzoek gedaan naar 
de relatieve omvang van bioactivering en detoxificering van safrol bij verschillende orale 
doses. Zowel bij hoge als bij lage doses komt vooral in de lever conversie van safrol voor, 
gekatalyseerd door cytochroom P450 (P450) waarbij DHAB als voornaamste P450-
metaboliet van safrol kan worden verwacht. Een dosis- afhankelijke verschuiving in P450-
gemedieerde omzetting naar een relatieve toename in bioactivering bij hoge doses werd niet 
waargenomen. Dit kan worden verklaard door het feit dat voor P450- gemedieerde 
omzetting van safrol geen verzadiging van een belangrijke metabole route voorkomt in een 
dosisreeks van 0.05 tot 300 mg/kg lichaamsgewicht. Extrahepatische conversie van safrol 
draagt niet significant bij aan het safrolmetabolisme. In mannelijke rattenlever is 
glucuronidering de belangrijkste route voor de omzetting van 1ʹ-hydroxysafrol, gevolgd 
door oxidering terwijl sulfatering van 1ʹ-hydroxysafrol een minder belangrijke route is maar 
wel de route die de uiteindelijke carcinogene metaboliet 1ʹ-sulfooxysafrol genereert. 
In hoofdstuk 3 van dit proefschrift wordt een PBPK-model voor safrol in de mens 
beschreven dat is gebaseerd op via in vitro- en in silico- experimenten bepaalde parameters. 
Het model bestaat uit 8 compartimenten, waaronder lever, nier en long als metaboliserende 
compartimenten, en compartimenten voor vet, veneus en arterieel bloed, en sterk- en 
  
 
minder sterk doorbloed weefsel. Met het verkregen model werden de tijd- en 
dosisafhankelijke vorming van de voorloper van de carcinogene metaboliet 1ʹ-
hydroxysafrol en van de carcinogene metaboliet 1ʹ-sulfooxysafrol, in menselijke lever 
berekend. Aanvullend werd een Monte Carlo-simulatie uitgevoerd om interindividuele 
variatie te voorspellen in de vorming van deze metabolieten in de populatie als geheel. Het 
PBBK-model voor de mens werd geëvalueerd door de voorspelde PBBK en de beschreven 
experimentele data te vergelijken op het niveau van de totale safrol metabolietvorming, 
gemeten in de urine van menselijke vrijwilligers die waren blootgesteld aan safrol 
(Benedetti et al, 1977) wat resulteerde in een goede match. De vergelijking van het PBBK-
model voor rat en mens liet zien dat het verwachte niveau van vorming van 1ʹ-
hydroxysafrol in humane lever vier maal hoger is dan dat in rattenlever en de voorspelde 
vorming van 1ʹ-sulfooxysafrol is ongeveer vijf keer hoger in humane lever dan in 
rattenlever. Dit toont aan dat de interspeciesverschillen in toxicokinetiek voor bioactivering 
van safrol tussen ratten en mensen in overeenstemming zijn met de onzekerheidsfactor van 
4 die normaal gesproken in acht wordt genomen voor interspeciesverschillen in 
toxicokinetiek (IPCS, 2010). Speciesverschillen tussen mensen en ratten wat betreft de 
eigenschap van de detoxificeringsroutes van 1ʹ-hydroxysafrol waren groter. De vorming 
van 1ʹ-oxosafrol is de belangrijkste detoxificeringsroute in de mens, maar een minder 
belangrijke route in de rat en glucuronidering van 1ʹ-hydroxysafrol is de belangrijkste 
detoxificeringsroute in de rat, maar een minder belangrijke route in de mens. Het PBBK-
model voorspelde dat de vorming van 1ʹ-sulfooxysafrol in de lever van de mens en de rat 
een lineair verband laat zien met de dosis, over het hele gebied van dosisniveaus waarvan 
bekend is dat deze kanker veroorzaken in knaagdier-bioassays (100 mg/kg 
lichaamsgewicht) naar de dosisniveaus die relevant zijn voor de dagelijkse menselijke 
inname en even laag als de virtuele veilige dosis (vitual safe dose, VSD). Dit betekent dat 
PBBK-modellen de interspeciesverschillen kunnen evalueren en een nuttige bijdrage 
kunnen leveren in de risk assessment van in voedsel voorkomende chemicaliën bij het 
evalueren van menselijke risico’s. Monte Carlo-simulaties toonden aan dat de vorming van 
1ʹ-sulfooxysafrol in de populatie 4-voudig tot 17-voudig bleek te verschillen (verschil 
tussen achtereenvolgens de 95e percentiel en de mediaan, en 95e en 5e percentiel). 
  
 
Bovendien kan een CSAF (chemical-specific adjustment factor) worden bepaald voor 
interindivuele verschillen in kinetiek voor voorspelde vorming van 1ʹ-sulfooxysafrol, 
berekend als de ratio van de parameter van het 95e percentiel en de mediaan, die uitkomt op 
3.9 (IPCS, 2005). Vergelijking van deze CSAF met de standaard onzekerheidsfactor van 
3.16 voor interspeciesvariabiliteit in biokinetiek (ervan uitgaand dat een factor 10 evenredig 
verdeeld is in twee sub-factoren van elk 10-0.5 (3.16) voor biokinetiek en biodynamiek) 
(IPCS, 2010) laat zien dat de standaard onzekerheidsfactor van 3.16, 91% van de populatie 
voldoende beschermt. 
Om de dagelijkse inname te reduceren, heeft het huidige EU-voorschrift No. 1334/2008 
toevoeging van safrol als pure stof aan voeding verboden Als gevolg van deze regels komt 
de huidige inname van safrol door de mens voornamelijk door het gebruik van specerijen 
die safrol bevatten, zoals foelie, nootmuskaat, peper etc., of door voeding waaraan deze 
specerijen of de essentiële oliën daarvan zijn toegevoegd. Daarom moet risk assessment van 
safrol door consumptie van kruiden en specerijen die safrol bevatten, worden uitgevoerd 
met inachtneming van het mogelijk modulerend effect van andere stoffen die in die kruiden 
of specerijen zitten. De gevolgen van mogelijke matrixafhankelijke effecten op de 
bioactivering en detoxificering van safrol zijn onderzocht in hoofdstuk 4. Omdat bekend is 
dat foelie relatief hoge niveaus van safrol bevat (Archer, 1988) werd foelie-extract, en 
fracties daarvan, getest op remming van SULT-activiteit, de reactie die verantwoordelijk is 
voor de laatste stap in de bioactivering van safrol. De foelie-fractie die malabaricone C 
bevatte, vertoonde de hoogste SULT-remmingsactiviteit. De Ki (remmingsconstante) voor 
remming van SULT-activiteit door het malabaricone C-bevattende extract was 8.3 en 1.0 
mg/L voor respectievelijk ratten- en mensenlever S9. Remming door foelie-extract van 
oxidering en glucuronidering van 1ʹ-hydroxysafrol werd niet gevonden bij een foelie-
extractconcentratie van 100 mg/L en dat toont aan dat foelie-extract SULTs selectief remde. 
In hoofdstuk 4 bewijzen verdere studies met menselijke HepG2 cellen blootgesteld aan 1ʹ-
hydroxysafrol in aan- en afwezigheid van foelie-extract, dat de vorming van het DNA 
adduct N2-(trans-isosafrol-3ʹ-yl)-2ʹ-deoxyguanosine (S-3ʹ-N2-dGuo) werd geremd voor 60 
en 80% bij foelie-extraxtconcentraties van respectievelijk 25 en 100 mg/L. Het foelie-
  
 
extract vertoonde geen cytotoxiciteit tot concentraties van ten minste 100mg/L, de hoogst 
geteste concentratie. 
Om te onderzoeken of deze effecten op safrol-bioactivering via remming van SULT 
gemedieerde omzetting van 1ʹ-sulfooxysafrol door malabaricone C- bevattende foelie-
extract eveneens in vivo kunnen worden verwacht, werd de SULT-remming geïntegreerd in 
het PBBK-model op basis van de Ki-waarden voor ratten- of humaan S9. Het PBBK-model 
dat op die manier werd verkregen, gaf aan dat bij een dosis van 50 mg/kg lichaamsgewicht 
safrol en een dosis van malabaricone C-bevattend foelie-extract in een ratio gelijk aan het 
niveau van deze bestanddelen in foelie (44 mg/µmol), remming van 1ʹ-
sulfooxysafrolvorming door malabaricone C-bevattend foelie-extract voor ratten en mensen 
op zal treden op een niveau van 90 en 100%, wanneer de biobeschikbaarheid van de foelie-
extractingrediënten 100% zou zijn. Dit toont een potentiële reductie aan van bioactivering 
en van het kankerrisico als safrol-inname een gevolg is van de voedselmatrix die 
malabaricone C- of andere SULT-remmers bevatten in het reguliere dagelijkse dieet, 
vergeleken met resultaten die verkregen zijn bij dosering van safrol als pure stof. 
In hoofdstuk 5 werd onderzocht of de remming van safrol DNA-adductvorming door 
malabaricone C-bevattend foelie-extract, waargenomen in het in vitro model systeem, ook 
gezien kan worden in een in vivo experiment. Daartoe werden Sprague-Dawley ratten oraal 
blootgesteld aan foelie-extract en safrol en het niveau van safrol DNA-adducten die in de 
lever werden gevormd, werd gekwantificeerd en vergeleken met het niveau van safrol 
DNA-adducten die gevonden zijn in de lever van ratten die alleen aan safrol zijn 
blootgesteld. De verkregen resultaten toonden aan dat safrol DNA-adductvorming in de 
lever van Sprague-Dawley ratten door het foelie-extract met 55% werd gereduceerd. Het 
PBBK-model voorspelde dat een 55% remming van safrol bioactivering op 1ʹ-
sulfooxysafrol zou worden verkregen als de biobeschikbaarheid van de SULT-remmers in 
het malabaricone C-bevattend foelie-extract 68% zou zijn in plaats van 100%, wat mogelijk 
niet onrealistisch is. De resultaten van de in vivo studie komen dus overeen met de op het 
PBBK-model gebaseerde voorspellingen voor safrol bioactivering. De in vivo studie liet 
ook een remming zien van 64%van de safrol DNA-adductvorming in de lever bij 
combinatieblootstelling van de ratten aan safrol en de bekende SULT-remmer PCP. Dit 
  
 
resultaat komt overeen met eerder beschreven resultaten in ratten of muizen die werden 
blootgesteld aan safrol of 1ʹ-hydroxysafrol, gecombineerd met PCP (Boberg et al., 1983; 
Daimon et al., 1997; Randerath et al., 1984). In hoofdstuk 5 is ook aangetoond dat urinaire 
excretie van de belangrijkste safrolmetabolieten, (geconjugeerde) hydroxysafrol en DHAB 
niet significant was gereduceerd als safrol gelijktijdig werd gedoseerd met foelie-extract of 
PCP. Deze waarneming sluit uit dat de reductie in DNA-adductvorming het gevolg is van 
een gereduceerde biobeschikbaarheid van safrol als die samen met malacaribone C-
bevattend foelie-extract of PCP wordt gedoseerd. 
Hoofdstuk 6 van het proefschrift is een algemene discussie over de verkregen resultaten. 
Met het PBBK-model dat is ontwikkeld voor ratten en mensen, kan de tijd- en dosis-
afhankelijke vorming van de voor bioactivering relevante carcinogene metabolieten, 1ʹ-
hydroxysafrol en 1ʹ-sulfooxysafrol, in ratten- en mensenlever worden voorspeld. 
Menselijke interindividuele verschillen in bioactivering van safrol kan worden gesimuleerd 
door Monte Carlo-simulatie te gebruiken. Bovendien zijn de voorspellingen door de PBBK-
modellen voor rat en mens vergeleken om de speciesverschillen in bioactivering en 
detoxificering van safrol te evalueren. De resultaten van de in vitro en in vivo studies die 
remming vertoonden van de vorming van safrol DNA-adducten door foelie-extract, 
bevestigen dat in risk assessment rekening moet worden gehouden met gecombineerde 
effecten als safrol zou worden getest in combinatie met een relevante voedselmatrix. Om de 
van de voedselmatrix afhankelijke modulering van safrol bioactivering in de risk 
assessment van safrol te integreren, kan de zogeheten Margin of Exposure (MOE) worden 
gebruikt. Deze benadering laat zien dat, als safrol zou worden getest in knaagdierbioassays 
samen met een matrix die SULT-remmers bevat, de MOE-waarden hoger zouden zijn en de 
noodzaak voor risk management geringer. Tot slot geeft hoofdstuk 6 enkele onderwerpen 
die voor verder onderzoek naar bioactivering en risk assessment van safrol van belang 
zouden zijn. 
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Abbreviations 
1′HOS, 1′-oxosafrole   
1′HS, 1′-hydroxysafrole   
1′HSG, 1′-hydroxysafrole glucuronide   
1′HSS, 1′-sulfooxysafrole   
7HC, 7-hydroxycoumarin   
7HCS, 7-hydroxycoumarin sulphate   
ADME, absorption, distribution, metabolism and excretion   
ALARA, as low as reasonably achievable 
BMD, benchmark dose  
BMDL10,  lower confidence limit of the benchmark dose that gives 10% increase in tumor 
incidence over background level 
bw, body weight 
CEFS, Committee of Experts on Flavouring Substances   
CSAF, chemical-specific adjustment factor 
CV, coefficient of variation  
DAD, diode array 
DHAB. 1,2-dihydroxy-4-allylbenzene   
DMSO, dimethyl sulfoxide   
E-3′-N2-dGuo, N2-(trans-isoestragol-3′-yl)-2′-deoxyguanosine   
EDI, estimated daily intake 
EFSA, European Food Safety Authority   
EU, European Union   
F, female  
FDA, Food and Drug Administration   
GRAS, generally recognized as safe  
GSH, glutathione reduced   
h, hour 
i.p, intraperitoneal   
JECFA, Joint FAO/WHO Expert Committee on Food Additives  
  
 
K, kidney 
Ki, inhibition constant 
L, liver 
LC, liquid chromatography 
LC-MS, liquid chromatography–mass spectrometry 
Lu, lung 
M, male   
MOE, margin of exposure   
MPL, microsomal protein yield of the liver 
MTT, 3-(4,5-dimethylthiazol-2-y1) 2, 5-diphenyl tetrazolium bromide   
NAD, β-nicotinamide adenine dinucleotide 
NADPH, reduced β-nicotinamide adenine dinucleotide 
NOAEL, no observed adverse effect level   
nt, nucleotide 
P450, cytochrome P450 enzyme 
PAPS, 3′-phosphoadenosine-5′-phosphosulphate   
PBBK, physiologically based biokinetic   
PCP, pentachlorophenol   
s.c, subcutaneous   
s.t, stomach tube   
S-1′-N2-dGuo, N2-(safrol-1′-yl)-2′-deoxyguanosine   
S-3′-N2-dGuo, N2-(trans-isosafrol-3′-yl)-2′-deoxyguanosine   
S-3′-N6-dAdo, N6-(trans-isosafrol-3′-yl)-2′-deoxyadenosine   
S9PL, yield of S9 protein 
SCE, sister chromatid exchange   
SCF-EU, Scientific Committee on Food of the European Union 
SCOGS, Select Committee on GRAS Substances  
SD, Sprague Dawley 
SPDE, spleen phosphodiesterase   
SULT, sulfotransferase   
  
 
UDPGA, uridine 5′-diphosphoglucuronic acid   
UGT, UDP-glucuronosyltransferase 
UPLC, ultra performance liquid chromatography 
VPDE, venom phosphodiesterase   
VSD, Virtual Safe Dose 
wk, week 
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